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Many South African psychiatrists, and particularly those working in 
psychiatric hospitals with Black and Coloured patients, have the firm 
clinical impression that in many of these patients>acute psychotic 
illness is associated with the abuse of cannabis. 
Most of the previous work in this field had been done by clinicians 
of Eastern countries where the use of cannabis has been endemic for 
thousands of years. However, those workers were handicapped because 
they lacked both the sophisticated techniques for standardized 
psychiatric evaluation and the availability of an assay to confirm 
cannabis use. 
It was decided to investigate acute psychoses in Cape Coloured males 
admitted to Valkenberg Hospital with the following aims: 
i. To identify a cohort of acutely psychotic patients who had 
recently been using cannabis and to compare them with a matched con-
trol group who were free of any drugs. The recently available EMITR 
immunochemical analytical technique was used for the detection of 
urinar~ cannabinoids. To exclude the contribution of other psycho-
tropic agents to the aetiology of the psychoses, gas chromatography 
was performed to detect ethanol and thin-layer chromatography to 
screen for· other psychotropic agents. 
ii. To assess the comprehensive mental state of patients on ad-
mission and then again after a 7-10 day period the Present State 
Examination (PSE), a well validated and standardized diagnostic 
instrument, was used. 
iv 
iii. To determine serum creatinine phosphokinase (CPK) and serum 
lactate dehydrogenase (LOH) levels (indicators of muscle damage) in 
view of the published reports of elevated levels in psychotic patients. 
Patients were studied in three groups based on the urinary cannabinoid 
concentration on admission: 
~~ 
High cannabis group (n=20): these patients had~levels greater than 
or equal to b() 'µg Cross-Reacting Cannabinoids per gramme creatinine 
(]..gCRC/g creatinine). 
V 
Low cannabis group (n=20): these patients had initial levels less than 
or equal to 59i.gCRC/g creatinine. 
Psychotic control group (n=29): these were patients in whom urinary 
cannabinoids were absent on admission and who were matched as closely 
as possible with the high cannabis group with regard to clinical 
. diagnosis, age, social class and number of previous admissions. 
Our results showed that: 
i. The only detectable toxins present were the cannabinoids which 
occurred in 60% of the randomly selected patients. 
ii. The presence of urinary cannabinoids was an important factor in 
the nature and course of psychiatric illness. The psychosis described 
in this study was one in which a hypomanic component and a lack of the 
more typical schizophrenic symptoms were the outstanding features. 
Seven (35%) of the patients in the high cannabis group presented with 
a manic psychosis which was clinically indistinguishable from naturally 
occurring mania. Although the remainder of the patients in the high 
cannabis group were diagnosed on the PSE as paranoid schizophrenia, 
they differed from paranoid schizophrenic controls in having a 
prominent affective colouring and lacking the typically schizophrenic 
features of auditory hallucinations, flattening of affect, and in-
coherence of speech~ 
The illness in the cannabis groups resolved rapidly (7-10 days) 
compared to the controls. Even when exactly matched with the control 
group .for total amount of medication received, the cannabis groups 
still exhibited a more rapid remission rate, particularly with regard 
to the psychotic symptoms. In contrast, the symptomatology of the 
control group remained virtually unchanged after the 7-10 day period. 
The CPK and LD-l levels were significantly raised in the high cannabis 
group; this reflected the muscular overactivity which characterized 
the hypomanic behaviour in this group. 
In essence, this study, preliminary as it was, succeeded in 
delineating a psychosis in which excessive quantities of cannabis 
appeared to play a major aetiological role. &Jggestions for further 
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1.1. INTRODJCTION 
Names are legion for the plant material first classified in 1753 by 
Linnaeus as Cannabis sativa. Kif, ganga, hemp, boom, pot, weed, Mary 
Jane, grass, D..Jrban Poison, and marijuana are only a few synonyms used 
for the herb most generally known in South Africa as 'dagga'. All of 
these terms have an ethnographic and geographic specificity and this 
study will use the term cannabis. 
1.1.1. Geographic Migration of Cannabis 
This herb originated south and east of the Caspian Sea in semi-desert 
regions and gradually it spread to the Himalayas and Central Asia. 
Six thousand years ago man used the plant for its fibre content rather 
than for its medicinal values. Schultes (1973) (quoted by du Tait, 
1976) suggested that Neolithic man in China and China Turkestan used 
the plant for fibre. The earliest written record of this plant and 
its medicinal use was in a Chinese Pharmacopoeia of Emperor Shen 
Nuhng (2737 B.C.). Scythians cultivated the plant in the Volga regions 
some 3000 years ago (Schultes, 1973). At about the same time, the herb 
was used in Egypt and gradually it spread to Morocco and Spain in the 
14th century (Rosenthal, 1971; as cited by du Tait, 1976). It was 
introduced to Chile by the Conquistadores for the production of fibre 
for cordage (du Tait, 1976). Part of the geographical spread of 
cannabis was due to its association with migrant Muslim communities; 
Arab traders were responsible for its spread down the east coast of 
Africa. In the southern part of Africa the herb was used in pre-
Portuguese times - before A.O. 1500 (du Tait, 1976) . It is thought 
that cannabis was introduced to modern European society by the return-
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ing troops from Napoleon's Egyptian campaign in 1798 (Grinspoon, 1969; 
Mechoulam and Gaoni, 1967). 
1.1.2. Use of Cannabis in Southern Africa 
Cannabis was long used and accepted throughout sub-Saharan Africa by 
the Khoi~hoi herders, San people and Bantu-speaking r-..ations by the 
time the Europeans settled at the Cape of G:Jod Hope (du Tait, 1976). 
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The first written record of the term 'dagga' in Southern Africa was by 
Jan van Riebeeck (the first G:Jvernor of the D.Jtch settlement at the Cape 
of G:Jod Hope) in 1658. In his diary it is spelt as 'daccha'. 
Early workers were confused by the various preparations (which may or 
may not have included cannabis) which were eaten or drunk, since 
Leonotus leonoris, in addition to Cannabis sativa, was also frequently 
smoked. References to 'Wild Hemp', 'Klip D:igga', and 'Red D:igga' do 
not always exclude cannabis, just as references to 'dagga' do not 
necessarily exclude Leonotus. The superficial similarity in appear-
ance and apparent related effects of both plants led to this confusion 
(James, 1970; du Tait, 1976). DJ Tait (1976) suggested that while 
many of the early writers used the term 'dagga', they might have been 
observing the use of Cannabis sativa along with other herbs and roots 
including Leonotus and Salsola. 
Cannabis was used in African and D...itch folk medicine to treat snake 
bite, to facilitate child-birth, and as a remedy for malaria, black-
water fever, blood poisoning, anthrax and dysentery. It was also used 
to treat asthma by all race groups (du Tait, 1976). Cannabis was 
described in the Extra Pharmacopoeia of the Pharmaceutical Society of 
Great Britain, for the last time in 1967 as formerly being prescribed 
for "mania, and nervous disorders, as a cerebral sedative or narcotic, 
the relief of migraine and of headache due to hypertension" (Todd, 
1967). 
1.1.3. Snaking Paraphernalia 
A variety of pipe forms and methods of smoking have been used: (du 
Tait, 1976). 
i. G::lurd Water Containers 
A gourd was used to contain the water, and a hole was made in the 
neck over which the mouth of the smoker was placed. The pipe bowl was 
placed in another hole in the gourd (directly or attached by a con-
necting reed). The smoker inhaled through the aperture, thereby 
drawing the smoke through the water, thus cooling and condensing the 
smoke . 
ii. Horn Water Containers 
A hollow horn was used in place of a gourd. The horn was half-filled 
with water and the pipe stem entered at an angle; the smoke was in-
haled through the open end of the horn. A short piece of the shin bone 
of a small animal was a more simple form of this type of pipe. 
iii . Sandstone and Earthenware Water Containers 
A hollow rectangular block or a simple hand-moulded container with 
two holes, one to hold the pipe bowl and the other for the insertion 
of a reed mouthpiece, was fashioned. 
4 
iv. Ground and Wet Sand Pipes 
The pipe was made in the ground, either below the surface or built up 
on the ground surface. Campbell (1822) (quoted by du Tait, 1976) ex-
plained how the Batlapin (Botswana) "dug a hole in the ground the 
shape of a basin, in which they formed with their finger, a round 
passage, down one side, and up the other, in the shape of an inverted 
bow, this they arched over with clay, and filled their tobacco (or 
rather wild hemp) with a lighted cinder at one end, and putting their 
mouths close to the other they sucked out the smoke". 
v. Modern Adaptations 
Shaw (1938) quoted a case where a commercial brick had been hollowed 
out to form an earthenware container. A pickle jar and a coconut shell 
have also been used (Shaw, .1938) . Two basic forms of smoking are used 
in modern urban conditions, a pipe with a clay bowl and a cigar form 
(du Tait, 1976). The pace of modern life and the fear of discovery 
have necessitated the dispensing with the paraphernalia of a leisurely 
smoke (du Tait, 1976). The tops of broken bottles (nekkies), cans, 
pumpkins and clay pots have al1 been used (Levin, 1974; du Tait, 
1976). The home-rolled, crude cigarette (zol, skyf , reefer, joint) 
can be smoked on its own or through a reed or bamboo 'cigarette holder' 
(du Tait, 1976). 
1.1.4. Early Scientific Research in Southern Africa 
The earliest known treatise on cannabis in South Africa was read by 
Dr R.M. Armstrong, one-time district surgeon in Cradock, Cape Province, 
before the Chirurgical Society in Grahamstown, Cape Province on 31 July, 
1855 (du Tait, 1976). Armstrong (quoted by du Tait, 1976) collected 
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samples of cannabis in the Cradock district, discussed the morpho-
logical features of the plant and questioned" ... Hottentots and other 
Natives who were in the habit .of using the dacca as to the effect it 
had on them the time of gathering the plant ... if they used both 
male and fenale plants". He found that" ... there was a peculiar dull-
ness about the eye, the conjunctiva was of a dirty yellow colour and 
the lassitude of the whole system was particularly observed in the 
muscles of the face ... when allowed to use their favourite herb (the 
dacca) that they changed their appearance altogether from being dull, 
stupid and morose they became lively, talkative and communicative ... 
that when they smoked the dacca, that it caused a pleasing excitenent, 
and even in some instances an intoxicating effect". No discussion or 
other study followed Armstrong's account. 
More than half a century passed before cannabis was given further 
detailed attention. C.J.G. Bourhill conducted the first full study 
of Cannabis sativa in southern Africa between 1908 - 1912, the results 
of which were submitted to the University of Edinburgh as a thesis for 
the degree of D:Jctor of Medicine in 1913 (du Tait, 1976). Bourhill 
observed 627 male inhabitants of the Pretoria Native Asylum and at a 
number of mining compounds. Part of Bourhill's thesis dealt with 
'dagga insanity' and he claimed that 18ic of all patients studied 
between 1908 - 1912 suffered from this malady. Quantitative material 
on physical criteria such as pulse, tenperature and urine, general con-
clusions with respect to memory, hallucinations and illusions were 
presented (du Tait, 1976). The use of the label 'dagga insanity' by 
Bourhill is questionable since there was difficulty in the exclusion 
of alcohol as a factor and, according to Ames (1958), there was no 
good reason why many of the cases could not have been schizophrenics 
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who smoked cannabis since "his emphasis of auditory hallucinations is 
much more suggestive of schizophrenia than cannabis intoxication". 
Nearly 25 years later as a result of a resolution passed at the Medical 
Congress held at Grahamstown in 1935, another serious investigation of 
72 Black patients was undertaken by the medical staff of Pretoria 
Mental Asylum. Participation was voluntary. The patients were 
observed while smoking cannabis and the results recorded. These 
results are questionable as the authors themselves seem to be doubt-
ful of the information gleaned and some of the effects observed may 
well have been due to the activation of the original psychosis. 
1.1.5. Components of Cannabis 
Cannabis is .not a single unifoni, plant but is an 'unstable' species 
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with hundreds of chemovariants arising due to inherent genetic 
plasticity, human manipulations, and environmental influences (Nahas, 
1973). The latter, including climate, are not as important as 
hereditary factors in the determination of the cannabinoid content of 
the plant (D:::Jornbos et al, 1971). Broadly speaking, two main plant-
types occur: the fibre-type plant having a delta-9-tetrahydrocannabinol 
(~9 -TI-C) content of le~s than 0,2%; the drug-type plant having a 
~9 -Tf-C content of 3,4 - 4,Bia (Nahas, 1973). 
At present it is estimated that there are 50 different compounds with 
potential pharmacological activity in cannabis (f-bllister, 1974). 
These compounds are the cannabinoids, a term defined by Mechoulam and 
Gaoni (1967 a,b)"as the group of C21 compounds typical of and present 
in Cannabis Sativa, their carboxylic acids, analogs and transformation 
products". The cannabinoids are concentrated in the leaves and flower-
ing tops of the plant. It is the opinion of the scientific community 
that cannabis and its preparations can be evaluated on the ~9 -TI-C 
content alone, since this is the recognised psychogenic compound 
(Mechoulam and Gaoni, 1965; Mechoulam and Gaoni, 1967(a); Isbell, 
1967; Hollister et al, 1968). 
1.1.6. Research on Cannabis in South Africa 
It is estimated that in excess of 300 million people world-wide use 
this drug in one or more of its preparative forms. Internationally 
more than 7 000 scientific papers have been published on Cannabis 
sativa encompassing its vast chemistry, biochemistry and biosynthesis 
(Turner et al, 1980), and many more papers concern themselves with 
the sociological, psychological, pathol ogical and psychiatric aspects 
of the drug's use and abuse. However, in view of the widespread use 
of . cannabis in South Africa, relatively little has been published on 
this subject in this country (James, 1970; du Tait, 1976). In an 
early paper on the subject, Ames (1958) administered single doses of 
cannabis to human volunteers and noted the following features: 
thought disorder, delusions, temporal disorientation, disturbances of 
visual perceptions, visual psuedohallucinations, body image distur-
bances, depersonalization and euphoria. Logie, Morley and Bensusan 
(1972) surveyed the use of cannabis among university students in 
Johannesburg. Levin (1974) described psychiatric morbidity associated 
with cannabis use in South African national servicemen. A major com-
prehensive ethnographic study on cannabis use in Africa was done by 
du Tait (1976) and it is the definitive work on the subject. 
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The reason for the dearth of published papers in South Africa could 
be that possession of cannabis carries a heavy punishment thereby 
making the task of obtaining spontaneous and reliable information 
extremely difficult. Unfortunately the feelings of Shapiro (1951) 
still apply 30 years later: "a careful study of the social effects 
and the psychological actions of dagga is long overdue". 
1 . 2. NCMEI\CLA TURE OF THE CANNABINOIDS 
Currently two systems are used for the numbering of the 
cannabinoids. The one system uses the formal rules for the numbering 
of pyran-type compounds such as the cannabinoids. The disadvantages 
of this system are, that in passing from one compound to another in a 
series, a carbon atom frequently has i t s number changed and this sys-
tem is not applicable to cannabinoids that are not pyrans. This sys-
tem has been adopted by "Chemical Abstracts". The second numbering 
system, has a biogenetic basis where the cannabinoids are seen as 
substituted monoterpenoids. The advantages of this system are that in 
the majority of chemical transformations a carbon will usually retain 
its number, and all the cannabinoids, whme.r c.on\:.a,n'11•,3 
a pyran ring or not, can be numbered in this way. (See Figure 1.2.1) 
1.3. STRUCTURE-ACTIVITY RELATIONSHIPS 
The chemistry of the cannabinoids is complex and it has been estimated 
that at least 50 compounds have been isolated from various strains of 
Cannabis sativa which possess potential pharmacological activity. 
Structure-activity relationships have been extensively studied in 
animals , but the majority of findings remain to be validated in humans 
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FIG. 1.2.1. Nomenclature of cannabinoids. 
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It was long suspected that 69-THC was the major active component of 
cannabis (Adams, 1942; Leowe, 1946). Chemical studies over the last 
fifteen years have definiteJ,y established that the structure of 69 -THC 
is the laevo-isomer (Mechoulam and Gaoni, 1964; Mechoulam and Gaoni, 
1965) and this is considered to be the principle psychoactive component 
of cannabis. Besides 69-THC, the two most abundant cannabinoids in 
cannabis are cannabidiol (CBD) and cannabinol (CBN). According to 
Field and Arndt (1979) S:Juth African cannabis appears to rank among 
the more potent classes of Cannabis sativa in terms of the 69-THC con-
tent, but the CBD content seems to be very low, even though the exact 
CBD content could not be accurately determined. 
Mechoulam et al (1970) found that CBD, CBN, cannabichromene, cannabi-
gerol, and cannabicyclol were inactive in monkeys and did not alter the 
response of these animals to concurrently given doses of 69-Tf-C. 
Hollister (1974) confirmed that both CBD and CBN lacked pharmacological 
activity in man. He compared the effects of 69-Tf-C and 68-THC in man 
using oral doses and found that the spectrum of clinical effects was 
similar with both isomers, but 68-THC was considered to be only 75% as 
potent as 69-THC. The potency of the 11-hydroxy metabolites of 69-THC 
and ~8-THC were also investigated using intravenous administration of 
these metabolites. Typical chemical effects were observed - pulse 
rate markedly increased, and reddened conjunctivae. It was concluded 
that the 11-hydroxy metabolites of ~g-THC and 68-THC were approximately 
20% more potent than their parent compounds and these metabolites had 
the same ratio of potency as the parent compounds i.e. 11-hydroxy-68-THC 
was 75% as potent as 11-hydroxy 6g-THC. On the other hand, Perez-Reyes 
(1972) found that 69-Tf-C and 11-hydroxy 69-THC were equally potent and 
that the 11-hydroxy compound had a very rapid onset of action, a longer 
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duration of action and mimicked the action of 69 -THC. 
s--a-Hydroxy-69 -THC and 8-8-Hydroxy-~9-THC have had very little pharma-
cological study in any animal species. Hollister (1974) found that 
placement of the hydroxyl group in the 8-position created an active 
metabolite, but one which was much less potent than when the hydroxyl 
group was in the 11-position. The 8-8-hydroxy metabolite of 69 -THC 
was judged to be 
2 
3 as potent as the 8-a.-hydroxy metabolite. Tetrahydro-
cannabivarin was found to be ~~~ potent as 69 -TI-C. 
Hollister maintains that the qualitative actions of THC will persist, 
though the potency may alter radically, so long as the fundamental 
structure of THC remains, irrespective of change of length of side 
chain, production of hydroxy metabolites at the 8- or 11-position and 
placement of double bonds. 
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Although the metabolism of 69 -THC produces a more potent 11-hydroxy 
metabolite, it is not settled whether the parent compound must be 
hydroxylated to this metabolite to possess its characteristic pharma-
cological activity or not. Present evidence favours 69-THC as the 
active principle in mice and the 11-hydroxy-metabolite in man (King et al 
1976). 
The whole picture of structure-activity relationships remains incomplete 
and, to date, no compound has been found in cannabis which is qualitative-
ly different from, or more active than, 69 -TI-C itself. 
1.4. ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION AND TOXICITY 
The pharmacological activity of any drug is usually affected by the 
dose, the vehicle, and the route of administration. Cannabis is in-
gested in some countries but in Western cultures it is generally 
inhaled b~ smoking (Thomas and Chesher, 1973; King et al, 1976). 
Cannabis frequently contains ~9 -tetrahydrocannabinolic acids, 
6a,7,8,10a-tetrahydro-1-hydroxy-6,6,9~trimethyl-3-pentyl-6-H-benzo[c] 
chromene-2 carboxylic acid and 6a,7,8,10a-tetrahydro-1-hydroxy-6,6,9-
trimethyl-3-pentyl-6-H-benzo[c]chromene-4-carboxylic acid, which 
readily decarboxylate to yield 69-THC when exposed to light and/or on 
heating (Baker et al, 1981). This phenomenon contributes to the 
greater activity of cannabis products when they are smoked compared 
with ingestion (Mechoulam e~ al, 1970). However, Truitt (1971) and 
Jaffe (1980) estimated that no more than 50% of the ~9 -THC content of 
a marijuana cigarette is usual l y absorbed after smoking with pyrolytic 
transformations and loss as side-stream accounting for the deficit of 
A9 -THC absorption (Thomas and Chesher, 1973; Ohlsson et al, 1980). 
The ·physicocher.nicalproperties of the drug itself are also important: 
~9-THC is highly lipophilic, having an octanol : water partition co-
efficient of 3 000 (Paton and Pertwee, 1971), which accounts for the 
rapid absorption, accumulation and persistence of the drug (Paton; 1975). 
Figure 1.4.1. illustrates the general physiological disposition of a 
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Figure 1.4.1 Schematic representation of the Physiological Disposition 
of Drugs 
Therefore following intravenous administration, . ~9-THC is rapidly 
taken up from the central compartment and redistributed to tissues 
where it is temporarily sequestrated, resulting in a rapid decline in 
the plasma levels of ~9-THC (Lemberger et al, 1973(b)). Lemberger 
(1973) and Gilsson et al (1980) showed the plasma profiles of r4c-~9-
THC after smoking and intravenous injection to be similar to each 
other, whereas plasma levels following oral ingestion were low and 
irregular. 
The onset of effect of cannabis depends primarily on the route of 
administration: onset of effects were noticed within a few minutes 
inhalation (Weil et al, 19Ei8; Hollister, 1971; King et al, 1976 ; 
Jaffe, 1980) and within 30 to 60 minutes of ingestion (Thomas and 





alveolar capillary surfaces following inhalation would account for 
the rapid onset of action; the delay in response to an ingested dose 
is explained by the slower abso~ption of the drug into the blood and 
tissue from the gastro-intestinal tract (Le.mberger et al, 1972). It 
was noted that approximately three times as much cannabis was required 
orally to obtain the same pharmacological effects as that produced by 
inhalation (Claussen and Korte, 1976). Since it is rapidly absorbed, 
less 69-THC or its active matabolite reached the brain when ingested 
than when smoked and the possible reasons for this are that 69-THC 
might be converted to inactive compounds by gut flora, mucosal cells, 
and the liver (King et al, 1976). 
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69 -THC is extensively bound to the lipoproteins of human plasma and 
further experiments suggest that albumin, a.-lipoprotein and 8 -lipopro-
tein (to a minor degree) are involved in the protein binding of 11-
hydroxy-69-THC (Whalqvist, 1970; Widmen et al, 1973). Acute animal 
experiments with injections of labelled drug have shown very high 
activity in the lung, liver, and kidney; moderate to high in the 
heart, salivary glands, gastric mucosa, bone marrow, Harderian cortex, 
spleen, placenta, adrenal cortex, follicular epithelium of the thyroid, 
pituitary, mammary gland, corpora lutea; low to moderate in the brain, 
epididymis, testes and foetus (Freudenthal et al, 1972; Kennedy and 
Waddel, 1972; Shannon and Fried, 1972; Ryrfeldtet al, 1973 ). Widman 
et al (1 973) suggested that besides the lung, spleen and other fatty 
tissues, plasma proteins may also serve as a depot for 69-THC and its 
hydroxylated metabolites. When allowance is made for the factor of 
blood flow, the distribution of the drug is generalised (Paton, 1975). 
Species variations make it difficult to extrapolate these results with 
any degree of confidence in man. There is no evidence of accumulation 
of 69 -THC or its metabolites in man (Hollister et al, 1972). 
The presence of 69-THC in the brain has generated considerable interest 
since this is the site of its most important phannacological action. 
t9-THC is metabolized chiefly in the liv~r (to a lesser pegree in · 
various other tissues) but not, however, in the brain (see below). 
Therefore 11-hydroxy-Ag-THC, the primary metabolite of 69-THC, is 
fanned outside the brain and transported there via the blood. Both 
69-THC and 11-hydroxy-69-THC rapidly penetrate the central nervous 
system as no effective blood-brain barrier exists. The reasons for 
the differences in brain penetration of 69 -THC and 11-hydroxy-69-THC 
a~ not known (Gill and Jones, 1972). Perez-Reyes et al (1976) found 
that 11-hydroxy-69-THC left the intravascular compartment of humans 
more rapidly than A9-THC and penetrated the brain of mice four times 
faster. Ho et al (1970) showed that tissue concentrations in rat 
brains were constant over a period of 20 minutes to 8 hours following 
inhalation of tritiated-ll~-THC; a decline of less than 25°/a of the 
initial brain level was found seven days later. In mouse brain a 
ratio of 6:1 69-THC to 11-hydroxy-69:...THC after intravenous dosing with 
69-THC was reported by Gill and Jones (1972) and a ratio - nearer 2:1 
by Christensen et al ( 1971) and Ryrfeldt et al ( 1973). 
There are no data available regarding the presence of 69 -THC or any of 
its metabolites in the human brain; to extrapolate any data resulting 
from animal studies in this context is hazardous. Cannabinoid metabol-
ism in man is complex and the marked species differences in metabolic 
patterns make the task of correlating in vitro and in vivo animal data 
with expectations in man even more difficult. 
The liver is considered to be the main metabolic site for cannabinoids 
(Christensen et al, 1971; Caldwell and Sever, 1974; Wall , 1971; Wall , 
Brine and Perez-Reyes, 1976); other tissues such as the spleen, lung 
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and small intestine have been reported to be metabolically active 
(Widman et al, 1975; Paton, 1975; Greene and Saunders, 1972) and 
there is evidence that 6 8 - and 6 9 -Tf-C may be partly metabolised at 
the site of its absorption (Lemberger et al, 1973). A microsomal 
drug-metabolising mixed-function oxygenase system involving cytochrome 
P450 is responsible for the matabolism of the cannabinoids to the 
hydroxylated metabolites. NAOPH and molecular oxygen are required 
as cofactors in the pathway (Burstein and Kupfer, 1971). 
Lemberger et al (1970) reported the presence of the 11-hydroxy 
metabolite in plasma as early as ten minutes after administration of 
6 9 -Tf-C but this rapid biotransformation does not lead to quick ex-
cretion (Caldwell and Sever, 1974). It was noted that chronic users 
of cannabis had a more· rapid rate of metabolism than naive subjects 
presumably because of enzyme induction by t he cannabinoids (Lemberger 
et al, 1971 (a), (b)). Cannabidiol and cannabinol have a somewhat 
slower rate of metabolism (Hollister et al, 1972). 
Drug metabolic processes, such as hydroxylation, almost invariably 
result in the metabolite being more polar, and hence more rapidly ex-
creted, than the parent compound. This is typified by the primary 
transformation of 6 9 -Tf-C, cannabidiol, and cannabinol into their 11-
hydroxy derivatives (Agurell et al, 1976; Wal l et al, 1972; Foltz 
et al, 1970; Burstein et al, 1970). Further hydroxylation to the 
B,11-dihydroxy-6 9-THC and 8,11-dihydroxy-6 8-Tf-C leads to reduced 
activity or inactivation (Wall, 1971). 
Hydroxylation of the pentyl side chain at G' 1 and C'2
, further oxida-
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tion to acids, and conjugation, occur before elimination. The full pattern 
of conjugation is not yet clear (Burstein et al, 1972). However 
these compounds are highly polar and lack psychomimetic activity 
(Agurell et al, 1976). In man most of the urinary radioactivity is 
represented by the 11-carboxyl compound (Lemberger et al, 1973). 
As has been shown, the metabolic profile of the cannabinoids is 
highly complex and can be represented as in Figure 1.4.2. 
studies on the excretion patterns of metabolites have relied mainly 
on the excretion of radioactivity from 14c- and 3H-labelled com-
pounds. As may be expected of a lipophilic compound susceptible to 
metabolism, virtually no ~9-TI-C is excreted as such in the urine or 
the faeces (Lemberger et al, 1970; f-bllister, 1974; f-bllister et al, 
1972; Caldwell and Sever, 1974; Lemberger, 1976), the major frac-
tion of-metabolites is excreted via the faeces (Agurell ~t al, 1969; 
Lemberger et al, 1974), with the majority of the urinary radioactivity 
represented by the 11-carboxyl compound (Lemberger et al, 1973). 
Excretion patterns of natural and synthetic cannabinoids other than 
69-THC are not known (King et al, 1976). 
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The elimination of 69-THC in man is biphasic with an initial rapid 
disappearance from the plasma (in a few minutes), followed by a slow 
excretion over several days (Lemberger et al, 1971 (a); Hollister, 
1971). Strong plasma lipoprotein binding (Wahlqvist et al 1970) and high 
affinity of 69-THC for cellular components (Dingle et al, 1973) may 
account, in part, for the slow elimination. 
The pharmacokinetics of 14c-6~-THC in man differ between regular 




1- 2- 3- 4- 5-
CH2CH2CH2CH2CH2 
Hydroxylation at 11-position in vivo and in 
~ or in combination with hydroxylation in 
other positions. Oxidation to a carboxyl com-
pound frequently observed. 
Hydroxylation at 8-position (only in the ~9-
series) 8,11-dihydroxy metabolites frequently 
observed. Sa and BB found only as minor 
metabolites. 
Hydroxylation at 7-position (only in the ~8 -
series) 7,11-dihydroxy metabolites observed. 
Dihxdroxy metabolites 1',11; 2',11, etc. 
occasionally observed Hydroxylation at 1', 2', 
3', 4'. 
Figure 1.4.2. Hydroxylation sites of Cannabinoids 9bserved in vivo 
and in vitro 
a= axial; e = equatorial 
(Adapted from Wall and Brine, 1976) 
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cretion radioactivity in the urine of chronic users of cannabis and 
narve subjects were reported by Lemberger et al (1971 a,b). Although 
both groups of subjects excreted a given dose within the same time 
period, over a 7-day period the proportion of radioactivity excreted 
by the chronic group was larger than that of the na!ve group. This 
evidence supported the claim that chronic users of cannabis had a more 
active metabolism than na1ve subjects probably because of enzyme induction. 
Lemberger et al (1971 a) reported the plasma half-life (t 1) of radio-
2 
activity in non-smokers of cannabis as double that of chronic smokers, 
with the values of t 1 = 56 hours for non-smokers and 27 hours for 
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regular smokers. This discrepancy in the plasma half-lives was at-
tributed to an increased rate of metabolism in chronic smokers rather 
than differences in tissue distribution (Lemberger et al, 1971 b). The 
t1 in specific tissues such as brain is not known (Paton, 1973). 2 
Cannabis is reported to be a safe drug (Leowe, 1946); animal experi-
ments with various pure cannabinoid preparations support this claim. 
Thompson et al (1974) report an Lo50 of oral ~
9 -THC one hundred times 
that of the intravenous route in Rhesus monkeys and Rosenkrantz, 
Fleischman and Grant (1981) report Lo50 values for intravenous injec-
tion of cannabidiol and cannabichromene into Rhesus monkeys of 
212mg/kg and 27Dmg/kg respectively at the 95% confidence level. 
1-bwever, acute toxicity does occur (Section 1.8.1.). 
1.5. MECHANISM OF ACTION 
The literature regarding the possible mechanism of action on the 
brain is controversial. To date, studies have concentrated on various 
animal species (Ho et al, 1976; Holtzman et al, 1969; 89.llager et 
al, 1972). Hollister (1974) found the clinical effects of ~9-THC in 
man were not primarily mediated through changes in the brain concen-
tration of catecholamines. However, recent data are consistent with 
a picture of reduced sympathetic and enchanced parasympathetic activity 
(Benowitz and Jones, 1977). The work of Drew et al (1980) suggests 
that cannabis acts in the hippocampal region and produces behavioural 
changes similar to those resulting from lesions to that region. Effect 
on the concentrati~n of any specific neurotransmitter has not been 
unequivocally demonstrated (Paton, 19'75) and the mechanism of action 
in man remains obscure (Mechoulam and Carlini, 1978; Jaffe, 1980). 
1.6. TOLERANCE AND DEPENDENCE 
There is conflicting evidence in the literature with regard to the 
development of tolerance to, and dependence upon, cannabis. There is 
mounting evidence in favour of a development of tolerance and depen-
dence. The mechanism of tolerance is complex and inadequately under-
stood since there are a number of components of ·~oleranceu (see 






, Figure 1.6.1. Components of Tolerance 
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Pharmacokinetic tolerance refers to alterations in absorption, dis-
tribution, metabolism, and excretion of a drug. Functional tolerance 
means that the target tissue becomes less sensitive to the same dose 
of the drug. Physiological tolerance implies that the target tissue 
undergoes changes to compensate for the drug. Psychological tolerance 
refers to the organisms ability to learn compensatory skills to offset 
the drug-effects on the target tissue. Tolerance to cannabis may be 
related to an adaption by the cells of the central nervous system 
(Lemberger and Rubin, 1978). 
The development of tolerance to the different effects of the drug 
in animal species varies between speci.Bs; daily administration of 
~9-TI-C produces analgesia, hypothermia, and antithyroid effect in 
rats, ataxia and a general depression in dogs, and ptosis and docility 
in monkeys (Kaymakcalan and Ceneau, 1972). 
Cohen (1976) observed tolerance in relation to an increased heart 
rate, reduction of intraocular pressure and bronchial dilation. All 
these effects diminished significantly with continued use of the drug. 
The issue of cannabis tolerance is further complicated by the develop-
ment of· "reverse tolerance", where an increased experience of the drug 
increases the sensitivity to its pharmacological effects. Weil et al 
(1968) showed that experienced habitual users required less cannabis 
than naive subjects to produce the same effects. This phenomenon is 
in contrast to the usual tolerance where an increased experience of 
the drug leads to a decrease in sensitivity. Reverse tolerance is 
thought to be a consequence of enzyme induction leading to increased 
metabolism, in this case the increased rate of conversion of ~8- and 
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ti 9 -THC to their more potent 11-hydroxyl metabolites (s.ee Section 1 .4.) 
(Granville-Grossman, 1978; Lemberger and Rubin, 1978). Experienced 
users would ·have induced enzyme systems and would therefore need less 
drug to produce the desired effects as opposed to naive subjects. 
Other suggestions for the development of reverse tolerance are that 
experienced users become adept in the techniques necessary to obtain 
the maximum absorption of the drug after its inhalation, and that 
they are more likely to perceive subtle drug-induced changes than 
naive users (Hollister, 1971; Granville-Grossman, 1978; Lemberger 
and Rubin, 1978). 
Jones et al (1976) reported that abrupt withdrawal of cannabis, 
following prolonged use of the drug, led to disturbances such as in-
creased salivary flow, hand tremor, raised body temperature, hyper-
activity, and raised intraocular pressure. Subjective complaints 
included impairment of appetite, loss of weight, sweating, chills, 
irritability, restlessness, sleep disturbances and occasional nausea 
and muscle spasms. These withdrawal symptoms essentially agreed with 
the earlier observations of Chopra and Jandu (1973). Bensusan (1971) 
reported intense abdominal cramps in young South African adults who 
were temporarily deprived of cannabis and he alleges that a definite 
withdrawal syndrome occurs following regular cannabis abuse. Chopra 
I 
and Jandu (1976) and Bensusan (1971) emphasize that a large percen-
tage of heavy cannabis users developed dependence on cannabis. 
However, based on studies in Western countries, Thomas and Chesher 
(1973) suggested that cannabis did not cause a true addiction but 
that a psychological dependence may develop in a very mild form . 
In contrast Granville-Grossman ( 1978) makes it clear that cannabis 
users take the drug for its pleasant effects; they show 
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neither drug-seeking behaviour nor craving for the drug on withdrawal 
and thus there is no psychological dependence. 
1.7. PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CANNABIS 
W~despread use of cannabis in Western countries prompted a great deal 
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of research into the psychological and physiological effects of cannabis 
use (Ameq 1958; Weil et a~ 1968; Tart, 1970; Campbell et al, 1971; 
Negrete, 1973; Hollister, 1974; Tylden, 1974; Campbell, 1976; Chopra and 
Jandu, 1976; .Cohen·,. 1976; Mellinger et al, 1976; Mendelson et al, 1978). 
The effect of cannabis varies from individual to individual and there 
is considerable variation in the potency and effects of the drug . 
• 
The expectations and personality of the user, dose of the drug, and 
the setting in which the drug experience takes place all have a strong 
influence on the subjective feelings and the objective signs observed 
following cannabis smoking (Negrete, 1973; Granville-Grossman, 1978). 
Effects due to cannabis are highly dose-dependent and at fairly high 
doses the agent has been thought to induce a psychotic illness present-
ing with hallucinations, delusional ideas, disorganised thought processes, 
depersonalization, alterations of time sense, and panic. This is dealt 
with in detail in Section 1.8. 
1.7.1. Psychological Effects 
Ames et al (1979) conducted an important study with baboons after ad-
ministration of varying oral doses of cannabis. Neuropathological ex-
amination revealed no significant abnormalities. However, the animals 
showed behavioural changes (possibly indicative of cannabis encephalo-
pathy). A striking feature was that all the animals became increasingly 
apathetic and none more aggressive; these changes were dose-related. 
Tart (1970), on the basis of his knowledge of the effects of 
cannabis, designed and distributed a questionnaire among college 
students (mainly Californians) with the instruction that it should 
be answered only by experienced users of cannabis. Experienced users 
were considered to be those individuals who had used the drug 
on a minimum of twelve occasions. The questionnaire contained 206 
net 
items related to .the alleged effects of the drug and 14 itemsAr~lated 
to known effects. This was intended to test the truthfulness of 
the respondents The study provides a fairly comprehensive listing 
of the characteristic subjective effects of the drug which were de-
fined as those rated by more than 50°/o of the respondents as "very 
often" or "usual". These are presented in a modified fora . (Table 
' 
1.7.1.1.)andinclude effects on the mood, memory, motor co-
ordination, cognitive ability, sensorium, time sense and self 
perception. 
t.\io!>C.. ot 
The findings of Hollister ( 1971) concur with "Tart ( 1970) in that 
pronounced euphoria, an altered time sense, sleepiness, difficulty 
in concentration and thinking and dream-like states were observed in 
subjects. It was also observed that vision was sharper (accompanied 
by distortions) and hearing was more discriminating. Jaffe ( 1980) 
reported enhanced visual imagery and a keener sense of hearing and 
Tylden (1974) alteration in mood and motivation in subjects, dis-
tortion of sight and sound, and euphoria. Both Hollister (1971) and 
Tylden (1974) described depersonalization as an effect of cannabis 
administration and prolonged depersonalization occurring months after 
cannabis use has been described by Szymenski (1981). 
The effects of cannabis administration on various aspects of 
psychological perfomances were observed as early as the 1930's 
(Bromberg, 1934) and more systematic research has verified the 
earlier clinical descriptions. A wide range of impaiment of 
intellectual perfomance has been found, including the following 
tasks: digit symbol substitution (Weil et al, 1968) choice 
reaction time (Clark and Nakashima, 1968), digits backwards and 
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Table 1.?.1.1. Characteristic Subjective Effects of ~annabis 
(Adapted from Tart, 19?0) 
VISUAL EFFECTS 
Clarity of visual imagery 
Visual perceptions take on newer meanings 
AUDITORY EFFECTS 
Quality of sound changes 
Notes of music are purer and more distinct 
TACTILE EFFECTS 
Sense of touch is more sensual and exciting 
Touch sensations take on newer qualities 
GJSTATORY EFFECTS 
Food is more enjoyable 
Newer qualities of taste sensations 
OLFACTORY EFFECTS 
New qualities of smell sensations 
SPACE-TIME PERCEPTION 
Changed experience of distance travelled 
Altered time sense 
PERCEPTION OF BODY 
Greater awareness of individual body organs 
PHYSICAL MOVEMENTS 
Enhanced feeling of relaxation 
A,ysical movements s eem exceptionally well co-ordinated and smooth 
INTERPERSONAL RELATIONS 
Enhanced awareness of others 
Less noisy and boisterous 
SEXUAL EFFECTS 
Orgasm has new pleasurable qualities 
THOUGHT PRCCESSES 
Greater awareness of subtle humour 
Present time seems all important 
Difficulty in reading 
Greater acceptance of contradictions of views and ideas 
Short-term memory advers ely affected 
EMOTIONS 
More strongly felt 
Feel more child-like 
Euphoria is experienced 
SELF CONTROL 
Greater acceptance of situations 
Can return to normal psychological state at will 
Difficulty in pursuing tasks 
EFFECTS ON SLEEP 
Easier to go to sleep 
26 
forwards and serial subtractions (Melges et al, 1971; Manna et al, 
1970). other tasks such as concept formation (Klanoff et al, 1973) 
and reading comprehension (Clark ·et al, 1970) were also impaired. 
Cannabis flashbacks - spontaneous recurrences of feelings and per-
ceptions similar to those produced by the drug itself - have been 
reported, The occurrences may range from the vivid recreation of a 
drug-related experience to a mild evocation of a previous incident. 
The origin of such experiences is uncertain and those who have had 
them require little or no treatment (Stanton et al, 1976). 
1.7.2. Effects of Cannabis in combination with Alcohol and other 
Drugs 
Cannabis has been used in combination with alcohol and other drugs and 
the combined effects of these drugs have potentially important implica-
tions. The range of drug combinations is extranely wide but the 
commonest one is alcohol plus cannabis. 
Animal studies of the behavioural effects of the alcohol-cannabis 
combination have generally found that the combined effect is greater 
than that of either when taken singly (Siemans et al, 1974; Pryor et 
al, 1977) the limited human research to date is generally consis-
tent with the results of animal research. Experiments using alcohol 
levels within the range commonly found after social drinking showed 
that performance reductions from combined use with cannabis are greater 
than those from the use of either alone. Such decranents have been 
detected in reasoning, manual dexterity, and standing steadiness 
(Chesher et a l , 1976; Chesher et al, 1977). Combined use increased 
reaction time and reduced cognitive performance and psychomotor 
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co-ordination more than either alone (Belgrave et al, 1979). 
In a study of seven healthy male volunteers aged 29 - 29, &Jlkovski 
and Vachon (1977) found that four of the seven developed intense 
nausea and vomiting after drinking a moderate amount of alcohol. All 
four men were markedly incapacitated during the height of the adverse 
effects, recovering in 3 - 4 hours. The fact that not all seven 
subjects tested were equally affected illustrates the large individual 
differences in responses. No adverse effects occurred when the ex-
periment was repeated with half the initial dose. 
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Hemphill and Fisher (1980) found that of 604 White and Coloured male 
offenders in the Cape referred for inpatient psychiatric observation, 
52% habitually indulged excessively in alcohol, drugs (mostly cannabis) 
or both. There was no evidence of a potentiating action between alcohol 
and cannabis towards violent behaviour. If anything, cannabis appeared 
to attenuate the action of alcohol and possibly to inhibit violent im-
pulses in aggressive and psychopathic individuals. 
Animal research has raised the question of a possible cross-tolerance 
between alcohol and cannabis (Siemans et al, 1979) but this has not 
yet been resolved in humans. 
There have been few human studies of the interactive effects of 
cannabis with drugs other than alcohol. However, limited evidence 
suggest that such interactions may be significant. Benowitz and 
Jones (1977 (a)) showed that chronic cannabis use may affect the 
persistence of barbiturates in the body as well as their rate of 
absorption. The possibility that absorption, distribution and 
metabolism of therapeutic drugs might be modified by concomitant 
cannabis use has been raised. Much work remains to be done in this 
area. 
1.7.3. The A-notivational Syndrome 
The term "amotivational syndrome" is used to describe the progressive 
changes in what are accepted as conventional levels of motivation 
(Thomas and Chesher, 1973). This syndrome was defined by the 
Canadian Commission of Inquiry on the Non-Medical Use of Hemp (quoted 
by Granville-Grossman, 1978) as "a set of symptoms including apathy, 
ineffectiveness and non-productiveness considered to reflect a 
deficit in general motivation ... resulting from the chronic use of 
certain drugs". 
Thomas and Chesher (1973) in their review report that the syndrome 
manifests as a marked decline in personal hygiene, social interaction 
and sexual drive. In its extreme form the individual becomes very 
passive, his only interest being related to the acquisition and use 
of cannabis. There is also intellectual deterioration as manifested 
by shortened attention span, impaired ability to plan and organize 
normal activities of life, low frustration tolerance, and the use of 
magical or primitive modes of thought. 
A study claiming to support the concept of an amotivational syndrome 
due to cannabis was that of Chopra and Jandu (1976) who observed 275 
chronic users of cannabis in India. They noted that subjects were 
depressed, quiet, apathetic, and lacked interest in their surroundings, 
work and families. However, because the subjects were in poor 
physical health and malnourished, their apparent intellect ual 
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deterioration could not be ascribed primarily to cannabis. 
Mellinger et al (1976) studied 960 freshmen of the University of 
California at Berkeley over a 2! year period and noted that approx-
imately 59% used cannabis. Of the cannabis users, 6% did not com-
plete their courses of study compared to only 3% of the abstainers. 
On further analysis of the data, it energed that failure to complete 
the course of study was dependent on social factors other than can-
nabis use. The concept of a cannabis-induced amotivational syndrome 
was thus considered to be invalid. 
Campbell (1 9761 in a study of 1000 Canadian university students, 
reported that the higher the intake of cannabis the greater the ten-
dency to poor examination scores although he recognized the contribu-
tion of socio-cultural factors. 
Levin (1973) believes cannabis use to be implicated in a number of 
psychiatric conditions. Levin (1974) studied 444 white South African 
l\ational Servicenen. A significant correlation between cannabis use 
and amotivation was found and cannabis use was therefore found to be 
a prominent factor in an amotivational syndrome. 
Opinions therefore differ as to whether the relationship between 
chronic cannabis use and an amotivational syndrome is a casual or an 
associative one and more emphasis on social factors and psychological 
background is required when evaluating such a syndrome in Western 
countries. Much of the previous work relates to countries such as 
India and Jamaica where cannabis use is endenic (Thomas and Chesher, 
1973; Thacore, 1973; Beaubrun and Knight, 1973; Knight,1976). 
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1.7.4. Physiological Effects 
Acute physiological effects of cannabis use has generated extensive 
investigation, particularly in the past 15 years (Weil et al, 1968; 
Cohen, 1976; Jaffe, 1980; Ohlsson et al, 1980). 
The most consistently reported cardiovascular effects following 
cannabis use are a moderate increase in heart rate, an increase in 
systolic pressure, and a reddening of the conjunctivae (Weil et al, 
1968; Jaffe, 1980; Ohlsson et al, 1980). The increase in heart rate 
is dose-dependent both in onset and duration of action and an inc-
rease of 20-50 beats per minute is not uncommon, tachycardias of 140 
beats per minute having been reported (Jaffe, 1980). 
Weil et al (1 968) found no change in the respiratory rate in na!ve 
users of cannabis but a significant increase in the respiratory rate 
of chronic users. This increase in respiratory rate was accompanied 
initially by a mild bronchial airways obstruction and later by dila-
tion of the bronchi. The acute response to &9-Tf-C administration by 
oral, intravenous, or aerosol routes was relatively long-lasting with 
significant bronchodilation (Jaffe, 1980). 
Cohen (1976), Crawford and Merrit (1979) and Merrit et al (1981) 
reported a lowering of intraocular pressure with no alteration of 
pupil size following the use of cannabis, which may therefore be use-
ful in the treatment of glaucoma. 
Blood sugar levels were not altered following the use of cannabis and 
therefore the hunger produced by the drug must be mediated by mechan-
isms other than those involving hypoglycaemia (Weil et al, 1968). 
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The possibility of damage to physical health by the long term use of 
cannabis has become a matter for serious concern and investigation in 
recent years but the findings to date tend to be equivocal. 
Campbell et al (1971) did air encephalography on chronic users of 
cannabis who showed personality changes; they demonstrated a partic-
ular pattern of cerebral atrophy. Stefanis et al (1976) however, 
found no evidence of cerebral atrophy in 47 long-term cannabis users 
in Greece; and Co et al (1977), using computerized axial tomography, 
also failed to demonstrate cerebral atrophy among their chronic users 
of cannabis. DiBenedetto et al (1977) could not demonstrate deterior-
ation of peripheral nerve function in heavy and casual users of 
cannabis. 
Kolodney et al (1974) found depression of plasma testosterone levels 
in proportion to the degree of cannabis use. On withdrawal of the 
drug, or when cannabis use continued with the concomitant administra-
tion of human chorionic gonadotrophin, plasma testosterone levels 
were elevated above normal. Cohen (1976) showed that the smoking of 
cannabis caused a significant depression of plasma testosterone levels 
within 2 - 3 hours of administration, with chronic intoxication per-
sistently associated with lowered plasma testosterone levels. However, 
Mendelson et al (1978) in a study of 24 males before, during and after 
a 21-day period of cannabis use, noted that plasma testosterone 
levels were unchanged and that chronic users had higher levels than 
casual users. The question of plasma testosterone elevation and 
depression in cannabis users thus remains unsettled. 
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~9-THC has been investigated as an analgesic in humans. Noyes et al 
(1975) reported good analgesic activity in patients with chronic pain 
of metastatic carcinoma. Raft et al (1977) rep:1rted ti-9-THC as a poor 
analgesic for surgical pain and pain induced by pressure and shock in 
experimental conditions. However cannabinoids are being investigated 
in the hope that one of them will prove to be an effective analgesic 
with a lower dependence liability than the narcotic analgesics in 
humans (Harris, 1979). 
83.llan et al (1980) and The Lancet (Editorial, 1981) reported the use 
of ~9-Tf-C as an antiemetic in patients receiving chemotherapy for 
cancer. However, there is some evidence to suggest that oral~9-THC is 
not the ideal drug to prevent the emetic side-effects of cytotoxic 
chemotherapy (Calls, 1981). It has been claimed that cannabis has 
anti-convulsent and anti-pyretic actions and that it may be used in 
the treatment of wide-angle glaucoma (The Lancet, (Editorial), 1975; 
Pradhan, 1977; Newell et al, 1979) and cannabidiol has been used to 
treat epilepsy (Cunha et al, 1980). 
Abel (1980) summarized the possible teratogenic effects of cannabis 
in various animal species and he concluded that the cannabinoids did 
not produce gross malformations except at relatively high doses. The 
oral route of administration produced the least and the intraperitoneal 
route the most teratogenic effects. Direct teratological potential of 
the cannabinoids remains equivocal. To date there is no available 
data on the possible teratogenic effects of cannabis in humans and 
further investigation is indicated. 
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1.8. CANNABIS PSYCHOSIS 
Cannabis is usually smoked by subjects for its hedonistic qualities 
and the degree of intoxication achieved and the range of experiences 
is highly variable (see Section 1. 8.). However, as varied as the 
pleasurable effects, so too are the adverse reactions, which are 
generally threatening and extremely unpleasant (Talbott and Teague, 
1969). There is much controversy surrounding the cause and nature of 
these undesired psychological effects and Negrete (1973) has proposed 
a classification of possible psychological effects of cannabis. This 
scheme (modified slightly) is presented below and has been adopted as 
a working classification. 
1.8.1. severe intoxication 
1.8.2. pathological intoxication 
1.8.3. acute cannabis psychosis 
1.8.4. sub-acute and chronic cannabis psychosis 
1.8.1. Severe Intoxication 
~ The ratio of the lethal dose to the effective dose of cannabis is high. 
However, in larger than customary doses, or among those with a partic-
ular sensitivity to the drug, following administration of the drug, 
paranoid ideas may be expressed, dizziness, depression, fatigue and 
visual impairment may be experienced. Cbjective effects may inc1ude 
loss of control of behaviour, clouding of consciousness and distur-
bance of memory. Physical disturbances such as headaches, gastro-
intestinal distress, soreness and dryness of the tongue, cough and a 
bad taste in the mouth may also be experienced. 
On the administration of much larger amounts of cannabis, or with 
accidental overdosage, more serious disturbances are noted. Garret, 
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Braithwaite and Teale (1977) reported a case of a young man who was 
found collapsed and unresponsive; features of decorticate rigidity 
were noted with brisk deep reflexes and equivocal plantar responses. 
Twelve hours after hospitalization the patient began to improve and 
over the next two days he seemed to be hallucinating and his speech 
was incoherent. After 4 days he recovered completely. Analysis by 
radioimmunoassay of a sample of the patient's blood showed cannabinoid 
levels of 180µg/e cannabinoids. 
Intravenous administration of crude cannabis extracts resulting in an 
acute illness with multi-system involvement, including gastro-
intestinal, cardiovascular, haematologic and pulmonary manifestations 
have been reported. All observed abnormalities reversed within a 
few days of onset with no significant sequelae (Hendersen et al, 
1968; King and Cowen,. 1969; Gary and Kelong, 1970; King and 
Petchet, 1970; Lundberg, Andersen and Prosnitz, 1971; Payne and 
Brand, 1975; Farber and huertas , 1976; Vaziri et al, 1981). 
1.8.2. Pathological Intoxication 
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Occasionally the common psychological experiences of the drug may be 
replaced by unpleasant feelings of anxiety, fear (especially of becom-
ing insane) and a sense of helplessness. Occasionally acute depression, 
severe depersonalization and derealization are associated with these 
unpleasant feelings. The individual usually has a good recollection 
of the events and the symptoms experienced. Because of their benign 
course, the majority of these reactions subside spontaneously and are 
not bro~~nt to the medical practitioner's attention. 
1.8.3. Acute Cannabis Psychosis 
Reports of acute psychoses have appeared in the literature. These 
occurred among chronic users of cannabis (who had no previous history 
of psychiatric illness) usually after a period during which 
the drug was taken in larger than customary doses (D1unjibhoy, 1930; 
Bromberg, 1934; D3.vison and Wilson, 1972; Thacore, 1973; Chopra and 
Smith, 1974; Thacore and Shukla, 1976; Talbott and Teague, 1969). 
This category includes all thoEEpsychotic and hallucinatory experiences 
which follow a cannabis experience. Thi$. type of psychosis ic.. less 
corrmon in developed Western countries and this diagnostic category has 
evoked considerable sceptic.ism and controversy. The clinical picture is 
pleomorphic but generally full recovery is the rule after a period of 
a few days to a few weeks. 
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Thacore (1973) noted the schizophrenia-like nature of the illness in 
four Indian cases where the prominent symptoms included paranoid idea-
tion, anxiety, apprehension, suspiciousness, and auditory hallucinations: 
all these features cleared within a few days. There was no disturbance 
of memory, disorientation,nor clouding of consciousness. In a separate 
study Thacore and Shukla (1976) compared 25 consecutive cases of 
schizophrenia-like psychosis attributed to cannabis with 25 consecutive 
patients with paranoid schizophrenia. Those patients -with cannabis 
psychosis differed from the cases of schizophrenia in terms of 
behavioural manifestations; they demonstrated bizarre and violent 
behaviour and possessed some insight into the nature of their illness. 
Patients with cannabis psychosis shared rapid ideation and flight of 
ideas, whereas the characteristic thought disorder was found mostly in 
schizophrenic patients. 
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Chopra and Smith (1974), in contrast to the case descriptions of Thacore (1973) 
Thacore & Shukla 6976) where there was no evidence of obvious organic 
mental disturbance, cited 200 cases of acute psychotic reactions 
among Indians with the following organic symptoms present: 
sudden onset of confusion, emotional lability, depersonalization, 
delusions, visual hallucination£, temporary am~esia, disorientation, 
and delirium. Recovery was extremely rapid in those patients without 
a previous history of psychiatric disturbance, but recovery of 
patients with a history of personality disturbance was less certain. 
Talbott and Teague ( 1969) observed a clinical syndrome of acute 
psychosis associated with cannabis derivatives in 12 Jlmerican soldiers 
in Vietnam. The syndrome was characterised by organic and paranoid 
features. These cases · differed from those described by Thacore (1973), 
Thacore and Shukla (1976) and Chopra and Smith (1974) in that in all 
the American patients the symptoms resulted from a first exposure to 
the drug. Talbott and Teague (1969) were convinced that cannabis was 
directly and essentially involved in the development of the syndrome 
although they recognized that extraneous factors, such as environmen-
tal stress, might have affected the symptoms. 
The case of a young white Englishman , reported by Davison and Wilson 
(1972), demonstrated that cannabis caused the patient's mental dis-
turbance. The improvement in his condition was rapid in hospital but 
relapses occurred on a number of occasions during weekend leave and 
shortly after discharge. When the possibility of a drug-induced 
psychosis was realised and suggested to the patient, he admitted to 
cannabis smoking prior to the psychotic episodes. 
. "Ganja" psychosis, as described by Knight (1976), is included in this 
diagnostic category. The clinical features in Jamaican patients were 
a history of disturbed (aggressiv~) behaviour and schizophrenic-like 
features following several days of unaccustomed cannabis use - either 
in larger than usual amounts, or by persons who had not previously 
used the drug. Many of these patients were ultimately diagnosed as 
schizophrenic (Knight, 1976). 
Bourhill (1912), quoted by du Tait (1980), found that 18% of all males 
admitted to the Pretoria Native Asylum suffered from "dagga insanity". 
Watt and Breyer-Brandwijk (1932) found that cannabis could precipitate 
an acute psychosis in their South African Blacks. Tacker (1966) des-
cribed a psychosis similar to schizophrenia in South African Blacks 
who habitually used cannabis. 
1 . 8. 4. fub-Acute and Chronic Cannabis Psyc_hosis 
The psychoses in this category are believed to be caused by heavy, 
chronic consumption of the drug, characterised by severe deteriora-
tion of the higher cognitive functions. Negrete (1973) cites the 
work done by Christozov (1965) on 140 cases in Morocco. Although 
patients manifested symptoms of schizophrenia, Christozov recommended 
that this diagnosis be discarded since patients showed complete 
recovery. 
Spencer (1971) reported a number of cases of sub-acute schizophrenia-
like psychoses in the Bahamas. The features of the illness included 
aggressive behaviour, gross psychomotor over activity, bizarre and 
grandiose delusions, passivity and amnesia for the onset of their 
illness. These l asted a few weeks only and they were apparently 
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precipitated by the excessive use of cannabis. However, this psy-
chosis, which differed from classical schizophrenia and manic-
depressive illness, was specifically rel ated to the hcbitual use of 
cannabis by predisposed individuals. 
Chronic schizophreniform psychosis in Jamaicans has been described by 
Knight (1976). Cannabis use was considered a contributory factor to 
the cause of the psychosis. 
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Kolansky and Moore (1971; 1972; 1975) reported a number of cases in 
the United States all of whom demonstrated symptoms which began while 
using cannabis - flattening of affect, impairment of memory, delusions, 
and depression. The severity of symptoms correlated with the fre-
quency and duration of cannabis use. It was concluded that the drug 
was the cause of mental disturbances and that tJ..9 -THC caused c hemical 
damage to the cerebral cortical cells resulting in an encephalopathy. 
Kolansky and Moore (1975) considered the psychological symptoms to be 
representative of the cerebral atrophy as reported by Campbell et al 
(19?1) (see Section 1.7.3.). 
Treffert (19?8) reported 4 cases of well-documented schizophrenia in 
which the use of cannabis allegedly induced an exacerbation of psy-
chotic symptoms in patients whose psychoses were in partial or total 
remission prior to use. It was concluded that "while marijuana can 
perhaps be safely used by many persons, this is not so with the 
schizophrenic". 
Most of the work derives from the East where cannabis has been used 
for centuries (Diunjibhoy, 1930; Bromberg, 1934; Christozov, 1965 ; 
Thacore, 1973; Chopra and Smith, 1974; Thacore and Shukla, 1976). 
The paucity of descriptions from Western countries might be ascribed 
to the mildness of local cannabis preparations and ~he relatively 
recent use of the drug (Milman, 1969; Persyko, 1970; Jaffe, 1980). 
In summary, cannabis-induced psychosis is a highly controversial 
subject and its existence will continue to be debated upon for many 
years. Some argue that a valid clinical syndrome exists, having a 
central core and consistent signs and characteristics; others refute 
the existence of a cannabis-induced psychosis and maintain that 
affected individuals had a predisposition to psychosis which, on ex-
posure to the drug, declared itself overtly. The present study has 
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2.1. PATIENT SELECTION 
This study formed part of the Medical Research Council Clinical 
Psychiatry Research Unit's study entitled 'The Course and Progress of 
Serious Mental Illness'. Coloured male patients from certain magis-
terial districts of the Valkenberg Hospital catchment area of the 
Western Cape were sel~cted (see Appendix). Patient selection was done 
independently of the investigator. It was made randomly and included 
every fourth patient from these specified areas actnitted to the 
Coloured actnission ward of Valkenberg Hospital. All selected patients 
were investigated with respect to urinary cannabinoids, toxicological 
screening, and ethanol determination; the PSE was also administered 
in each case on two occasions - on admission and seven days later. 
Patients were studied in three groups of twenty each on the basis of 
the following criteria: 
i. Those patients in whom urinary cannabinoid levels exceeded 
60 micro grammes cross-reacting cannabinoids per gramme creatinine 
(µgCRC/g creatinine) on admission; this group was described as the 
'high cannabis' group. 
ii. Those patients in whom urinary cannabinoid levels were less 
or 
thanhequal to 59µgCRC/g creatinine on admission; this group was des-
cribed as the 'low cannabis' group. 
iii. Those patients in whom urinary cannabinoids were not detected 
' 
on admission. This group served as the control group and were matched 
as closely as possible with the high cannabis group with reference to 
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clinical diagnosis on adnission, race, sex, age, first or multiple 
admissions to Valkenberg Hospital, and social class '(see Appendix); 
this group was described as the 'psychotic control' group. 
2.2. PRESENT STATE EXAMINATION 
In psychiatry, mental disorders are not dealt with as discrete 
clinical entities but rather as constellations of overlapping symptoms; 
this results in a blurring of diagnostic categories. Techniques for 
classifying abnormal mental states are many, the most familiar being 
a clinical diagnosis. Since laboratory tests are infrequently avail-
able for the confirmation of diagnosis, history taking and clinical 
observations are critical in this field. 
The traditional medical approach to diagnosis may be too narrow for 
dealing with psychotic patients. Psychiatric and medical interviews 
share the same objective: they elicit information from a patient, 
lead to an accurate diagnosis and result in an effective treatment. 
They differ, however, in detail and emphasis. The techniques of 
questioning range from a non-directive (patient-orientated) interview 
to a directive (doctor-orientated) interview. In general a compromise 
between these extremes is used to satisfy the needs of both parties 
the patient's need to communicate and the doctor's need to elicit 
information. 
The advances in the pharmacological, biochemical, and genetic aspects 
of psychiatry emphasize the need for a more scientific approach to 
clinical analysis. The Present State Examination (PSE) was devised 
for this purpose. 
The PEE is a guide to structuring a clinical interview to assess the 
'present mental state' of adult patients. Wing and his colleagues 
(1967) developed the PSE as a research instrument to represent the 
current clinical practice and teaching. Although originally con-
structed in English, the PEE has been translated into other languages 
including Arabic (Ckasha and Ashour, 1981), Afrikaans, and Xhosa (MRC 
Clinical Psychiatry Research Unit, 1981). 
Studies on its reliability have been carried out and coefficients of 
variation in measuring psychotic symptomatology for various symptoms 
based on a single interview ranged from 0,62 to 0,97. The reliability 
between interviewer and observer ratings ranged from 0,58 to 0,96 
(Wing et al, 1967; Kendell et al, 1968). The inter-observer 
reliability ratings of individual items have been extensively studied 
by the US-UK Diagnostic Project and the World Health Organization in 
various countries. High levels of reliabilit y have been achieved 
even when there were marked transcultural differences (Wing et al, 
1974). 
The PSE is virtually a miniature textbook of 'functional' psych-
pathology and, together with the glossary of definitions of symptoms , 
can be used as a standardization of the diagnostic examination common 
to world psychiatry (Wing et al, 1974). 
The interview is structured by following a question-schedule (see 
Appendix) to elicit information concerning 140 rateable items, most 
of which represent psychiatric symptoms defined in a glossary of 
definitions. Glossary definitions are given as clearly as possible 
so that ratings are comparable even when undertaken by psychiatrists 
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of different schools of thought; this makes reliability the outstand-
ing feature of the PSE. The PSE ratings are made by a competent 
interviewer familiar with the glossary definitions and able to reach a 
good clinical judgement on the presence or absence of symptoms. Ex-
perience and training are therefore important (Wing and Sturt, 1978). 
Based on the interview which covers symptoms experienced during the 
previous four weeks, and abnormalities of speech, behaviour and affect 
observed during the interview itself, the interviewer records his 
decision as to whether each symptom is absent or present and, if 
present, to a moderate or severe degree. A computer programme named 
CATEGO processes the data rated during the interview to give a stan-
dardized diagnostic grouping according to the International Classific-
ation of Diseases (1965 Revision). The majority of symptoms are 
grouped into 38 'syndromes' (such as 'auditory hallucinations' or 
'situational anxiety') and a score can be derived for each syndrome, 
consisting of the summed ratings on the constituent items. The syn-
drome scores can themselves be summed to give a total PSE score. The 
syndromes can be summed into four subclasses: behaviours~ 8"\a other 
Sj"'dromes (BSD), delusional and hallucinatory syndromes (DAH), specific 
neurotic syndromes (SNR), and non-specific neurotic syndromes (NSN). 
(See Appendix) 
As a reliable system of measurement and classification, the PSE allows 
comparison with diagnoses given by clinicians and the class allocation 
given by the CATEGO Programme. The scientific uses of the PSE are the 
description (in terms of symptoms , syndromes and classes) of psycho-
pathological characteristics of groups of people at a specific point 
in time, the provision of an instrument capable of reliably providing 
scores representing various areas of psychopathology and valuable for 
measuring change. 
2.2.1. Method for Implementing PSE 
Every patient admitted to the study was subjected to two PSE assess-
ments. The initial PSE was administered as soon after admission as 
possible, and seven days were allowed to elapse before a second PSE 
was administered. The second PSE was to assess the change in 
symptomatology over that period. If in certain cases the seven-day 
period between PSEs could not be strictly adhered to owing to patient 
non-co-operation or other factors the time interval between PSE 
assessments was allowed to be extended to eight to ten days. 
All interviews were performed by trained members of the MRC Clinical 
Psychiatry Research Unit; all completed PSE ratings were computerized 
by the Medical Research Council, Bellville. 
2.3. URINARY CANNABINOID Af:EAY 
2.3.1. Introduction 
Several qualitative tests have been available for the detection of 
cannabinoids but these methods could only detect cannabinoids in 
plant material and were too insensitive for use with biological 
fluids from man. 
Major problens were associated with the development of detection 
methods for cannabinoids in biological fluids; tetrahydrocannabinol 
is highly lipophilic and therefore distribution from the central 
compartment is rapid; the oral effective dose in humans is 20-SOµg/kg 
body weight and the amount absorbed when smoked is 25-SOµg/kg 
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(Mechoulam and 83.oni, 1967 (b)) so that blood levels would be expected 
• to be low; a major proportion of the metabolites is excreted in the 
faeces. 
Several years ago Schneider et al (1973) described a homogenous 
immunoassay technique that utilized the observation that certain 
enzymes can be inhibited by antibodies directed against the haptens to 
which the enzymes were covalently bound. This technique, called 
Enzyme Multiplied Immunoassay Technique (EMITR) is used for the micro-
analysis of specific compounds in biological fluids. 'Homogenous ' 
enzyme immunoassay was so termed to distinguish this method from other 
immunochemical methods that are 'heterogenous', in which at some stage 
the antigen is physically separated from the antibody to which it is 
bound. 
R The principle of the EMIT assay: 
A drug is labelled with an enzyme. 'Mien the enzyme-labelled drug 
becomes bound to an antibody against the drug, the activity of the 
enzyme is reduced. Free drug in a sample competes with the enzyme-
labelled drug for the antibody, and thereby decreases the antibody-
induced inactivation of the enzyme. Enzyme activity correlates with 
the concentration of the free drug in the sample and it is measured 
by an absorbance change resulting from the enzyme's catalytic action 
on a substrate (Rubenstein et al, 1972). 
R In the performance of an EMIT assay for urinary cannabinoids urine is 
mixed with a reagent containing a tetrahydrocannabinol derivative 
together with the coenzyme nicotinamide adenine dinucleotide (NAO) for 
the enzyme malate dehydrogenase. Binding occurs to any drug in the 
urine that is 'recognized' by the antibody . A drug labelled with the 
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enzyme malate dehydrogenase is then added. The labelled drug combines 
with any renaining unfilled antibody binding sites, and the enzyme 
activity is thereby proportionally reduced. The residual enzymatic 
activity is directly related to the concentration of the drug present 
in the urine. The active enzyme converts NAO to NADH, resulting in an 
absorbance change that is measured spectrophotometrically. 
Using different enzymes this technique has been used clinically to 
assay various compounds: lysozyme from Micrococcus luteus in the 
determination of opiates (Schneider et al, 1973); glucose-6-phosphate 
dehydrogenase from Leuconostoc mesenteroides in the measurement of 
digoxin (Chang et al, 1975); pig heart mitochondrial malate dehydro-
genase in the assays for morphine (RONley et al, 1975), thyroxine 
(Ullman et al, 1975), and cannabinoids (Ra.vley et al _, 1976). The 
latter enzyme, labelled with a derivative of t:,9-THC, was used by 
Rodgers et al (1978) for the measurement of cannabinoid metabolites 
and t:,9-THC in urine. 
Rodgers et al (1978) used 11-nor-t:,9-THC-9-carboxylic acid, a metabolite 
of t:,9-THC, to calibrate the EMITR assay quoted in this study . It was 
shown that with 15µg 11-nor- t:,9-THC-carboxylic acid per liter as the 
cut-off concentration, the assay could detect 25µg 11-nor-!:,9-THC-9-
carboxylic acid with greater than 95% confidence. The assay was 
found to be most sensitive to 11-nor- t:,9 -THC-9-carboxylic acid and to 
11-hydroxy-t:,9-THC, with the response to cannabinol and t:,9-THC itself 
approximately 39% less. 
The cross-reactivity of the assay to a number of other drugs, natural 
hormones and their metabolites was also examined and none of these 
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compounds was found to cross-react significantly, even when their 
concentration grossly exceeded that normally found in the urine. 
Pooled normal urine was supplemented with 15, 25, and 75 µg 11-nor L\9 -
Tf-C-9-carboxylic acid per liter to determine the precision of the 
cannEbinoid enzyme immunoassay. Each portion was analyzed repetitive-
ly by a single operator. The results showed high precision at all 
three concentrations (Table 2.3.1.1.). 
Table 2.3.1.1. Precision of replicate cannabinoid assays of pooled 
urine containing 11-nor-6 9-THC-9-carboxylic acid (From Rodgers et al, 
1978). Cue to the unavailability of 11-nor-69 -THC-9-carboxylic acid 
the validation of Rodgers et al (1978) who used the identical materials 
and equipment is quoted. 
Concentration (µg/i) 15 25 75 
Assayed Mean (µg/i) 15, 1 25,3 74,9 -
Replicate Assays 20 20 20 
SD (µg/i) 0,60 D,75 1,48 
CV ( °/o) 4,0 3,0 2,0 
Very recent work by O'Connor and Rejent (1981) tested the validity of 
the EMITR system by comparing it with other established analytical 
methods including RIA and two different G::/MS procedures. They sugges-
R ted that the EMIT assay may be superior to other techniques in sen-
sitivity, ease, speed of performance, and capacity for multi-sampling 
handling. Peel and Perrigo (1 981) found the method precise, useful, 
and applicable in the screening of blood samples for the presence · of 
cannabinoids. It should be noted that the period of intoxication lasts 
for anything from one to four hours (Paton and Pertwee, 1973), while 
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the peak cannabinoid concentration in human urine occurs between two to 
six hours and can remain high for longer than twenty four hours follow-
ing exposure to the drug (Rodgers et al, 1978), the assay is thus limited 
in that it cannot measure the degree of intoxication but is useful as an 
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indicator of the recent use of cannabinoids. The advantages of the 
homogenous immunoassay for cannabinoids lie in the non-invasive collec-
tion of sample, only 50µt being required; the assay itself requires 
little sample manipulation or operator training, is relatively cheap 
(84.50 per assay), and rapid (45 seconds). More important, this 
assay was the only practical choice for this study; patients may 
have been delayed entry into the hospital and further delayed before 
a sample could be taken and the chances of detecting any meaningful 
cannabinoid level in the blood at the time of admission were 
negligible. 
2.3.2. Instruments and Operating Conditions 
i. Spectrophotometer 
A Stasar 111 spectrophotometer (Gilford Instrument Laboratories, Ohio, 
USA), equipped with a 3017T thermal control unit was used. The enzyme 
reaction was monitored by the change in absorbance at 340nm. The mode 
was set at concentration, the concentration calibrator was adjusted 
for an amplification factor of 2,667 amplification, the temperature 
was set at 30°C, sample volume at 0,5-0,7ml, vacuum at 200-250mmHg, 
and the slit at 0,8mm. 
ii. Cata Processor 
A Syva CP-5000 8v1ITR Clinical Processor was used. The instrument 
interfaces with the spectrophotometer and was programmed to assign a 
sample number, provide a printed record of the initial absorbance of 
a sample, and print the change of absorbance as a function of time. 
The instrument controlled the timing of the assay and was set to 
provide a fifteen second delay for temperature equilibration after 
the sample was aspirated into the flow cell, followed by two absorbance 
readings, thirty seconds apart. 
iii. Pippeter-Diluter 
A Syva Pippeter-Diluter (Model 1500) was used. The instrument was set 
to aspirate 50µe of sample and to deliver the sample plus 250µe of 
buffer solution. 
iv. Miscellaneous Apparatus 
Plastic containers were used to collect the urine samples and 
VacutainerR glass tubes for the storage thereof. These containers are 
used routinely for the storage of drug-containing specimens. 2ml dis-
posable conical beakers (Fisher Scientific Company, Pittsburgh, USA) 
were used in the assay. 
2.3.3. Reagents 
R R The EMIT -d.a.u. Cannabinoid Urine Assay and the EMIT -d.a.u. Canna-
binoid Urine Calibrators were manufactured by Syva, Palo Alto, USA. 
The EMITR-d.a.u. Cannabinoid Urine Assay was supplied containing: 
i. EMITR Cannabinoid Antibody/Coenzyme Reagent A 
ii. EMITR Cannabinoid Reagent 8 
iii. EMITR Cannabinoid Buffer Concentrate 
i. EMITR Cannabinoid Antibody/Coenzyme Reagent A 
This was supplied as a lyophilized preparation in a rubber-stoppered 
clear glass vial. The reagent contained a standardized preparation of 
immunized sheep gamma-globulin, the coenzyme nicotinamide adenine 
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dinucleotide (NAO), stabilizers, and preservatives. The reagent also 
contained 0,15M glycine to buffer the reagent at pH 5,0. 
ii. EMITR Cannabinoid Reagent 8 
Reagent 8 was supplied as a lyophilized preparation in a rubber--
stoppered clear glass vial. The reagent contained an unspecified 
~9 -TI-C derivative chemically coupled with pig-heart mitochondrial 
malate dehydrogenase. The reagent also contained stabilizers, pre-
servatives, and 0,01M Tris-HC1 to buffer the preparation at pH 7,4. 
Reagent A and Reagent 8 were supplied to be used together; it was 
considered mandatory that the Reagent A and the Reagent 8 supplied in 
any one kit be used together. 
iii. EMITR Cannabinoid Buffer Concentrate 
The buffer concentrate was supplied as a clear liquid in a rubber--
stoppered clear glass vial. The buffer concentrate contained malate 
as enzyme substrate. 
The EMITR-d.a.u. Cannabinoid Calibrators were supplied in rubber--
stoppered amber-coloured glass vials. Calibrators were supplied con-
taining D, 20, and 75µg/ml 11-nor-~9-THC-9-carboxylic acid as 
lyophilized preparations. 
2.3.4. Collection and Storage of Urine Samples 
A single urine sample was collected from each patient within one hour 
(or as soon as possible) after admission to the hospital ward. Within 
twenty four hours of collection two 5ml aliquots were drawn from the 
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bulk specimen. One aliquot was retained for the cannabinoid assay. 
The second aliquot was sent to Conradie Hospital Regional Laboratory 
for urinary creatinine determinations; the cannabinoid assay is semi-
quantitative and a urinary creatinine determination would allow an 
improved result to be reported. 
The pH of each specimen was checked on collection of each sample using 
MerckR Universal Indicator strips. 
Samples that could not be assayed immediately upon collection were 
stored in rubber-stoppered glass tubes at -20°C. The samples were 
allowed to stand at room temperature for at least two hours and the 
pH checked prior to the assay. 
Subsequent samples were taken each morning between 7 a.m. and 8 a.m. 
from patients in whom cannabinoids were detected in the initial sample. 
This procedure was repeated until a negative assay result was obtained 
for two succesive days. 
2.3.5. Preparation and Storage of Reagents 
Reagent A was reconstituted by the addition of 8,0ml distilled water. 
Reagent B was reconstituted by the addition of 6,0ml distilled water. 
The reagents were allowed to equilibrate overnight at 2-8°C before 
use and thereafter they were stored at 2-8°C. The reconstituted re-
agents could be used for twelve weeks under normal conditions. 
Each Cannabinoid Urin~ Calibrator was reconstituted by the addition 
of 3,0ml distilled water and allowed to equilibrate overnight at 2-8°C 
before use. The reconstituted calibrators could be us ed for at least 
fourteen days under normal conditions. 
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The Buffer Concentrate was diluted to 150ml with distilled water. The 
diluted buffer was stored at room temperature in a glass-stoppered 
opaque glass container and could be used for twelve weeks under normal 
conditions. 
2.3.6. Posay Procedure 
All samples and reagents were allowed to approach room temperature by 
standing at ambient temperature for at least one hour prior to use. 
All instruments were set and checked for the correct settings. The 
spectrophotometer was zeroed using distilled water. Sufficient dis-
posable cups were set in the work rack. The assay was run as follows: 
i. Using the Pippeter-Diluter, 50µ~ sample (or calibrator) w~s 
sampled and delivered with 250µ~ buffer into a 2ml disposable cup. 
ii. Using the Pippeter-Diluter, 50µ~ Reagent A was sampled and 
delivered with 250µ~ buffer to the same cup. 
iii. 30 seconds was allowed to elapse for Reagent A and sample (or 
calibratot) to equilibrate. 
iv. The spectrophotometer flow cell was purged with water. 
v. Using the Pippeter-Diluter. 50µ~ Reagent B was sampled and 
delivered with 250µ~ buffer to the same cup. 
vi. The contents of the cup were aspirated into the spectrophoto-
meter flow cell. The cup was discarded. The printer was automatically 
activated by the aspiration of the sample to time and record the change 
of absorbance. 
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vii. The above procedure was repeated with each sample. 
Before any samples were assayed the calibrators were run in duplicate 
and a blank was run. The blank consisted of buffer solution. The 
first sample from each patient was assayed in duplicate but subsequent 
samples were assayed once only. 
Table 2.3.6.1. R Validation of EMIT assay for the determination of 
cannabinoids in urine. 
Concentration Number Mean Standard Coefficient Standard 
(ng/ml) of + lliviation of error of 
samples t:,A variation the mean 
0 5 409,00 0,63 o, 15 0,28 
20 5 455,80 0,26 0,26 0,11 
75 5 500,80 0,75 o, 15 0,33 
+ After aspiration of the sample two readings are automatically made 
on each sample, the first at 15 seconds and the second at 45 seconds. 
The difference between the two readings ~) is used to calculate 
results. 
2.4. TOXICOLCX3ICAL SCREEN 
2.4.1. Introduction 
Chromatography is the separation of the components of a mixture by 
utilizing their .different .relative absorptions ·onto a stationary 
phase. Development (elution) of the mixture is carried out by pass-
ing a mobile phase over a stationary phase which may be a solid (or, 
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more rarely, a viscous liquid), and the mobile phase may be a gas (gas 
chromatography (EL)) or a liquid (high pressure liquid chromatography 
(HPLC)), or thin layer chromatography (TLC)). 
The local practice to screen for unknown drugs is to extract plasma 
with isopropanol, salt out the water with ammonium sulphate to 
evaporate the extract. The latter is redissolved in methanol and is 
spotted near one corner of each of ten 5cm x 5cm fluorescent thin-
layer plates for TLC. A fluorescent indicator is incorporated into the 
stationary phase to yield a light-green fluorescence when exited by UV 
light of wavelength 254nm. This facilitates the identification of some 
classes of chemicals (Johnson, 1968; van der Meer, 1976). It is 
virtually impossible to cause a separation of all the compounds that 
may be present using one mobile phase and a two-dimensional separation 
using two different solvent systems is considered more appropriate. 
The choice of solvent remains essentially a matter of trial and error 
(Snyder, 1975) and ideally one solvent should separate acidic drugs 
and the other solvent basic drugs (van der Meer, 1976). Therefore the 
plates are run first in one dimension to separate the acids, then the 
other at right angles with the basic eluent to separate the bases. 
Most of the endogenous, but extracted material remains at the origin 
and the fats and very non-polar drugs run to the opposite corner. The 
other drug-spots are distributed about the plate in a fairly predict-
able pattern, the position being determined by certain variables in 
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the composition of the plate and by the balance of polarity and intrinsic 
acidity or basicity of the drug. A known reference compound is run in 
the margin of the plate as a check on the conditions of chromatography; 
paracetamol is usually used but, if a particular drug is suspected to 
be present, that will be used instead. 
Once the chemicals have been separated on the plate a number of 
method, can be used to identify the compounds - for example UV spectro-
photometry, mass spectrophotometry, HPLC, and GC, all of which require 
complex and expensive equipment. The most widely used technique for 
the visualization of compounds on chromatograms is the spraying of 
plates with specific reagents. Each reagent is designed to indicate 
the presence of certain reactive groups on the drug molecule (van der 
Meer, 1976). In theory one should be able to identify about 150 drugs 
simultaneously present on each plate but in practice the limit is a 
good deal lower, about 50. Tables displaying migratory distances and 
specific reactions of chenicals to specific colouring reagents have 
been drawn up and are used to identify the drugs present oM TLC 
chromatograms. 
2.4.2. Apparatus and Reagents 
Centrifugation of samples was performed using a bench-top centrifuge 
(Rota-Uni 11, West Germany) with the speed set at 2500 min-1. A 
Vortex mixer (Scientific Industries Inc. New York, USA) Model K-550-GE 
was used to mix various solutions. 
Ammonium sulphate, isopropanol, and methanol were guaranteed Reagent 
Grade chenicals (Merck, Carmstadt, Germany). An 11ml glass-stoppered 
Quickfit test tube and a 25ml round-bottomed Quickfit flask were used 
for the extraction procedure. Disposable Pasteur pipettes were used 
to transfer solutions. A Buchi Rotovapor (w. Buchi, Flawl, 8.vitzerland) 
was used to evaporate the serum extract to dryness. 
Thin-layer chromatography was carried out on silica gel 60 F
254 
plates (Merck, Carmstadt, Germany). The plates were split into 5cm x 
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5cm squares and marked lightly in pencil with a 3cm x 3cm square ruled 





Figure 2.4.2.1. Demarcation of silica gel plates 
A = direction and distance of elution with acid eluent 
B = direction and distance of elution with alkaline eluent 
0 = origin 
X = position of spotting of external reference standard 
1µt micropipettes were used to spot the extract onto the plates. A 
UV lamp set at 254nm and 360nm was used to view the prepared plates. 
2.4.3. Sample Collection and Extraction Procedure 
A 10ml blood sample was drawn from each patient as soon as possible 
after admission to the hospital ward. The samples were stored at 2-8°C 
and then separated by centrifugation before analysis. 5ml serum and 
4ml isopropanol were thoroughly mixed for two minutes, then3g ammonium 
sulphate was added and dissolved as completely as possible using a 
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vortex mixer. The mixture was separated by centrifugation and the 
upper, isopropanol, layer was collected and evaporated under reduced 
0 
pressure at 60 C. The residue was triturated with 200µe methanol and 
the resulting mixture was again separated by centrifugation. The clear 
supernatant was distributed evenly between the origins of the TLC 
plates by repeated application of 1µe aliquots, solvent being evaporat-
ed in a stream of hot air between applications. 
All plates were eluted simultaneously. The elution was performed in 
two dimensions succesively, at right angles. The eluting solvent in 
the first dimension (acid elution) was 94% formaldehyde dimethyl acetal; 
in the second dimension (alkaline elution) the eluting solvent was ethyl 
acetate: methanol: concentrated aqueous ammonia:: 85:10:5 and was 
freshly prepared. An external reference standard of paracetamol was 
run in the margins of each plate. 
The spots formed by drugs present were located , in the first instance, 
by the quenching of inherent fluorescence of the TLC plates at 254nm. 
In addition partial identification could be made by observing fluores-
cence when the plate was exited by light of wavelength 360nm. The 
apparent migration distances of the spots under acidic and under basic 
conditions were calculated relative to the paracetamol= 100 units. 
The following visualizing reagents were then used: iodine, 
Oragendorff's, iodoplatinate, Marquis', Mandelin's, Forrest's, 
FPN, diphenylcarbazone, Trinder's, and mercurous nitrate. (See 
~ 
Appendix~for formulations). From all the data gained, the identifica-
tion of any drug spots could be made. 
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2.5. ETHANOL DETERMINATION 
2.5.1. Introduction 
Gas Chromatography (GC) is limited to those substance or their 
derivatives which vaporize without decomposing. The most widely used 
detector in GC, responding withli.gh sensitivity to all organic com-
pounds, is the flame ionization detector which measures the ionization 
current generated when a compound emerges from the chromatographic 
column and burns in a hydrogen flame. The sensitivity of this 
-9 detector enables 10 g of many components to be detected and does 
not respond to inorganic gases or water (Andrews, 1970). 
GC allows the detection and identification of a variety of volatile 
substances, including the common alcohols. A suitable internal stan-
dard is select~d whose elution properties resemble those of the sub-
stance to be determined and known concentration of the internal sta~ 
dard is added to the sample under investigation. The relative 
response of internal standard compared with that of the alcohol to be 
measured allows an accurate result to be established. 
GC has become a widely accepted analytical technique for the detec-
tion and quantification of various alcohols in blood, tissue and 
plasma. The advantages of GC in this context are its capacity for 
measuring volatiles, its speed and the micro-volume sample required 
(Freudiger and Vignau, 1965; Mather and Assimosis, 1965; Ce.vis, 1966; 
Andrews, 1970) . 
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2.5.2. Instrumentation and Operating Conditions 
A 8:Jw-Mac Series 750 Gas Chromatograph, Model 69-752 (8:Jw-Mac Instru-
ment Co. New Jersey, USA) ·fitted with a flame ionization detector was 
used for the detection of ethanol in plasma. 
A 1,2 m, 2mm i.d. glass column packed with 0,2% Carbowax 1500 on 
Carbopack A 60/80 mesh was used under the following conditions: in-
jection port temperature at 120°C, the detector at 140°C, and the 
column oven at 115°C. Nitrogen was used as the carrier gas with a 
flow rate of 20 ml/minute, hydrogen was set at a flow rate of 30 ml/ 
minute and oxygen at 300 ml/minute. 
A Hewlett Packard Automation System 3385A Integrator/recorder was 
used to record the chromatograms and retention times. 
2.5.3. Reagent and Sample Preparation 
i. Solvent test solution 
1 ml each of methanol, ethanol, acetone, isopropanol, and n-propanol 
were mixed and diluted to 500 ml with distilled water to give final 
concentrations of 157 mg%, 157 mg%, 157 mg%, 156 mg%, 160 mg% respec-
tively. All reagents were guaranteed Reagent Grade (Merck, 03.rmstadt, 
Germany). 
ii. Internal Standard 
1 ml isopropanol and 1 ml n-propanol were mixed and diluted to 1000 ml 
with distilled water to give concentrations of 78 ,1 mg% and 80 ,2 mg% 
respectively. 
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iii. Ethanol control solution 
1 ml absolute ethanol was diluted to 500 ml with distilled water. The 
resulting solution had a concentration of 158 mg%, 
iv. Standard ethanol solutions 
2,0 ml absolute ethanol was diluted to 500 ml with distilled water. 
The resulting solution had an ethanol concentration of 316 mg%; this 
was labelled Solution A. Various subsidiary standards containing 
158 mg%, 79 mg%, and 31,6 mg% were made by dilutions of Solution A. 
200 µl of the standard solutions were mixed with 200µ1 of internal 
standard solution and the tubes were sealed with Parafilm. Five 
aliquots of each standard solution were prepared. 
From the blood sample drawn from each patient (See Section 2.2.3.) 
200 µl serum was mixed with 200 
sealed with Parafilm. 
2.5.4. Assay Procedure 
internal standard in a tube and 
i. 1 µl of the test solution was injected directly onto the 
column and the retention times (RT) were recorded. The solvents 
elute in the following order: methanol, ethanol, acetone, isopropanol, 
n-propanol. 
ii. The syringe was rinsed 20 times with distilled water. 
iii. 1 µl of the prepared sample from each standard solution was 
injected directly on to the column and the RT values were recorded. 
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The syringe was washed 20 times between each injection. 
iv. The plasma sa~ples were injected in the same way. 
Following the determination of the standard solutions, 1 µl of the 
prepared sample from each patient was assayed in the same way. 
The ratios of ethanol to isopropanol were calculated for standard and 
serum samples. The ratios for the standards were used to prepare a 
standard curve which, in turn, was used in the determination of ethanol 
concentrations in the plasma samples. 
Table 2.5.4.1. 
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Ethanol Concen- Number Mean Ethanol/ Standard Coefficient Observed 
tration of of Isopropanol Devia- of Varia- Concen-
Standard Samples Ratio tion tion (io) tration 
Solutions (mgio) 
0 4 o,oo o,oo o,oo o,oo 
31,6 4 0,344 0,010 2,9 30,5 
79 4 0,937 0,005 0,53 79,5 
158 4 1,910 0,011 0,57 160 
316 4 3,780 0,010 0,26 315 
Table 2.5.4.1. Validation of ethanol determination by Gas Chromatography 
Slope = 0,012 
Y-intercept = 0,020 
r = 0,9998 
See Figure 2 .. 4 .1. Calibration curve for the determination of ethanol 
in serum by gas chromatography. Co-ordinates plotted represent the 
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Fig. 2.5.4.1. Calibration curve for the determination 
of ethanol in serum by gas chromatography 
coordinates plotted represent the means of the 
observed values. 




A. FIG. 2.5.4.2. Chromatogram of test solution. 
a= methanol ( 157 mg%; RT 0,56 l 
b= ethanol (157 .mg% ;RT=0,87) 
c = acetone ( 157 mg%; R,-1, 19 I 
d = isopropanol ( 156 mg % ; RT 1,491 
e = n- propanol 1160 mg%; RT 1,961 
B. FIG 2.5.4.3. Chromatogram of 
a= ethanol 
b = isopropanol 
c = n-propanol 
a standard solution. 
(31,6 mg%; RT 0,87 J 
l78,1mg%;RT 1,49) 
(80,2 mg%; RT 1,96) 
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2.6. SERUM CREATININE PHOSPHOKINASE (CPK) AND SERUM LACTATE 
DEHYDROGENASE (LOH) DETERMINATIONS 
There are a number of publications which document the association 
between elevated serum CPK and acute psychosis (Meltzer, 1968, 1969, 
1970, 1973a, 1973b; Meltzer et al, 1969, 1970, 1971; Taylor and 
Abichandani, 1980). Elevated serum CPK levels occurred in psychotic 
patients with a variety of psychiatric diagnoses; levels of 5 to 10 
times normal values were noted, and on occasion 50 times the normal 
value (Meltzer, 1969). Despite the heterogeneity of psychotic diag-
noses, 8.Jterman (1973) and Gosling et al (1972) suggested that specific 
psychiatric disorders are more commonly represented. A significant 
correlation between elevated CPK levels and the "non-affective aspects 
of the psychosis" was found (8.Jterman, 1973), and Gosling et al (1972) 
reported that CPK elevation was more likely to be found in patients 
with mania and paranoid schizophrenia than in patients with depression 
and the nonparanoid schizophrenias. However, Meltzer (1973b) suggested 
that Gosling's data may be explained by a greater delay in the admis-
sion of depressed patients and non-paranoid schizophrenic patients to 
hospital; this would increase the chances of missing elevated serum 
CPK levels. 
Farber and Huertas (1976) reported 2 patients with adverse effects 
following the intravenous injection of a cannabis preparation; serum 
CPK and serum LOH levels were elevated in both cases and remained 
so for six days following admission to hospital. 
Therefore serum CPK and L[)-J determinations were done on the majority 
of patients admitted to the study; the assays were performed by the 
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3 .1. PHARMACOLOGICAL ASSAYS 
3.1.1. Ethanol Determination 
Analyses of samples from all patients were done. No ethanol was 
present in any patient. 
3.1.2. Toxicological Screens 
Toxicological screens were performed on all patients. No positive 
result was found in any patient. 
3.1.3. Cannabinoid Determinations 
Sixty percent of all the randomly selected patients screened had a 
positive . result i.e. the urinary cannabinoid level was above 20ng/ml 
the lower detection limit of the assay used. (See Table 3 .1.1.). 
Table 3.1.1. Initial urinary cannabinoid determinations of randomly 
selected patients who were positive for cannabinoids (n = 49) 
Urinary cannabinoid concentration (ng/mlt 
20-100++ 101-200 201-500 >500 
23 9 10 7 
(46,9%) (18,4%) (20,4%) 14,3%) 
+ The assay used was semi-quantitative (see Section 2.3.). For the 
purpose of further analysis these results were converted to µgCRC/g 
creatinine to quantify the results. 
++ 20ng/ml was the lower detection limit of the assay (see Section 
2.3.). 
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This indicates that the only detectable toxins present in the patients 
on admission were the cannabinoids. 
3.2. PATIENT SELECTION, CATEGO CLASSIFICATION OF PSEs, AND 
SYNDRCJ\/1E PROFILES 
3.2.1. Patient Selection 
All patients selected were Coloured males. There were twenty 
patients in each group - the high cannabis group, the low cannabis 
group, and the psychotic control group. (See Tables 3.2.1., 3.2.2., 
and 3.2.3.). f-bwever, in view of the small number of manic patients 
obtained in the psychotic control group, seven additional manic 
patients (with CATEGO classifications of Manic-Depressive psychosis, 
manic type) were accepted into the study . . These patients fulfilled 
all the criteria for selection (see Section 2.1.) except that they 
were assessed on the PSE only on admission. The seven patients 
together with three manic patients (CATEGO diagnosis) in the psychotic 
control group constituted the 'manic control' group. None of these 
patients had detectable urinary cannabinoids. (See Appendix I for 
case studies). 
Age of patients 
The ages of patients in the high cannabis group ranged from 17-52 
years with a median age of 23 years, in the low cannabis group from 
18-50 years with a median age of 28 years, and in the psychotic con-
trol group from 16-52 years with a median age of 25 years. There -·~re 
no significant differences among the three groups with regard to age. 
Urinary cannabinoid levels on admission 
The urinary cannabinoid levels on admission ranged from 80-435 µgCRC/g 
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creatinine with a median level of 262 µgCRC/g creatinine (high cannabis group); 
low cannabis group from 4,9-56,5 µgCRC/g creatinine with a median 
level of 16 µgCRC/g creatinine. 
Previous admissions 
The number of patients in the high cannabis group, the low cannabis 
group, and the psychotic control groups who had one or more previous 
admissions to Valkenberg Hospital was 14, 12, and 16 respectively. 
Of these patients the median number of admissions was 1, 2, and _2 
respectively. There were no significant differences among the three 
groups with respect to the number of admissions. 
9::Jcial Class 
Two patients in the high cannabis group and 2 in the psychotic control 
group were assigned a social class of II; the other patients in all 
three groups were assigned a social class of III. 
Period between PSE assessments 
The period between PSE assessments in all three groups ranged from 
7-9 days with a median period of 7 days. The number of patients in 
each of the three groups with a 7-day period between PSEs was 14; the 
number of patients in the high cannabis group, the low cannabis group 
and the psychotic control group with an 8-day period between PSEs was 
4, 4, and 5 respectively; and the number of patients in the same 
three groups with a 9-day period between PSEs was 2, 2, and 1 respec-
tively. There were no significant differences among the three groups 
with respect to period between PSE assessments. 
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Table 3.2.1. High cannabis group 
' Urinary cannabinoid Previous Provisional Clinical level on ad- Social Initials Age 
mission Class Ad- Diagnosis on 
( µgCRC/g missions Admission 
creatinine) 
CM 21 200,9 III 4 Paranoid schizophrenia 
AA(1) 22 390,3 III 5 Hypomania 
JS 19 211,8 III 0 Hypomania 
FJ 22 250, 1 II 1 Paranoid psychosis 
GM 38 303 III 3 Hypomania 
JvR 27 109 III 1 Paranoid schizophrenia 
AS 24 101,7 III 1 8::;hizophreniform ps ychosis 
JF 21 292 III 0 8::;hizophreniform 
psychosis 
JG 26 103 III 0 Paranoid schizophrenia 
RJ 30 80 III 2 Hypomania 
FD 23 432,8 III 2 Paranoid schizophrenia 
RS 18 289,5 II 0 Paranoid schizophrenia 
WW 23 86,8 II 1 Paranoid psychosis 
AP 18 106,4 III 1 Paranoid schizophrenia 
JP 21 310 III 0 8::;hizophreniform 
psychosis 
RM 33 273 III 1 8::;hizophreniform 
psychosis 
AA(2) 26 103 III 9 Paranoid schizophrenia 
MI 27 383,5 III 1 Paranoid psychosis 
MJ 52 435 III 7 Paranoid schizophrenia 
GD 17 412,5 III 0 Paranoid psychosis 
(AA(1) and AA(2) refer to two different patients with the same initials). 
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Table 3.2.2. Low cannabis group 
Urinary 
cannabinoid 
Previous Provisional Clinical level on Social Initials Age admission Class Admis- Diagnosis on 
( µgCFC/g sions Admission 
creatinine) 
ON 22 19,2 III 0 8:Jcial and behavioural 
problens 
AS 34 57,3 III 8 Chronic schizophrenia 
RM 30 10, 1 III 1 Hypomania 
GvW 26 24,9 III 4 Chronic schizophrenia 
Jvdl 36 20, 1 III 0 Paranoid schizophrenia 
AJ 30 6,7 III 5 8::hizo-affective 
disorder 
JM 19 4,9 III 0 8::hizophreniform 
psychosis 
LA 46 13,4 III 1 Paranoid schizophrenia 
BW 24 10,5 III 0 8::hizo-affective 
disorder 
EM 50 13,5 III 2 Aggressive and anti-
social behaviour 
GD 18 7,6 III 0 8::hizophreniform 
psychosis 
SC 49 8,5 III 2 Hypomania 
FJ 24 10,5 III 1 Paranoid schizophrenia 
YD 24 21, 1 III 0 Hypomania 
EW 23 56,5 III 2 Paranoid psychosis 
CM 23 26,2 III 0 8::hizophreniform 
psychosis 
27 18,4 III 0 8::hizophreniform 
psychosis 
JLR 29 9 ,3 III 2 Hypomania 
LK 37 29 ,8 III 1 Paranoid schizophrenia 
DN 32 49,5 III 3 Hypomania 
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Table 3.2.3. Psychotic control group 
Urinary 
cannabinoid 
Previous Provisional clinical level on Social Initials Age 
admission Class Admis- diagnosis on 
( µgCRC/g sions admission 
creatinine) 
KA 29 II 1 Paranoid schizophrenia 
P£. 26 III 6 Paranoid schizophrenia 
SG 52 III 7 Paranoid schizophrenia 
JV 16 III 0 Early schizophrenia 
HM 27 III 1 Paranoid schizophrenia 
MP 25 III 1 Paranoid schizophrenia 
GT 18 III 3 Paranoid schizophrenia 
LJ 20 III 1 5::hizophreniform psycho-
sis 
GJ 20 III 0 5::hizophreniform 
psychosis 
OP 18 III 2 Paranoid schizophrenia 
LA 23 III 2 Paranoid schizophrenia 
RE 16 II 0 5::hi~o~breniform psyc o 1.s 
FA 25 III 2 5::hizophreniform 
psychosis 
AD( 1) 30 III 3 Paranoid schizophrenia 
CK 20 III 0 Hypomania 
AD(2) 39 II 9 Hypomania 
JK 30 III 5 Hypomania 
JM 30 III 1 Paranoid schizophrenia 
NF 23 III 1 Paranoid schizophrenia 
[l3 25 III 1 Paranoid schizophrenia 
(AD( 1) and AD(2) refer to two patients with the same initials). 
Medication during the period between PSE assessments 
All patients received neuroleptic medication during the period 
between PSEs (see Tables 3.2.4., 3.2.5., 3.2.6.). The total dose 
received by patients in the high cannabis group ranged from 7 - 207 
units with a median of 34 units, in the low cannabis group from 6 
214 units with a median of 42 units, and in the psychotic c.ontrol 
group from 16 - 64 units with a median of 44 units (see Table 3.2.7. 
for equivalent doses of medication). The Kruskal-Wallis one-way 
analysis of variance by ranks was used to test for significant dif-
ferences among the three groups with respect to the total amount of 
neuroleptic medication during the period between PSEs; there were no 
significant differences. 
3.2.2. CATEGO Classification 
The CATEGO classification of completed PS::s was made according to the 
International Classification of Diseases (1967 Edition) and is presen-
ted in Tables 3.2.8 , 3.2.9., and 3,2,10. 
3.2.3. Syndrome Profiles 
3.2.3.1. Syndrome profiles of PSE1 
Syndrome profiles were drawn up for each of the three groups and are 
presented in Figure 3.2.1. and Tables 3.2.11., 3.2.12., and 3. 2 .13. 
for the high cannabis group, the low cannabis group and the psychotic 




Table 3.2.4. Total medication received during the period between PSE1 
and PSE 2 in the high cannabis group 
Medication (units/period between PSE1 and PSE2)+ 
Flu- Chlor-
Halo- Trifluoperazine Patient phenazine promazine Pimozide Total 
decanoate HCl peridol dihydrochloride 
CM 8 6 28 42 
AA(1) 6 35 28 69 
JS 70 28 98 
FJ 9 6 36 51 
GM 28 28 
JvR 6 28 34 
AS 7 70 77 
JF 24 24 
JG 7 48 55 
RJ 14 105 28 147 
FD 6 28 34 
RS 6 28 34 
WW 7 14 21 
AP 7 28 35 
JP 7 200 207 
RM 7 14 21 
AA(2) 14 14 28 
MI 7 7 
MJ 9 18 27 
GD 8 16 24 
+Medication is reported as units, see Table 3.2.7. for equivalent doses 
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Table 3.2.5. Total medication received during the period between PSE1 































































































+Medication is reported as units, s ee Table 3.2.7. for equivalent doses 
Table 3.2.6. Total medication received during the period between PSE1 
















































































+Medication is reported as units, see Table 3.2.7. for equivalent doses 
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Table 3.2.7. Cbse relationship among neuroleptics (adapted from 
Hollister, 1978). 
+ 1 unit= 25mg Fluphenazine decanoate per month 
_ 100mg Chlorpromazine f-Cl 
_ 2mg Haloperidol 
_ 5mg Trifluoperazine dihydrochloride 
_ 2mg Pimozide 
_ 40mg Clothiapine 
+The calculation of daily dose of Fluphenazine decanoate was adapted 
from Hollister, 1978. 
To identify any differentiating features of the psychoses on admission 
in the three groups, syndrome profiles of PSE1 for each group were 
compared; (see Figure 3.2.1.). The Chi-square test for independent 
samples was used to test for significant differences among the three 
groups and to test where the most significant differences lay; the 
significant differences are summarized in Table 3.2.15 .. From these 
results it is clear that on admission the high cannabis group is 
characterized by a higher frequency of hypomania, agitation and dis-
orientation. The psychotic control group is characterized GY a higher 
occurrence of hysteria, auditory hallucinations, flattening, visual 
hallucinations, and inco.herent speech. The low cannabis group has no 
characterizing features. 
3.2.3.2. Comparison of syndrome profiles of PSE1 of patients in the 
high cannabis group and the psychotic control group with CATEGO class-
ifications of Paranoid schizophrenia or Manic-Depressive psychosis, 
manic type 
It is evident that in the CATEGO classification of the first PSE in 
the high cannabis group Paranoid ~hozophrenia and Manic-Depressive 
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psychosis, manic type predominate (see Table 3.2.8.). Therefore it 
was decided to compare patients in the high cannabis group with a 
CATEGO classification of Paranoid schizophrenia with patients in the 
psychotic control group with the same diagnostic classification (see 
Figure 3.2.2. and Table 3.2.16.). Similarly patients in the high 
cannabis group with a CATEGO classification of Manic-Depressive 
psychosis, manic type were compared with patients in the manic control 
group. (See Figure 3.2.3. and Table 3.2.17.). The Chi-square test 
for independent samples was used to test for significant differences. 
The results (Tables 3.2.16. and 3.2.17.) indicate that with respect 
to manic psychosis, the high cannabis group does not differ significant-
ly in its profile from the endogenous psychosis. With the paranoid 
schizophrenics, on the other hand, there are significant differences 
between the two groups. The 'high cannabis' paranoid schizophrenics 
have a higher incidence of agitation and simple depression and a 
lower incidence of auditory hallucinations and hysteria than their 
'psychotic control' counterparts. 
3.2.3.3. Assessment of improvement in the symptomatology between 
PSE1 and PSE2 
To assess the improvement in symptomatology over the period between 
PSE1 and PSE2 (7 - 9 days), the McNemar test for the significance of 
changes was used. Each patient was compared with himself and, in this 
context, improvement means total improvement i.e. where t he patient 
scored on a particular syndrome on PE£1, this score achieved zero on 
the second PSE. The syndrome profiles of PSE1 and PSE2 of the high 
cannabis group, the low cannabis group, and the psychotic control 
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Table 3.2.11. Features of the syndrome profiles of PSE1 in the high 
cannabis group 
PSE Syndromes (numbers refer to number of patients scoring on a syndrome) 
More than 10 
patients scoring 
Hypomania 16 






















Special features of 
depression 
Ideas of reference 
Social unease 
Loss of interest 
and concentration 
Other symptoms of 
depression 
5 or less patients 
scoring 
10 Flattening 5 
10 Slowness 4 
8 Incoherent speech 3 
8 Visual hallucinations 4 
6 Olfactory hallucinations 4 
Auditory 
9 hallucinations 3 
Cepressive delusions 
8 and hallucinations 2 
8 Sub-cultural delusions 1 
8 General anxiety 5 
Obsessional neurosis 4 
8 
6 Situational anxiety 4 
6 Hysteria 4 




Hypochondrias is 3 
Catatonic syndrome 4 
( 
93 
Table 3.2.12. Features of the syndrome profiles of PSE1 in the low 
cannabis group . 
PSE Syndromes 





6 - 10 patients scoring 
Hypamania 6 
Non-specific psychosis 7 
Flattening 
Slowness 












Special features of 
Depression 
General anxiety 










5 or less patients scoring 
Agitation 4 
Self neglect 4 
Residual syndrome 1 
Overactivity 
Disorientation 0 
Incoherent speech 4 






and hallucinations 2 
Sub-cultural delusions 2 
Cbsessional neurosis 4 
Situational anxiety 3 
Hysteria 4 
Loss of interest and 
concentration 5 
other symptoms of 
depression 5 
Lack of energy 4 
CEpersonalization 1 
Hypochondrias is 2 
Catatonic syndrome 2 
Table 3.2.13. Features of the syndrome profiles of PSE1 in the 
psychotic control group 
PSE Syndromes 
More than 10 
patients scoring 
• Residual syndrome 11 
Flattening 14 














Sexual and fantas- Overactivity 9 Sub-cultural delusions 3 















Self neglect 10 









and hallucinations 7 














Lack of energy 





Ideas of reference 













Table 3.2.14. CATEGO syndrome abbreviations 
HM Hypomania 
AG Agitation 
NG Self neglect 
NP Non-specific psychosis 
OJ OJeractivity 
RS Residual Syndrome 
OR+ Disorientation 
AF Flattening 
CS Catatonic syndrome 
SL Slowness 
IS Incoherent speech 
SF Sexual and fantastic delusions 
RE Celusions of reference 
GR Grandiose and religious delusions 
PE Celusions of persecution 
NS f\llclear syndrome 
VH Visual hallucinations 
OH Olfactory hallucinations 
AH Auditory hallucinations 
DD Cepressive delusions and hallucinations 
SC Sub-cultural delusions of hallucinations 
SO Simple depression 
ED Special features of depression 
GA General anxiety 
ON Obsessional neurosis 






IR Ideas of reference 
SU Social unease 
IC Loss of interest and concentration 
OD Other symptoms of depression 
LE Lack of energy 
DE Depersonalization 
HY Hypochondriasis 
+Organic impairment (OR) was not assessed on the PSE. However, it 
was felt that the orientation of a patient was an important factor of 
the psychosis. Therefore, by rtle~ral to the clinical notes some 
assessment of the orientation of the patient could be made; a patient 
was rated as '2' if he was totally disorientated, '1' if he was 
orientated for time or place only, and 'O' if he was correctly 
orientated. The abbreviation 'OR' used by the PSE for organic im-
pairment now nepresents disorientation. This score is not reflected 
in the total PSE scores. 
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Table 3. 2. 15. Significant differences in the PSE on admission bet-
ween the high cannabis group, the low cannabis group, and the psychotic 
control group 
High cannabis group scores significantly more than the psychotic 




Disorient at ion 
No. of patients out 
of 20 scoring on 
syndrome 
High Low Control 
16 6 7 
10 4 3 
6 0 3 
p value 
0,05 
·-8::- 0, 02 
--!k- 0, 02 
High cannabis group and psychotic control group score significantly 









High cannabis group and low cannabis group 
than the psychotic control group in:-
Hysteria 4 4 14 
Auditory 
Hallucinations 3 5 12 
Flattening 5 7 14 
Visual Hallucina-
tions 4 2 9 
Incoherent speech 3 4 10 
0,01>p>0,0005 
0,05>p>0,02 
score significantly less 






Table 3.2.16. 8.Jmmary of significant differences and non-significant 
trends in PSE1 between the high cannabis patients and psychotic con-
trol patients with CATEGO classifications of paranoid schizophrenia 
Syndrome l\umber of patients scoring on p value 
syndrome 
High cannabis Psychotic control 
n = 10 n = 15 
Agitation 4 1 0, 05) p) 0, 02 
Auditory 
Hallucinations 2 11 O, 01>p>O, 001 
Simple Cepression 4 1 O, 05> p>O, 02 
Hysteria 3 11 0,05>p>0,02 
Hypomania 6 4 o, 1 (NS) 
Flattening 5 12 0, 1 (NS) 
Sexual and Fantastic 
delusions 9 9 0, 1 (NS) 
Celusions of reference 9 9 o, 1 (NS) 
98 
Irritability 10 11 o, 1>p>0,05 (NS) 
Tension 6 4 o, 1 (NS) 
Hypochondrias is 3 2 o, 1)p>0,05 (NS) 
Table 3.2.17. Non-significant trends in the high cannabis patients 
with CATEGO classifications of Manic-Cepressive psychosis, manic type, 






Number of patients scoring on 
syndrome 
High cannabis 










O, 1 (NS) 
O, 1 (NS) 
D, 1)p)0,05 (NS) 
A summary of significant improvements are presented in Table 3.2.18. 
The results in Table 3.2.18 indicate that the overall trend in the 
high cannabis group was one of marked improvement. Significant im-
provements were registered in the following syndromes - hypomania, 
agitation, sexual and fantastic delusions, delusions of reference, 
grandiose and religious delusions, delusions of persecution, and 
irritability. 
The profiles of the low cannabis group and the psychotic control 
group indicate significant improvement only in some of the neurotic 
syndromes - general anxiety, worry, and irritability. It must be 
noted that the psychotic control group shared virtually no improve-
ment in the psychotic symptomatology in the period between PS::1 and 
PSE2. 
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To assess any consistant improvement from PS::1 to PSE2 in the 4 sub-
scores and the total scores in the three groups, the Wilcoxon matched-
pairs, signed-ranks test (corrected for ties) was used. In this con-
text improvement indicated that there was a decrease in score (eg. 3-+2) 
and not necessarily a total improvement (eg. 2 ~ D) as was the case 
with the McNemar test for the significance of changes. The results 
are summarized in Table 3.2.19. 
Table 3.2.19. indicates that there was a significant improvement in 
all the sub-scores (BSD, DAH, SNR, and NSN) with the exception of (in 
the high cannabis group) the specific neurotic syndrome sub-scores. 
Although all three groups improved significantly on the total PSE 
score, it is clear from the median values that the high cannabis 
group and the low cannabis group improve markedly whereas the psychotic 
control group improved only marginally. 
All three groups were on neuroleptic medication throughout the period 
between PSE assessments. Therewereno significant differences in the 
total amount of medication among the groups. f-bwever, it was decided 
to select a sub-population from each group who were matched as closely 
as possible for total amount of medication received. The Wilcoxon 
matched-pairs signed-ranks test was used and the results are presented 
in Table 3.2.20. 
Table 3.2.20. indicates that the high cannabis group improved in all 
four sub-scores, the low cannabis group and the psychotic control 
group improved in only some of the sub-scores. However, all three 
groups improved significantly on the overall PSE score, but the 
median values of the total scores in each group indicate that the 
high cannabis and low cannabis groups improved to a marked extent while 
the improvement in the psychotic control group was marginal. It must 
be remembered that the three groups here were matched as closely as 
possible for the total amount of medication during the period between 
PSEs. This close matching of the groups for medication did not in 
any way reduce the magnitude of the improvement. 
3.3. PSE SYNDROMES CORRELATED WITH URINARY CANNABINOID CONCENTRATIONS 
The Spearman rank correlation coefficient (corrected for ties) was 
used to correlate urinary cannabinoid concentrations at the time of 
the first PSE with the syndrome scores of PSE1. Those syndromes that 
had a significant correlation with urinary cannabinoid concentrations 











































































































































































































































































































































































































































































































































































































Table 3.2.19. Significant improvenents in syndrome sub-scores from PSE1 
to PSE2 in the high cannabis group, the low cannabis group and the 
psychotic control group 
BEHAVICXJR, SPEECH AND OTHER SYNDROJ1ES 
Group Median value Median value 
of PSE1 of PSE2 
High cannabis 8 2 
Low cannabis 6 2 
Psychotic control 9,5 8 

















































































Table 3.2.20. Significant improvements in syndrome sub-scores from 
PSE1 to PSE2 in the high cannabis group (n=10), the low cannabis group 
(n=10), and the psychotic control group (n=10) matched for total 
neuroleptic medication received between PSE assessments 
BEHAVIOJR, SPEECH AND OTHER SYNDROMES 
Group Median value 
of PSE1 
High cannabis 8 
Low cannabis 6,5 
Psychotic control 8,5 
DELUSIONAL AND HALLUCINATORY SYNDROMES 
Group Median value 
of PSE1 
High cannabis 10,5 
Low cannabis 15 
Psychotic control 14,5 













































































Table 3.3.1. Syndrome significantly correlated with urinary 
cannabinoid concentrations 
Syndrome rho Correlation p value 
Hypomania 0,4894 positive 0,001 
Overactivity D,3176 positive D,05 
Disorientation D,4430 positive 0,01>p>D,001 
These results indicate that hypomania, overactivity, and disorienta-
tion were probably dose-related. 
3.4. SERUM CREATINII\E PHOSPHOKINASE (CPK) AND SERUM LACTATE CE-
HYDROGENASE (LOH) DETERMINATIONS 
The serum CPK and serum LOH determinations are presented in Tables 
3.4.1., 3.4.2., and 3.4.3. 
Twenty percent of patients in the high cannabis group, 50% in the low 
cannabis group and 35% in the psychotic control group had CPK levels 
within the normal range (D-130 IU/L). Eighty percent of patients in 
the high cannabis group, 50% in the low cannabis group and 65% in the 
psychotic control group had CPK levels above the upper limit of normal. 
A summary of CPK levels in the three groups is presented in Table 
3.4.4. 
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Table 3.4.1. Serum CPK and serum LOH determinations in the high 
cannabis group (CPK n=15; LDH n=12) 
Patient CPK LOH 
(IULL) (IULL) 
CM 228 422 
AA(1) 446 447 
JS 4425 '788 
JvR 125 6'79 
JF 99 732 
FD 1077 469 
RS 332 659 
WW 1914 594 
AP 174 876 
JP 1622 738 
RM 125 
AA(2) 445 
MI 111 890 
MJ 155 
GP 273 769 
Median ·273 706 
r--.brmal value 0-130 IU/L 0-375 IU/L 
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Table 3.4.2. Serum CPK and serum LD-l determinations in the low 
cannabis group (CPK n=10; LOH n=9) 
Patient CPK LOH 
(IULL) (IU/L) 
ON 160 858 
JvdL 131 
JM 125 237 
LA 131 220 
BW 111 140 
YD 494 
EW 958 
[Jy1 765 400 
AF 81 460 
JlR 2007 923 
LK 738 
DN 130 
Median 131 460 
-Normal range 0-130 IU/L 0-375 IU/L 
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Table 3.4.3 Serum CPK and serum L[)-j determinations in the 
psychotic control group (CPK n=16; LOH n=13) 
Patient CPK L[)-j 
(IULL} (IU£'.'.L) 
KA 105 593 
AE 137 626 
SG 192 237 
HM 131 434 
MP 81 237 
GT 125 858 
LJ 228 429 
GJ 242 
OP 534 2167 
LA 290 137 
RE 87 244 
FA 155 
A0(1) 273 62 
CK 3100 3407 
JK 806 1154 
DB 125 
Median 146 432 
Normal range 0-130 IU/L 0-375 IU/L 
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Table 3.4.4. 5.Jmmary of serum CPK levels in the high cannabis group, 









I\Jormal range: 0-130 IU/L 
p value: O, 05 









These results indicate that there was a significant difference among 
the three groups with respect to the serum CPK levels, with the high 
cannabis group having significantly more elevated levels than the low 
cannabis group and the psychotic control group. (Chi-square test 
used). 
A correlation between serum CPK levels and the PSE score on over-
activity on PSE1 was done using the Spearman rho correlation co-
efficient. There was a significant correlation between overactivity 
and CPK levels (p = 0,02). 
Serum LD-1 determinations 
I\Jo patients in the high cannabis group, 11% of patients in the low 
cannabis group, and 35% in the psychotic control group had levels 
within the normal range (0-375 IU/L). All the patients in the high 
cannabis group, 89% of patients in the low cannabis group, and 65% 
of patients in the psychotic control group had LD-1 levels above the 
upper limit of normal. A summary of LD-1 levels is presented in 
Table 3.4.5. 
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Table 3.4.5. 5.lmmary of LOH determinations in the high cannabis 
group, the low cannabis group and the psychotic control group 
Group Range 
High cannabis 422-890 
Low cannabis 140-923 
Psychotic control 137-3407 
Normal range: 0-375 IU/L 
p value: D,02 









These results indicate that there was a significant difference 
among the three groups with respect to the serum LOH determinations; 
the high cannabis group had significantly more elevated levels than 
the low cannabis group and the psychotic control group. 
There was no significant correlation between the PSE scorle on over-
activity on PSE1 and the LOH levels. 
3.5. ASSESSMENT OF URINARY CANNABINOID COI\.CENTRATIONS 
3.5.1. D3.ily urinary cannabinoid determinations 
109 
Daily urinary cannabinoids were determined in patients in the high 
cannabis group and the low cannabis group .until no cannabinoids were 
detected for two successive days (see Table 3.5 . . 1. ·and 3.5.2.). Urinary 
cannabinoid results are reported as µgCRC/g creatinine to allow 
quantification (see Section 2.3.). 
Tables 3.5.1. and 3.5.2. and Figures 3.5.1. and 3.5.2. indicate that 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.5. i. Daily urinary cannabinoid concentrations in the low 
cannabis group . 
Daily urinary cannabinoid concentration (µgCRC/g creatinine) 
1 2 3 4 5 6 7 8 9 10 11 
Patient 
DN 19,2 12,4 10,0 19,4 14,5 11 , 5 10,6 Neg Neg 
AS 57,3 44,3 48,5 24,7 26,3 20,1 49, 1 Neg Neg 
RM 10, 1 10,4 Neg Neg 
GvW 24,9 24,6 17,0 Neg Neg 
Jvd.L 20,1 21,8 18,3 12,2 13,6 Neg Neg 
AJ 6,7 4,5 Neg Neg 
JM 4,9 6,4 11 , 6 Neg Neg 
LA 13,4 9,7 Neg Neg 
BW 10,5 8,0 7,6 Neg Neg 
EM 13,5 13,3 38,0 12, 1 Neg Neg 
GD 7,6 7,8 Neg Neg 
SC 8,5 9,5 Neg Neg 
FJ 10,5 7,2 Neg Neg 
YD 21 , 1 18, 1 . Neg Neg 
EW , 56,5 45,5 60,0 ·38,8 60,0 Neg Neg 
IM 26,2 22,9 16,2 11 , 3 14,2 20,2 15,0 Neg Neg 
AF 18,4 52,5 49,9 34,9 29,7 21,0 Neg Neg 
JlR 9,3 8,4 6, 1 Neg · Neg 
LK 29,8 24,7 8,6 6,8 . 7 ,9 7,3 Neg Neg 
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FIG. 3.5.2. Daily urinary cannabinoid con-
centration in a low cannabis 
patient ILK) 
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3.5.2. Time Period required for a patient to have undetectable 
urinary cannabinoids 
A linear regression analysis of the initial urinary cannabinoid 
concentration versus days to level below detection was done on data 
obtained from the cannabis groups (see Table 3.5.3.). A slope of 
+ * + * 0,0254 - 0,0008, a y-intercept of 4,11 - 0,334 and r = 0,749 
(p<0,001) were obtained. Inherent factors in the assay used i.e. 
a cut-off point of 20ng/mi taken as zero may account for the line 
not passing through the origin. However, the following equation may 
be useful to calculate the number of days a patient would require to 
be free of urinary cannabinoids if the initial concentration was 
known: 
y = mx + c 
where 
y = number of days to undetectable levels 
m = slope 
X = initial concentration (µgCRC/g creatinine) 
C = y-intercept 
*Equations to calculate the slope~ confidence intervals and they-
intercept ~ confidence intervals were from Scientific Tables, 
D:Jcumenta Geigy, seventh Edition 1970 p 174. 
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Table 3.5. 3. Initial urinary cannabinoid concentrations of patients 
in the high cannabis group and the low cannabis group and the period 





( Cl3.ys) (D3.ys) 
CM 200,9 11 ON 19,2 7 
AA( 1) 390,3 23 AS 57,3 7 
JS 211,8 13 RM 10 J 1 2 
FJ 250, 1 14 GJW 24,9 3 
!Jv1 303 9 Jvdl 20, 1 6 
JvR 109 14 AJ 6,7 2 
AS 101,7 5 JM 4,9 3 
JF 292 9 LA 13,4 2 
JG 103 3 BW 10,5 3 
RJ 80 10 EM 13,5 4 
FD 432,8 17 GD 7,6 2 
RS 289,5 10 a:; 8,5 2 
WW 86,8 9 FJ 10,5 2 
AP 106,4 12 yp 21, 1 2 
JP 310 13 EW 56,5 5 
RM 273 11 OM 26,2 7 
AA 103 10 AF 18,4 6 
MI 383,5 11 JlR 9,3 3 
MJ 435 9 LK 29,8 6 
GD 412,5 9 DN 49 ,5 3 

















y- intercept = 4, 11 t 0,334 
Slope = 0,025 t0,0008 
r = O, 749 











. . . 
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• 
. .. . . . 
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0 100 200 300 400 500 
Initial urinary cannabinoids 
(.ug CRC/g creatinine) 
FIG.3.5.3. Linear regression analysis between the 
initial urinary cannabinoid concentration 
and the time required for a patient 
to be free of urinary cannabinoids. 
3.6. 8.Jr./MARY OF RESULTS 
I. The only detectable toxins were the cannabinoids. No patients 
showed evidence of ethanol or any other psychotropic agents. 
II. There were no significant differences among the three groups 
with regard to age, social class and number of previous 
admissions. 
III. There were no significant differences among the three groups 
with regard to neuroleptic medication received in the period 
between PSE assessments. 
DJ. The high cannabis group was characterized by a higher incidence 
of hypomania, agitation, and disorientation, the low cannabis 
group had no characterizing features, and the psychotic control 
group by a higher frequency of hysteria, auditory hallucina-
tions, flattening, visual hallucinations, and incoherent speech. 
V. With respect to manic psychosis, the high cannabis group did 
not differ significantly in its profile from that of the en-
dogenous manic psychosis (manic control group). The paranoid 
schizoprenics in the high cannabis group had a higher incidence 
of agitation and simple depression and a lower incidence of 
auditory hallucinations and hysteria than the paranoid schizo-
phrenics in the psychotic control group. 
VI. The overall trend in the high cannabis group was one of marked 
improvement between PSE assessments with significant improve-
ments in certain syndromes - hypomania, agitation, sexual and 
117 
fantastic delusions, grandiose and religious delusions, delusions 
of persecution, and irritability. The overall trend in the low 
cannabis group was one of improvement with significant improve-
ments in some neurotic syndromes - general anxiety, worry, and 
irritability. The psychotic control group showed virtually no 
improvement in the psychotic syndromes and a significant 
improvement in only one neurotic syndrome - worry . 
Although the three groups improved significantly on the total 
PSE score, the high cannabis group and the low cannabis group 
improved markedly whereas the psychotic control group improved 
only marginally. 
Even when matched specifically for total neuroleptic medication 
received during the period between PSE assessments, the high 
cannabis group and the low cannabis group improved to a marked 
extent whereas the psychotic control group improved only 
marginally. 
VII. Urinary cannabinoid concentrations correlated significantly with 
hypomania, overactivity and disorientation. 
VIII. There were significant differences among the three groups with 
regard to CPK and L[)--! determinations; the high cannabis group 
had significantly more elevated levels than the low cannabis 
group and the psychotic control group. There was a significant 
correlation between overactivity and CPK levels. 
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IX. It was shown that where the initial urinary cannabinoid concen-
tration is known it is possible to calculate the approximate 
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CHAPTER FClJR 
Discussion 
The group investigated was a recently hospitalized population who 
were admitted because of psychosis associated with behavioural distur-
bances. They therefore represent a select group and the discussion 
that follows does not pertain to cannabis abusers as a whole. 
4.1. PRESEI\CE OF TOXINS 
The only detectable toxins present on admission in the Coloured male 
patients studied were the cannabinoids. Sixty percent of the randomly 
selected patients were found to have these substances present; this 
is a large proportion and in comparison with a study in Jamaica, the 
value is almost double. Knight (1976) found 33ia of the male admis-
sions to a psychiatric hospital in Jamaica used cannabis. There are 
no figures available for other centres and it must be remembered 
that Knight's results were not confirmed by laboratory tests. 
It is possible that the delay in patients reaching the hospital after 
the onset of psychosis may have reduced the levels of toxins to below 
the sensitivity of the assays employed. This is unlikely since 
psychotropic drugs generally have long half-lives, eg methaqualone 
has a half-life of 20-40 hours, and if the latter drug had been used, 
its presence would have been detectable up to about one week later. 
The question of ethanol is more difficult. Its metabolism is fairly 
slow (100-110 mg/kg/hour) and follows zero order kinetics. Thus, if 
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the system were saturated, there would be an accumulation of ethanol. 
The assay used (~) is highly sensitive (lowest level of sensitivity 
10-2-0 µ g/ml (Mather ,and Assimosis, 1965)) and accordingly if patients 
had been abusing ethanol heavily the latter would have been present 
at detectable concentrations up to 24 hours later, depending upon the 
dose and the individual clearance capacity. It seems therefore that 
the only exogenous factor substantially contributing to the psychoses 
was the cannabinoids. 
No other study of cannabis-related psychiatric illnesses in the 
literature attempted to screen for the influence of other exogenous 
toxins. This constitutes an important omission and casts some doubt 
on the specificity of the findings of previous workers. Furthermore, 
no facilities were available for laboratory confirmation of cannabis 
abuse, so that workers were usually dependent on unreliable data such 
as the patient's own admission of cannabis use. In addition, when 
cannabis use is illegal or socially unacceptable many patients would 
have denied or minimized the taking of it. 
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In this study the EMIT method for the detection of urinary cannabinoids 
was a sensitive, reliable, and practical choice for qualitative 
identification and semi-quantitative estimation of major urinary 
cannabinoid metabolites. This method has become increasingly relied 
upon in situations of suspected drug abuse and its sensitivity, ease, 
speed of performance, and capacity for multisample handling may be 
considered to be superior to other techniques (RIA and ~/MS) 
(D'Conner and Rejent, 1981). Only recently has the EMITR method been 
successfully modified to detect cannabinoids in blood (Peel and Perrigo, 
1981) but it is as yet unavailable commercially. Even so , blood levels 
are less meaningful than urinary determinations since cannabinoids 
are rapidly sBquestrated from the central compartment into the fatty 
tissues (volume of distribution 500i) . 
4.2. AGE, PREVIOUS ADMISSIONS, AND SCX:::IAL CLASS CF THE CANNABIS 
GRCJJPS 
The patients in the cannabis groups, with only minor exceptions, 
were generally young adults, i.e. less than 30 years old. This is 
comparable with patients in other studies (Spencer, 1971; Chopra and 
&nith, 1974; Thacore and Shukla, 1976) and indicates that it is a 
young population that is at risk. 
Seventy percent of the high cannabis group and 60% of the low 
cannabis group had had one or more previous admissions to Valkenberg 
hospital prior to the current admission. In the high cannabis group, 
of the 6 patients (30%) who had had no previous admissions, only one 
patient was older than 21 years. It is possible that the youth of 
these patients contributed to the lack of previous psychiatric ad-
missions. It would appear likely that the previous admissions were 
episod~s of a cannabis-related illness. 
All patients - except two in the high cannabis group who had a 
social class allocation of II - were allocated to social class III 
(see Appendix). Therefore it seems as if a socio-economically 
deprived population are more at risk. However, since this study was 
confined to hospitalized Coloured males , no comparison was made with 
other social classes or racial groups. 
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4.3. MEDICATION 
Patients in all three groups received medication since it was deemed 
unethical to withhold this from these acutely ill patients. However, 
there were no significant differences among the three groups with 
regard to the amount of neuroleptic medication received during the 
inter-PSE period. (See Section 3.2.1.). (This is discussed in more 
detail in Section 4.5.). 
Since the amount of neuroleptic medication received, as well as the 
age, social class, and number of admissions were comparable in all 
three groups, the presence or absence of the cannabinoids appeared to 
constitute the only differentiating factor in the three groups. 
4.4. PRESENTATION OF PSYCHOSIS ON ADMISSION 
The high cannabis group was distinguished from the other two groups 
by a higher incidence of hypomania, agitation, and disorientation 
(Figure 3.2.1.). The high incidence of hypomania and agitation con-
firms the reports in the literature by Spencer (1971), WHO (1971), 
Chopra and 9nith (1974) and Thacore and Shukla (1976). Although only 
30% of the high cannabis group was disorientated, this was significant-
ly higher than the low cannabis group (Dia) and the ~sychotic control 
group (15%), It must therefore be noted that the majority of the 
high cannabis group was correctly orientated and were thus not 
manifesting a classical toxic confusional state. The relatively low, 
but significant, incidence of some degree of disorientation in the 
high cannabis group is in agreement with the reports by WHO (1971), 
Tennant and Groesbeck (1 972), and Chopra and Smith (1974). The low 
incidence of disorientation has a parallel with the description of 
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amphetamine psychosis (Connell, 1958). The latter is clinically in-
distinguishable from paranoid schizophrenia and the absence of dis-
orientation is one of its outstanding features. 
The psychotic control group was characterized by a higher frequency 
of hysteria, auditory and visual hallucinations, flattening of affect, 
and incoherent speech (Figure 3.2.1.). In contrast to the findings 
of WHO (1971), Thacore (1973), Chopra and Smith (1974), and Thacore 
and Shukla (1976) who showed that the predominant feature in their 
cases of cannabis-induced psychosis was auditory hallucinations, 
this study found a very low incidence of visual and auditory hallucin-
ations in both the low and the high cannabis groups (the incidence of 
visual hallucinations in the high cannabis group, the low cannabis 
group and the psychotic control group was 20%, 10% and · 45% respectively 
and the incidence of auditory hallucinations in the same three groups 
was 15%, 25% and 60% respectively. This is in agreement with Tennant 
and Groesbeck (1972) and Spencer (1971) who reported a very low 
incidence of auditory hallucinations. 
It therefore appears that the psychosis in the high cannabis group 
presented with a strong hypomanic element and tended not to exhibit 
those features usually associated with a nuclear schizophrenic ill-
ness (affective flattening, auditory hallucinations, and incoherent 
speech). 
The analyses of the syndrome profiles revealed no essential 
differences between the cannabis-related hypomanics and the control 
(endogenous) hypomanics (Figure 3.2.3. ). However, although not 
significant, there was a distinct trend for the control manics to 
have more depressive symptoms (Table 3.2.17.). 
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A different picture emerged in the comparison of cannabis-related 
paranoid schizophrenics and control (endogenous) paranoid schizo-
phrenics. (Figure 3.2.2.). The cannabis patients had a significantly 
higher incidence of agitation and simple depression and trends to-
wards higher scores on hypomania and sexual and fantastic delusions, 
delLSions of reference, irritability, tension and hypochondriasis. 
The high cannabis patients also had a significantly lower incidence 
of auditory hallucinations and hysteria and a non-significant trend 
towards less flattening of affect (Table 3.2.16.). It therefore 
seems that the high cannabis paranoid schozophrenics differed from 
their control counterparts in having a more affective (predominantly 
hypomanic) component and a lower incidence of those symptoms typical 
of a nuclear schizophrenic disorder. 
These findings are in agreement with the work of Thacore and Shukla, · 
(1 976) who showed that their cannabis-related paranoid psychosis 
differed from patients with 'functional' paranoid schizophrenia in 
having a high degree of affective psychopathology. We found there-
fore that the psychoses in the high cannabis group were diagnosed 
either as hypomanic illness or a form of paranoid schizophrenia with 
a strong hypomanic colouring. Excessive cannabis administration in 
our patients was associated to a lesser or greater degree wit h hypo-
manic symptomatology. This manifested either as a pure hypomanic 
state or as a paranoid schizophrenic state with a marked affective 
component. 
4.5. RATE OF .IMPROVEMENT 
It must be reiterated that there were no significant diff erences 
among the three groups with regard to the amount of neuroleptic 
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medication received during the period between PSE assessments. In 
this context improvement meant that in any particular patient there 
was a total resolution of a particular syndrome at the second PSE. 
The overall trend in the high cannabis group in the inter-PSE 
period was one of marked improvement with significant differences in 
hypomania, agitation, sexual and fantastic delusions, grandiose and 
religious delusions, delusions of persecution (psychotic syndromes), 
and irritability (a neurotic syndrome). (Figure 3.2.4. and Table 
3.2.18.). These rapidly resolving syndromes then belonged pre-
dominantly to the psychotic dimension. The low cannabis group 
showed overall improvement of syndromes with significant improvements 
in certain of the neurotic syndromes (general anxiety, worry, and 
irritability). In contrast, the psychotic control group showed 
virtually no change in the syndrome profile other than improvement 
in the neurotic syndrome of worry (see Figure 3.2.4., 3.2.5., and 
3.2.6.). 
The usual clinical impression is that it requires three weeks of 
neuroleptic therapy to control psychotic symptoms. This has been 
confirmed by Johnstone et al (1978) who studied forty five patients 
with acute schizophrenia . Their results are shown in Figure 4.1. 
and it is apparent that after one or two weeks of treatment with 
a-flupenthixol (a thioxanthene neuroleptic) there was no significant 
difference in symptomatology between placebo and active medication. 
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Figure 4.1. Improvement in total symptoms as a function of treatment 
with a -flupenthixol and placebo (from Johnstone et al, 1978) 
*p ~0,05 a-flupenthixol vs placebo 
Johnstone et al (1978) also noted that schozophrenic patients with 
significant affective symptoms (schizo-affective sub-group) showed 
little drug effect_ when compared with the non-schizoaffective sub-
group. This is pertinent as the majority of our patients in the 
high cannabis group had affective symptoms. Furthennore, improve-
ments with regard to psychotic symptoms in the high cannabis, the low 
cannabis, and the psychotic control groups were as follows: 75ia, 66ia, 
and 15,8ia respectively for the behaviour and speech syndromes and 
62ia, 85ia, and 15,8ia respectively for the delusional and hallucinatory 
syndromes. (Table 3.2.19.). This strengthens the argument that the 
rapid improvements were probably due to the progressive elimination 
of cannabinoids from the body with time. Ho et al (1970) reported 
that in mice 6Dia of an inhaled dose of cannabinoids reached the brain 
and less than a 25ia decrease in brain concentrations occurred after 
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seven days. Studies of this kind have not been done in human sub-
jects but in this study urinary cannabinoids were detected in some 
cases up to three weeks following admission to the hospital. The 
fact that patients had not recovered completely at the time of the 
second PE£ may have been a reflection of residual brain cannabinoids. 
In order to eliminate the influence of neuroleptic medication 
received during the period between PSE assessments, patients in the 
three groups were exactly matched for the total amount of medication 
received during that period and compared. These analyses confirmed 
that despite strict matching for medication our conclusions remained 
unchanged. The percentage improvenent on the overall score in these 
cases was 71,6io, 95io, and 33,3io for the high cannabis group, the low 
cannabis group and the psychotic contrql ·group respectively. However, 
the improvenents were specifically related to scores in the psychotic 
syndromes in which the psychotic control group renained basically 
unchanged (Table 3.2.20.). Since the presence of cannabinoids was 
the only distinguishing feature between the cannabis groups and 
the control group we hypothesize that this rapid and marked improve-
ment in the cannabis groups is attributable to the .progressively 
decreasing cannabinoid concentrations over the one week period. 
4 .6. THE LOW CANNABIS .GRCl.JP 
The low cannabis group resembled the high cannabis group in terms of 
certain clinical symptoms i.e. the former had a lower incidence of 
hysteria, auditory and visual hal lucinations, flattening of affect 
and incoherent speech compared to psychotic controls. On the other 
hand, it differed from the high cannabis group because, unlike the 
latter , there was no difference between the low cannabis and the 
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psychotic control groups in the incidence of hypomania and agitation 
(Figure 3.2.1. and Table 3.2.15.). The clinical course of the ill-
ness in the low cannabis group was very similar to that in the high 
cannabis group patients; there was a speedy resolution of the syn-
drome profiles after one week (see Figure 3.2.5. and Table 3.2.19.). 
Several probabilities might explain these findings. Perhaps the 
most likely - in view of the marked short-term improvement compared 
with psychotic controls - is that these patients had much higher 
urinary cannabinoid concentrations at the onset of the illness and 
that owing to lengthy delays in admission to hospital, both the 
urinary cannabinoid levels and the intensity of psychotic symptom-
atology had diminished. 
Another explanation is that as cannabis-induced psychosis may be 
dose-related, patients in the low cannabis group would have been 
more likely to show an attenuated form of this psychosis. 
The third possibility is that the low cannabis group contained an 
admixture of cannabis precipitated psychoses as well as endogenous 
psychoses occurring irrespective of cannabis. Such a mixture would 
be expected to produce a clinical picture intermediate between the 
high cannabis patients and the psychotic control patients. If this 
were so, however, then the rat e of improvement after one week should 
have been intermediate between the high cannabis group and the 
psychotic control group. This is not the case. Tables 3.2.19. and 
3.2.20. clearly demonstrate, as mentioned above, that the low cannabis 
group improved markedly and possibly even at a greater rate than the 
high cannabis group. 
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Serum CPK and Serum LOH 
The serum CPK and serum LOH levels were elevated in the three groups 
with the _high cannabis group having significantly more elevated 
levels than the other two groups (Tables 3.4.1., 3.4.2., and 3.4.3.). 
These data are consistent with those of Meltzer (1968, 1969, 1970, 
1973a, 1973b), Meltzer et al (1969, 1970, 1971) and Taylor and 
Abichandani (1981) who all reported elevated CPK levels in a hetero-
genous group of psychotic patients. More specifically, our results 
support those of Farber and Huertas (1976) who reported elevated 
CPK and LOH levels in two cases of acute cannabis intoxication, and 
the significantly elevated levels in our high cannabis group· seem to 
confirm this. 
Our results showed that there was a strong correlation between over-
activity and CPK levels. As the predominant feature of the high 
cannabis group was a hypomanic colouring with concomitant overactivity 
and agitation, the elevated CPK levels would seem to reflect 
heightened muscular activity rather than the presence of the psychosis 
per se. The same explanation probably holds for the elevated LG-I 
levels although the sample size was too small to obtain a significant 
correlation between this parameter and overactivity. 
4.7. PREDICTION OF THE PERIOD REQUIRED FOR A PATIENT TO BE FREE 
OF CETECTABLE URINARY CANNABINOIDS 
From the serial daily assessments of urinary cannabinoid concentra-
tions it was possible to plot a linear regression for the relation-
ship between time and initial urinary concentration (see Section 3.5.). 
Although approximate, this may have a place in the prediction of the 
time required for a patient to be free of detectable urinary cannabi-
noids where the initial level is known. For example, a patient with 
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an initial level of 400 µgCRC/g creatinine would require 14 days to 
be free of detectable urinary cannabinoids, and one with an initial 
level of 75 µgCRC/g creatinine would require 6 days. 
4.8. COf\CLUSIONS 
The following are the main conclusions derived from our study. 
I. Sixty percent of a random sample of Coloured males admitted to 
Valkenberg f-bspital abuse cannabis. 
II. The population at risk is young (median age 24) and most 
patients were in social class III. 
III. The presence of urinary cannabinoids was an important factor 
in the nature and course of a psychotic illness. 
IV. The high cannabis group exhibited certain syndromes which were 
of diagnostic importance - hypomania, overactivity, and some 
disorientation. This group were also markedly low on auditory 
hallucinations, flattening of affect, and incoherence of speech 
(these symptoms are more characteristic of a pure schizophrenic 
illness). It is relevant to note that in the majority of 
patients the illness occurred in a state of clear conciousness. 
V. The manic psychosis in the high cannabis group was not 
significantly different in its profile from that of the func-
tional psychosis. On the other hand the paranoid schizophrenics 
in the high cannabis group, when compared with control paranoid 
schizophrenics, showed a strong hypomanic el ement with a lower 
incidence of auditory hallucinations. 
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VI. The psychoses in the high cannabis group had an excellent prog-
nosis: they were short-lived and resolved more rapidly and to 
·a greater extent than those of the psychotic control group. 
VII. High enzyme levels, especially CPK in the high cannabis 
group, were probably secondary to muscular overactivity and 
appear to confirm the strong hypomanic component of the 
psychosis. 
Seven (35%) of the patients in the high cannabis group presented 
with a manic psychosis which was clinically indistinguishable from 
the naturally occurring mania except that the course of the illness 
was considerably shorter (7-10 days). The remainder of the patients 
were predominantly diagnosed by the PSE as paranoid schizophrenia. 
But on further analysis these patients differed from their matched 
controls in having a prominant affective colouring in addition to a 
lack of the typically schizophrenic features of auditory hallucina-
tions, flattening of affect, and incoherence of speech . In fact, 
diagnosticians might be justified in regarding them as being more in 
the realm of schizo-affective psychosis than true schizophrenia. It 
is suggested that the psychosis delineated in this study would be 
best catogerized in the schedule suggested by Negrete (1973) as 
belonging to the classification '.Acute Cannabis Psychosis'. Accord-
ing to that scheme the most consistent feature of the latter diagnosis 
is a rapid remission rate. 
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4.9. CANNABIS: IS IT AN ETIOLOGICAL FACTOR? 
The role that cannabis plays in the psychosis is debatable and it 
seems that there are three possibilities which will be considered 
in turn. 
i. The presence of cannabis plays no role in the psychosis and is 
merely an incidental finding. 
ii . Cannabis is a precipitant of a pre-existing and otherwise 
latent tendency to endogenous psychosis in certain individuals. 
iii. Cannabis has a direct causative role in the psychosis. 
The possibility that cannabis plays no role in the psychosis and is 
merely incidental to it is doubtful. Our data have unequivocally 
shown that the psychosis in the high cannabis group differs from 
the psychotic controls both in initial clinical presentation and 
subsequent course of illness. To some extent the same limitation 
holds true if cannabis acted as a precipitant of a pre-existing or 
latent psychosis. In this regard Treffert (1978) described four 
schizophrenic patients where cannabis use resulted in serious exaccer-
bation of the illness. If cannabis merely acted as a precipitant 
then the resulting psychosis would conform in its clinical and prog-
nostic aspects to the appropriate endogenous state. This has clearly 
not been demonstrat ed in the high cannabis group. The clinical 
characteristics of the low cannabis group however, were intermediate 
between the high cannabis and the psychotic control groups and it is 
probable that among these patients there were some where cannabis 
had exerted a trigger action. 
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The most acceptable explanation of our findings is that cannabis 
itself is causative of a psychosis; such an opinion has been held 
previously by several authors (Thacore, 1973; Chopra and 8'nith, 
1976; Thacore and Shukla, 1976) all of whom are of Eastern cultures. 
However, these workers lacked the sophisticated techniques that 
were available to us in this study. Their classification of mental 
illness tended to be arbitrary and they lacked a standard diagnostic 
instrument. Even more serious was the unavailability of an appro-
priate pharmacological biochemical assay for cannabinoids. These 
methodological short-comings made their work unreliable and 
scientifically unacceptable. As far as the author is aware the 
present project has been the first of its kind in studying cannabis 
psychosis with scientifically acceptable diagnostic and analytical 
methods. 
The psychosis described in our study was one in which a hypomanic 
colouring and a lack of the more typical schizophrenic features are 
outstanding features. The illness is short-lived and its course 
appears to be directly related quantitatively to the amounts of 
cannabis in the body tissues and, more specifically, in neural 
tissues. 
The production of hypomania by high cannabis intake in our patients 
confirms the results of earlier volunteer studies. Ames (1958), 
Hollister (1971) and Tylden (1974) all noted that euphoria and 
excitability occurred after cannabis administration in an experimental 
setting .(see Section 1.7.). These data again emphasize that cannabis 
has a direct causative link with the occurrence of hypomanic 
symptomatology. 
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It is interesting that Katin, Post and Goodwin (1973) used ~9-THC to 
treat 8 hospitalized depressed patients; however the drug failed to 
produce significant euphoria or anti-depressant response during the 
period of administration. It is felt that the brief period of 
administration (seven days) and the low doses administered (D,3mg/Kg) 
may have been responsible for the lack of positive results. 
The scepticism prevelant in Western cultures as to the existence of 
a valid clinical syndrome induced by cannabis seems to be based on a 
dearth of such psychotic cases in Western countries. Use of cannabis 
preparations in Eastern cultures has been endemic for centuries and 
it is used by all sectors of those societies (Thacore, Saxon, and 
Kumar, 1971~ cited by Thacore, 1973). Despite prevalant cannabis 
use in the West it is possible that qtJantities taken by western 
users were far lower than in the East. 
Carlini et al (1973) and Izquierdo et al (1973) showed that cannabi-
diol (CBD) (which has no hallucinogenic properties) was active in 
reducing or blocking convulsions produced in experimental animals. 
Other workers (Consroe and Walkin, 1977; Turkanis et al, cited by 
Mechoulam and Gaoni, 1978) confirmed these findings and showed that 
. the effects of CBD were comparable with those of diphenylhydantoin 
and other drugs clinically effective in major seizures. A trial with 
human volunteers showed that CBD did not induce toxic effects and 
that CBD-treated patients showed significantly improved seizure 
control when compared to placebo-treated patients tunha et al, 1980). 
The presence of cannabidiol in cannabis grown outside South Africa 
may have a protective action on individuals because of its anti-
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convulsant properties. It is very important to emphasize that the 
cannabis grown in South Africa lacks cannabidiol (Field and Arndt, 
1980). Teggin (1981) has speculated that this lack of cannabidiol 
(and therefore anti-convulsant activity) in the South African plant 
might render individuals more susceptible to a psychotic reaction. 
This possibility, combined with ready availability, cheapness and 
heavy usage, may be a factor in the high rate of cannabis-induced 
psychosis observed in South Africa. This area certainly warrants 
more specific investigation. 
It must be borne in mind that the population studied was a select 
one in that it represented acutely psychotic patients admitted to a 
psychiatric hospital. From such a biased sample one cannot generalize 
to the population at large. No attempt was made in this study to 
investigate the urinary cannabinoid levels and psychiatric status 
in this community at large. Hence it is feasible that many individuals 
who habitually abuse cannabis might have had levels as high, or even 
higher, than our own sample without becoming disturbed and requiring 
hospitalization. 
This study has shown the usefulness, simplicity , and relative in-
R expensiveness of the EMIT system for semi-quantitative assessments 
of urinary cannabinoids. It is recommended that in view of the 
importance of cannabis in the etiology of psychiatric illness, routine 
screening should be instituted of all psychiatric admissions. 3.Jch 
screening would aid in the evaluation, diagnosis and management of 
psychiatric patients and influence treatment and management and might 
have an important advantage in forensic psychiatry. 
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The fact that cannabis seems to be implicated in the production of 
hypomanic symptomatology is worthy of further research. Animal ex-
periments directed at exploring the influence of neurot~ansmitters 
may help us to understand the biochemical mechanisms operative in 
hypomania. 
In essence, the upshot of this preliminary study is that excessive 
quantities of cannabis play a major role in accounting for psychiatric 
morbidity among Cape Coloured male psychiatric patients in the Western 
Cape. This is a serious mental health problem and one that deserves 
to be investigated on many fronts. Such aspects as premorbid 
personality, socio-economic status, socio-cultural background, 
nutritional status, genetic predisposition, and local chemovariance 
in cannabis are some of the factors that conspire to produce the 
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Magisterial Districts of Valkenberg Hospital catchment area from which 






















Allocation of Social Class. 
Pooled Family Levels of Highest Social 
Income per Month Education I ! Occupation Class 
Greater than Higher than Professional I 
R 800-00 Std. 8 
R 251-00 to Std. 4-7 Skilled labourer / II 
R 800-00 artisan 
Clerical/ 
Technical 
RO - R 250-00 Up to Std. 3 Unskilled/ lII 
semi-skilled 
labourer 
A patient was allocated a particular social class if he fulfilled two 








APPENDIX C FULL VERSION OF PRESENT STATE EXAM~NATION 
1. INTRODUCTION 
The interviewer should introduce himself briefly, describe 
the purpose of the interview and explain about any record-
ing equipment. The purpose of the introductory section is 
to obtain an overall picture of the symptomatology, in the 
subject's own words. 
** To begin with, I should like to get an idea of the sort 
of problems that have been troubling you during the 
past month. What have been the main difficulties? 
Record the main symptoms spontaneously mentioned. 
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Means of exploration, if subject gives inadequate information: 
If subject's statement too brief Can you tell me more about 
If subject has no more to add 
If statements are difficult to 
understand 
If subject is vague 
that? 
What else has been 
troubling you? 
Can you explain what you 
mean by ••• ? 
Could you give an example 
of •.• ? 
If no'other response forth- Why did you come to the 
coming (hospital)? 
RATE PATIENT'S ACCOUNT OF SYMPTOMS. 
O = Subject responds adequately 
1 = Account somewhat inadequate but interview can proceed. 
2 = Account seriously inadequate but interview proceeds in 
an attempt to rate some subjective responses, as well 
as behaviour, affect and speech. 
3 = Impossible to continue with interview. Only behaviour, 
affect and speech section rated. 
REASONS FOR INADEQUACY (TICK AS MANY AS APPROPRIATE). 
Denial or guardedness 
Incoherence 
Irrelevance 
Replies too brief 
Poverty of content of speech 
Inattention 
Refusal 
Patient mute, stuporous, 
Other, specify 
IF (1) OR (2) CARRY ON WITH SECTION 2, UNLESS SUBJECT MENTIONS OR 
HINTS AT DELUSIONS OR HALLUCINATIONS-,t '" SECTION 18. 
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Current treatment, if subject not seen in hospital or clinic 
Rate the following if sufficient information has already 
emerged. 
If not, use the suggested question: 
May I ask if you are seeing any doctor for your nerves? 
Or specify if psychosomatic complaints. 
What kind of doctor is he? 
Your own GP? A private doctor? Psychiatrist? 
0 = No doctor 
1 = GP 
2 = Private doctor other than GP 
3 = Psychiatrist 
4 = Hospital out-patient (other than psychiatric) 
5 = Other paramedical specialist, or osteopath 
6 = Other specify 
Are you attending for treatment any person who is not medica-
lly qualified, e.g. lay therapist, herbalist, acupuncturist, 
faith healer, Christian Science, church which forbids medical 
advice? 
What were you complaining of at the time? 
Specify type of treatment 
Complaint 
2. HEALTH, WORRYING, TENSION 
** 
** 
Is your physical health good? 
(Does your body function normally?) 
Do you feel you are physically ill in any way? 
(What is it that like? How serious is it?) 
RATE SUBJECT'S OWN SUBJECTIVE EVALUATION OF PRESENT PHYSICAL 
HEALTH (irr~spective of whether physical disease is present). 
O = Feels physically very fit. 
, 1 = Feels particular physical complaint but does not say 
positively feels fit. 
** 
2 . = Feels unwell but not very seriously incapacitated. 
3 = Feels seriously incapacitated by physical illness. 
What does your doctor say is wrong? 




RATE PRESENCE OF PHYSICAL ILLNESS OR HANDICAP, D (2) 
taking results of recent investigations and physical state 
examinations into account. 
O = No physical illness or handicap present. 
1 = Mild but significant physical illness or handicap 
{e.g. influenza or limp}. 
2 - = More serious physical illness or handicap present 
but not incapacitating or threatening to life (e.g. 
deafness or duodenal ulcer). 
3 = Physical illness or handicap present which is incap-
acitating or threatening to life {e.g. blindness or 
carcinoma). 
Specify illness, disabilities and duration: 
RATE PSYCHOSOMATIC SYMPTOMS. D { 3) Special projects only 
** Have you worried a lot during the _past month? 
{What do you worry about?) 
PROBE: {Money, housing, children, health, work, marriage, 
relatives, friends, neighbours, other). 
{How much do you worry? Are you a worrier?) 
If any indication of worry, use further probes: 
** What is it like when you worry? 
{What sort of state of mind do you of mind do you get into?) 
{Do unpleasant thoughts constantly go round and round in 
your mind?) 
{Can you stop them by turning your attention to something 
else?) 
RATE WORRYING: A round of painful thought 
be stopped and is out of proportion to the 
about. 
1 = Symptom definitely present during past 
· moderate clinical intensity or intense 
of the time. 
which cannot be 
subject worried 
month, but of D 
less than 50% 
2 = Symptom clinically intense more than 50% of the time. 
** Have you had headaches, or other aches or pains, during 
the past month? 
{What kind?) 
RATE ONLY TENSION PAINS, e.g. 'band round head', 'pressure', 
'tightness in scalp'. 'ache in back of neck', etc. not mig-
{ 4) 
raine. D 1 = Symptom definitely present during past month, but of (5) 
moderate clinical intensity, or intense less than50% 
of the time. 
2 = Symptom clinically intense more than 50% of past month. 
** Have you been getting exhausted and worn out during the 
day or evening, even when you haven't been working very 
hard? 
RATE TIREDNESS OR EXHAUSTION: Do not include tiredness due 
to 'flu, etc. = 9. 
1 = Only moderate form of symptom {tiredness) present; or 
146 
intense form (exhaustioo) less than 50% of the time D (6 ) 2 = Intense f0r.m of symptom (exhaustion) present more than 
50% of the past month. 
** Have you had difficulty in relaxing during the past 
month? 
(Do your muscles feel tensed up?) 
RATE MUSCULAR TENSION: Do not include a subjective 
feeling of nervous tension, which is rated later. 
1 = Symptom definitely present during past ·month, but 
intensity, or intense less than 50% of the time. 
2 = Symptom clinically intense more than 50% of past D (7) 
month. 






(Do you have to keep pacing up and down?) 
v 1 = Only moderate form of symptom (fidgety restless) 
pr€sent; or · intense form · (p~cing, can't sit qown.). 
less . than 50% of the time. 
2 = Intense form of symptom (pacing, etc.) present 
more than 50% of past month. 
Do you tend to worry over your physical health? 
D (8) 
RATE HYPOCHONDR!ASIS: Overconcern with possibility of 
death, disease or malfunction. Re-rate at end of inter-
view if subject constantly reverts to hypochondriacal 
preoccupation. D 
Consider ratings of symptoms (1) and (3). (9) _ 
1 = Symptom present during past month, but not (2). 
2 = Subject constantly reverts to hypochondriacal 
preoccupations during interview. 
Do you often feel on edge or keyed up or mentally tense 
or strained? 
(Do you generally suffer with your nerves?) 
(Do you suffer from nervous exhaustion?) 
RATE SUBJECTIVE FEELING OF 'NERVOUS TENSION': 
There is no need for autonomic accompaniments for this 
symptom to be rated present. 
1 = Symptom definitely present during past month, but of 
moderate intensity, or intense less than 50% of the 
time. D 2 = Intense form of symptom present more than 50% of (10) 
the past month. 
Do you find that a lot of noise upsets you? 
(Do noises sometimes seem to penetrate, or go through 
your head?) 
RATE HYPERSENSITIVITY TO NOISE. 
1 = Moderate degree during month. D 
2 = Severe degree during month. 
3. AUTONOMIC ANXIETY 
In this section, rate only subjective anxiety with autonomic 
accompaniments, either free-floating or situational. Do not 
include worrying or nervous tension. Do not include anxiety 
due to, e.g. pers~cutory delusions, . except in the special 
i tern (no. 1 3) • 











** Have there been times lately when you have been very 
anxious or frightened? 
(What was this like?) 
(Did your heart beat fast?) Ask for other autonomic 
symptoms. 
(How often in the past month?) 
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RATE FREE-FLOATING AUTONOMIC ANXIETY: Exclude ~ (11) 
if due to delusions. Exclude if purely situational. 
** 
1 = Symptom definitely present, with autonomic accompani-
ment, during past month, but of moderate clinical 
intensity, or intense less than 50% of the time. 
2 = Symptom clinically intense more than 50% of the time. 
Have you had the feeling that something terrible might 
happen? 
(That some disaster might occur but you are not sure 
what? Like illness or death or ruination?) 
(Have you been anxious about getting up in the morning 
because you are afraid to face the day?) 
(What did it feel like?) 
RATE ANXIOUS FOREBODING WITH AUTONOMIC ACCOMPANIMENTS 
1 = Symptom definitely present, with autonomic accom-
paniment, during past month, but of moderate clinical 
intensity, or intense less than 50% of the time. 
2 = Symptom clincally intense more than 50% of the time. 
RATE AUTONOMIC ANXIETY DUE TO DELUSIONS, etc. 
and if necessary defer to end of interview. D (13) 
0 = No anxiety due to delusions or hallucinations 
1 = Subject complains of anxiety but no evidence of anxiety 
on examination. 
2 = Clearly anxious or frightened because of delusions or 
hallucinations. 
CUT OFF IF NO EVIDENCE OF ANXIETY OR IF ANXIETY DUE 
ONLY TO DELUSIONS+ SECTION 4. 
Have you had times whe~ you felt shaky, or your heart 
pounded, or you felt sweaty, and you simply had to do 
something about it? 
(What ·, was it like?) 
148 
(What was happening at the time?) 
(How often during the past month?) 
RATE PANIC ATTACKS WITH AUTONOMIC SYMPTOMS: 
A panic attack is intolerable anxiety leading 
action to end it, e.g. leaving a bus, phoning 




1 = One to four panic attacks during the month. 
2 = Panic attacks five times or more. 
Do you tend to get anxious in certain situations, such 
as trave·lling, or being alone, or being in a lift or 
tube train? 
(What situations? How often during the past month?) 
(CHECK LIST: Can be presented on separate card and each 
item rated separately, if needed. 
Crowds (shop, street, theatre, cinema, church). 
Going out alone; being at home alone. 
Enclosed spaces (hairdresser, phone booth, tunnel). 
Open spaces, bridges. 
Travelling (buses, cars, trains). 
RATE SITUATIONAL AU'rONOMIC ANXIETY. 
1 = Has not been in . such situations during the past 
month but aware that anxiety would have been present 
if the situation had occurred. 
2 = Situation has occurred during the past month and 
· patient did feel anxious because of it. 
What about meeting people, e~g. going into a crowded room 
making conversation? 
(CHECK LIST: Present card if necessary: 
Speaking to an audience. 
Eating, drinking or writing in front of other people. 
Parties) 
D RATE AUTONOMIC ANXIETY ON MEETING PEOPLE. 
1 = Has not been in such situations during the past month 
but aware that anxiety would have been present if the 
situation had occurred. 
2 = Situation has occurred during the past month and 
patient did feel anxious because of it. 
Do you have any special fears, like soma people are scared 
of feathers or cats 0r ·; spiders or birds? 
(CHECK LIST: Present card if necessayr: 
Heights, thunderstorms, darkness. 
Animals or insects of any kind. 
Dentists, injections, blood, injury.) 
( 16) 
RATE ONLY SPECIFIC PHOBIAS, NOT GENERAL SITUATIONAL ANXIETY. 
1 = Has not been in such situations during the past month 
but aware that anxiety would have been present if the 
situation had occurred. 
2 = Situation has occurred during the past month and 
ient did feel anxious because of it. 
pat-
0(17) 
Do you avoid any of these situations (specify as 
appropriate) because you know you will get anxious? 
(How much does it affect your life?) 
RATE AVOIDANCE OF ANXIETY-PROVOKING SITUATIONS. 
1 = Subject tends to avoid such situations whenever 
possible. 
2 = Marked generalisation of avoidance has occurred 
during past month, e.g. subject has not dared to 
leave the house or has gone out only if accompanied. 1 
Describe anxiety symptoms and list phobias. 
4. THINKING, CONCENTRATION, ETC. 




Do your thoughts tend to be muddled or slow? 
(Can you make up your mind about simple things quite 
easily?) (Make decisions about everyday matters?) 
RATE SUBJECTIVELY INEFFICIENT THINKING (if due to 
intrusion of alien thoughts, rate 9). D 
1 = Symptom definitely present during the past month, 
but of moderate clinical intensity, or intense less 
than 50% of the time. 
2 = Symptom clinically intense more than 50% of the past 
month. 
What . has your concentration been like recently? 
(Can you read an article in the paper or watch a TV 
programme right through?) 
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( 19) 
(Do your thoughts drift off so that you don't take 
things in?) 
RATE POOR CONCENTRATION. D (20) 
** 
** 
1 = Only moderate form of symptom present during the past 
month (e.g. can read a short article, can concentrate 
if tries hard): or intense less than 50% of the time. 
2 = Symptom clinically intense (cannot attempt to read 
or concentrate) more than 50% of the past month. 
Do you tend to brood on things? 
(So much that you even neglect your work?) 
RATE NEGLECT DUE TO BROODING. D (21) 
1 = Symptom has caused moderate impairment to work or 
social relationships. 
2 = Marked impairment. 
What about your interests, have they changed at all? 
(Have you lost interest in work, or hobbies, or recrea-
tions?) 
(Have you let your appearance go?) 
RATE LOSS OF INTEREST continu.ing during the past month. 
1 = Symptom definitely present during the past month, but 
150 
of moderate clinical severity nr severe loss less D (22) 
than 50% of the time. 
2 = Symptom clinically severe more than 50% of the past 
month. 
** Have you become interested in new things at all? 
IF EVIDENCE OF EXPANSIVE MOOD OR IDEAS~ SECTION 9. 
IF ODD IDEAS, EXPLORE FURTHER, PROCEED TO SECTION 15. 
IF APPROPRIATE. 
** Have you suffered any lapses of memory recently? (PROBE 
ONLY) 
IF EVIDENCE OF DISSOCIATION OR ORGANIC MEMORY LOSS ""7 
SECTION 16. 
ANSWERS, TO THESE QUESTIONS MAY SUGGEST THAT OTHER TYPES 
OF THOUGHT ' DISORDER ARE PRESENT, IF NOT, CUT OFF~ 
SECTION 5. 
IF ANY 'EVIDENCE OF THOUGHT DISORDER: 
Are you in full control of your thoughts? 
Can people read you~ mind? 
Is anything like hypnotism or telepathy going on? 
IF NECESSARY, PROCEED TO SECTION 13. 
5. DEPRESSED MOOD 
** Do you keep reasonably cheerful or have you been very 
depressed or low spirited recently? 
Have you cried at all? 
(When did you last really enjoy doing anything?) 
RATE DEPRESSED MOOD, N.B. When rating clinical severity D 
of depression remember that deeply depressed people may (23) 
nqt necessarily cry. See definition in glossary. 
** 
1 = Only moderately depressed during past month, or deep 
depression for less than 50% of the time and tending 
to vary in intensity. 
2 = Deeply depressed for more than 50% of the past month, 
and tending to be unvarying in intensity. 
How do you see the future? 
(Has life seemed quite hopeless?) 
(Can you see any future?) 
(Have you given up or does there still seem some reason 
for trying?) Do you still think you might get better? 
RATE HOPLESSNESS on subject's own view at present. 
1 = Hopelessness of moderate intensity but still has 
some degree of hope for the future (irrespective 
of time during month.) 
2 = Intense form of symptom (patient has given up 
hope altogether). ~ 
USE JUDGEMENT ABOUT WORDING 
D (24) 
** Have you felt that life wasn't worth living? 
(Did you ever feel like ending it all?) 
(What did you think you might do?) 
(Did you actually try?) 
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(Did you ever think of ending your life?) 
RATE SUICIDAL PLANS OR ACTS. D (25) 
1 = Deliberately considered suicide (not just a fleeting 
thought) but made no attempt. 
2 = Suicidal attempt but subject's life never likely to 
be in serious dang-e:r . except unintentionally. 
3 = Suicidal attempt apparently designed to end in death 
(i.e. accidental discovery or inefficient means). 
N.B. Examiner should judge clinically whether there was 
intent to end life or not. If in doubt, assume not. 
IF EVIDENCE OF BOTH DEPRESSION AND ANXIETY RATE ANXIETY 
OR DEPRESSION PRIMARY. 
If .s1rbje.ct suffers from both anxiety and depression, and 
both have been rated as present, try to decide which is 
primary. 
0. : Anxiety is primary. Depression appears to be entirely 
explicable in terms of the limitations placed on the 
subject by the symptoms of anxiety, e.g. being unable 
to leave the house, travel, meet people, etc., or being 
afraid of heart disease because of palpitations. 
1. Anxiety and depression both present but seem 
independent of each other or it is not· possible to 
decide whether one of them is primary. 
2. Depression is primary. Anxiety is either a result of 
the depression (e.g. subject is frightened because of 
morbid or suicidal ideas) or it takes the form of fears ' 
of catastrophe, forebodings about illness or death, 
dread of having to face the day when first waking in 
the morning, preoccupation that something awful is 
going to happen. Panic attacks and situational anxiety, 
if present, are secondary to depression. 
(26) 
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Is the depression worse at any particular time of day? 
RATE MORNING DEPRESSION (particularly on waking) 
0 = No depression. 
1 = Not specially marked in mornings. 
2 = Specially maiked in mornings. 
0(27) 
6. SELF AND OTHERS 
** Have you wanted to stay away from other people? 
(Why?) 
(Have ypu been suspicious of their intentions? 
Of actual harm?) 
RATE SOCIAL WITHDRAWAL 0(28) 
1 = Only passive form of symptom, i.e. subject does not 
seek company but does not refuse it if offered; or, if 
active withdrawal, less than 50% of the month. 
2 = Actively avoids company (refuses it if offered). 
Actively withdraws in this way for more than 50% of the 
month. 
** What is your opinion of yourself compared to other people? 
(Do you feel better, or not as good, or about the same 
as most?) 
(Do you feel inferior or even worthless?) 
RATE SELF-DEPRECIATION. 
1 = Some inferiority, not amounting to feeling of worthless-
ness. If subject considers self to be worthless, this 
intense form of the symptom is present less than 50% 
of the time. 
2 = Subject considers self to be completely worthless. 
Symptom present more than 50% of the month. 
** How confident do you feel in yourself: 
(for example, in talking to others, or in managing your 
relations with other people?) 
0 RATE LACK OF SELF-CONFIDENCE WITH OTHER PEOPLE. 
Consider only competence in social relationships, not 
competence at mechanical work, etc. 
1 = Moderate lack of self-confidence, or intense lack less 
than 50% of the month. 
2 = Intense lack of self-confidence more than 50% of the 
month. 
(30) 
** Are you self-conscious in public? 
(Do you get the feeling that other people are taking 
notice of you in the street or a bus or a restaurant?) 
(Do they ever seem to laugh at you or talk _about you 
critically?) 
(Do you consider people really are looking at you, or 
is it perhaps the way you feel about it?) 
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RATE SIMPLE IDEAS OF REFERENCE (NOT DELUSIONS). 0<31) 
1= Marked self-consciousness only (irrespective of time 
during month). 
2= Feels that people are criticising or laughing at 
self but can be reassured. 
IF NO EVIDENCE OF GUILT, CUT OFF - SECTION 7 
(IF EVIDENCE OF MISINTERPRETATIONS, DELUSIONS OF REFERENCE 
OR PERSECUTION - SECTION 15B, 15C). 
IF EVIDENCE OF GUILT: 
Do you have the feeling that you are being blamed for some-thing, or even accused? 
What about? 
RATE GUILT¥ IDEAS OF REFERENCE. Do not include justifiable blame or accusation. Exclude delusions of guilt. 
1= Subject feels blamed but not accused (irrespective of 
time during month). D 2= Subject feels accused of some sin or misdemeanour. (32) Not delusional. 
IF DELUSIONS OF REFERENCE MAY BE PRESENT~ SECTION 15B. 
Do you tend to blame yourself at all? 
(If people are critical, do you think you deserve it?) 
RATE PATHOLOGICAL GUILT ONLY. 
1= Subject feels over-guilty about some peccadillo 
(irrespective of time during month). 
2= Subject feels to blame for everything that has gone 
wrong even when not his fault, but not delusional. 
IF DELUSIONS OF GUILT MAY BE PRESENT f SECTION 15G. 
Do you blame anyone else for your troubles? 
IF DELUSIONS OF PERSECUTION 7 SECTION 15C. 
7. APPETITE, SLEEP, RETARDATION, LIBIDO 
** What has your appetite been like recently? 
~ (33) 
(Have you lost any weight during the past three months?) 
' I 
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RATE LOSS OF WEIGHT DUE TO POOR APPETITE. 
Do not include changes due to physical illness. D (34) 
1= Less than \5lbs (~:kg). 
2= 1 ~ (I'S lbs) or more. 
** Have you had any trouble getting off to sleep during the 
past month? 
(How long do you lie awake?) 
(What happens if you take sleeping tablets?) 
(How often does it happen?) D (35) 
RATE DELAYED SLEEP. 
1 = One hour or more delay (irrespective of sleeping tablets). 
2 = Two hours or more delay (irrespective of sleeping tablets). 
(In either case, ten or more nights during month.) 
** Do you seem to be slowed down in your movements, or to 
have too little energy recently? How much has it affected 
you? 
Do things seem to be moving too fast for you?} 
RATE SUBJECTIVE ANERGIA AND RETARDATION. D (36) 
1 = Marked subjective listlessness and lack of energy. 
2 ·= Marked retardation and underactivity (Irrespective 
of time during month}. 
IF NO APPETITE OR SLEEP DISTURBANCE, AND NO DEPRESSION, 
CUT OFF 7 SECTION 8. 
IF SLEEP DISTURBANCE OR DEPRESSION: 
Do you wake early in the morning? 
RATE EARLY WAKING (one hour before usual}. c=J (37) 
1 = One hour or more before ordinary time. 
2 = Two hours or more before ordinary time~ 
·(In either case, ten or more nights during month.} 
Has there been any change in your interest in sex? 
RATE LOSS OF LIBIDO WITHIN PRESENT EPISODE OF 
ILLNESS AND PERSISTING DURING PAST MONTH. 
1 = Marked loss of interest and performance. 
2 = Almost total loss of libido. 
D (38) 
Does the depression or tension get worse just before the 
start of the monthly period? 
RATE PREMENSTRUAL EXACERBATION 
0 = No definite exacerbation. 




** Have you been very much more irritable than usual recently? 
(How do you show it?) 








Keeps irritation to himself. 
Shows anger by shouting or quarrelling. 
Sh~ws anger by hitting people, throwing 
things. 
EXPANSIVE MOOD AND IDEATION 
D 
or breaking 
Have you sometimes felt particularly cheerful and on 
top of the world, without any reason? 
(Too cheerful to be healthy?) 
(How long does it last?) 
(40) 
RATE EXPANSIVE MOOD: not ordinary high spirits. D (41) 
1 = Moderately expansive mood (euphoria with marked 
element of inappropriateness or excitement, 
whether recognised by subject or not), present 
during past month, and persistent for hours at a 
time.* Do not .include transient high spirits. 
Not necessarily described by subject. · 
2 = Intense form of symptom (elation or exaltation) 
definitely present during past month and persistent 
for hours at a time. Described by subject. 
Have you felt particularly full of energy lately, or 
full of exciting ideas? 
(Do things seem to go too slowly for you?} 
(Do you need less sleep than usual?) 
(Do you find yourself extremely active but not getting 
tired?) 
(Have you developed new interests recently?) 
RATE SUBJECTIVE IDEOMOTOR PRESSURE. 
D (42) 
1 = Subjective equivalent of flight of ideas. Images 
and ideas flash through the mind, each suggesting 
others, at a faster rate than usual. State per-
sists for hours at a time.* Definitely occurred 
during past month. 
2 = As (1) but accompanied by very high energy output 
and activity which does not seem to make subject 
tired at the time. Definitely occurred during 
past month and persisted for hours at a time.* 
IF NO EVIDENCE OF EXPANSIVE MOOD AND IDEATION, CUT OFF~ 
SECTION 10. 
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IF EVIDENCE OF EXPANSIVE MOOD AND IDEATION: 
Have you seemed super-efficient at work, or as though you 
had special powers or talents quite out of the ordinary? 
Have you felt specially healthy? 
Have you been buying any interesting things recently? · 
RATE GRANDIOSE IDEAS AND ACTIONS. 
0(43) 
health, exceptionally high 
abilities, etc. Persis-
Symptom occurred at some 
1 = 
2 = 
Subjective feeling of superb 
intelligence, extra-ordinary 
tent for hours at a time.* 
time during the month. 
Grandiose ideas have been translated into action during 
the month, e.g. overspending, gambling, etc., under the 
influence of grandiose ideas and expansive affect. Do 
not include compulsive gambling unless clearly of this 
type. 
(7 GRANDIOSE DELUSIONS, SECTION 15D IF NECESSARY.) 
* If symptom was more transient but very intense or frequently 
repeated, it may still be included. 
10. OBSESSIONS 
These symptoms are usually experienced as occurring against 
conscious resistance (see definition in glossary). 
** 
** 
Do you find that you have to keep on checking things 
that you know you have already done? 
(Like gas taps, doors, switches, etc.) 
(Do you have to touch or count things many times or 
repeat the same action over and over again?) 
(What happens when you try to stop?) 
RATE OBSESSIONAL CHECKING AND REPEATING ·. D (44) 
1 = Symptom of moderate intensity or, if severe, present 
less tham 50% of the time. 
2 = Symptom present in severe degree, more than 50% of 
the past month. 
Do you find it difficult to make decisions even about 
trivial things? 
<D<? you constantly have to question the meaning of the 
universe?) 
(Do you get awful thoughts corning into your mind even 
when you try to keep them out?) 
(What happens when you try to stop?} 
RATE OBSESSIONAL CLEANLINESS AND SIMILAR RITUALS. 
1 = Symptom of moderate intensity or, if severe, present 
less time. 
2 = Symptom present in severe degree, more than 50% of the 
past month. 
** Do you find it difficult to make decisions even about 
trivial things? 
(Do you constantly have to question the .meaning of the 
universe?) 
(Do you get awful thoughts 
when you try to keep them 
(What happens when you try 
coming into your mind even 
out?) 
to stop?)' 
RATE OBSESSIONAL IDEAS AND RUMINATION. D (46) 
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1 = Symptom of moderate intensity, or, if severe, present 
less than 50% of the time. 
2 = Symptom present in severe degree, more than 50% of · 
the past month. 
11. DEREALISATION AND DEPERSONALISATION 
** Have you had the feeling recently that things around you 
were unreal? 
(As though everything was an imitation of reality, like 
a stage set, with people· acting instead of being themselves?) 
(What is it like? How do you explain it?) 
RATE DEREALISATION. 
1 = Moderately intense form of symptom definitely occurred 
during the past month, and persisted for hours at a time. 
Things appear colourless and artificial, people appear 
lifeless and seem to act rather than being themselves. 
2 = Intense form of symptom occurred during the past 
month and persisted for hours at a time·, e.g. 
w~ole.w~rld.app7ars like a gigantic stage set, ~1th 1m1tat1on instead of real objects and puppets 
instead of people. (If delusional, do not rate 
** 
here but symptom 90.) 
Have you yourself felt unreal, that you were not 
a person, not in the living world? 
(Or that you were outside yourself, looking at 
yourself from outside?) 
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(Or that you look unreal in the mirror?) 
(Or that some part of your body did not belong to you?) 
(How do you explain it?). 
RATE DEPERSONALISATION D (48) 
1 = Moderately intense form of the symptom 
definitely occurred during the past month and persisted for hours at a time. Sub-
ject feels himself unreal, a sham, a shadow. 
2 = Intense form of symptom definitely occurred during the past month and persisted for hours at a time. Subject feels he is dead, not a person, living in a parallel existence, a hollow shell, even that he does not exist. (If delusional, do not rate here but symptom 90.) 
12. OTHER PERCEPTUAL DISORDERS (NOT HALLUCINATIONS) 
** Do you ever get the feeling that something odd is going on which you can't explain? 
** 
** 
(Or that familiar surroundings seem strange? How do you explain it?) 
RATE DELUSIONAL MOOD: The subject feels that his familiar environment has changed in a way which puzzles him and which he may not be able to des-cribe clearly. The feeling often accompanies D delusion formation. 
1 = Symptom definitely present. No delusions have actually been formulated, though patient may feel that various delusional explanations are possible. 
2 = Full delusional elaboration has · occurred. 
Does your imagination sometimes play tricks on you? 
Is there anything unusual about the way things look or sound, or smell, or taste? 
(Does your body function normally?) 
(Is your own appearance normal? 
CONTINUE BELOW CUT-OFF IF NECESSARY, EVEN IF (49) NOT PRESENT. 
IF NO PERCEPTUAL ABNORMALITY+ SYMPTOM 54. 
( 49) 
IF THERE IS ANY HINT OF PERCEPTUA4 ABNORMALITY, CONTINUE 
BYOND CUT-OFF POINT AND ALSO CONSIDER LATER SECTIONS. 
RATE ONLY BASIC EXPERIENCE, NOT DELUSIONAL ELABORATION. 
In what way? Do sounds seem unnaturally clear or loud 
or things look vividly coloured or detailed? 
(How do you explain this?) 
RATE HEIGHTENED PERCEPTION: e.g. subject intensely aware 
of cracks in a wall, details of a wallpaper pattern, col-
ours in a picture. Sounds heard with exceptional clarity 
music appears particularly beautiful. 
1 = Subject unable to describe the symptom precisely, but 
examiner thinks it is likely to .have been present at 
some time during the past month. 
2 = Subject describes symptom. Definitely present at 
some time (even if only briefly) during the past month. 
Do things seem dark or grey-or colourless? 
(How do you explain it?) 
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RATE DULLED PERCEPTION: The reverse of symptom (50). 
Things look, sound and taste dull, flat colourless and 0(51 ) 
uninteresting. 
1 = Subject unable to describe the symptom precisely, but 
examiner thinks it is likely to have been present at 
some time during the past month. 





some time (even if only briefly) during the past month. 
the appearance of . things or pe_ople · change in a puzzling 
e.g • . distorted shapes ·or size · or. · colour? 
do you explain it?) 
CHANGED PERCEPTION 
1 = Subject unable to describe the symptom precisely, but· 
examiner thinks it is likely to have been present 
at some time during the past month. 
2 = Subject describes symptom. Definitely present at some 
time (even if only briefly) during the past month. 
Do you think your own appearance is normal? 
(Conviction that nose is too large, teeth misshapen, body 
crooked, etc. Ask questions here if convenient but rate 
symptom ( 89) • ) 
Does your experience of time seem to have changed? 
(Does it go too fast or too slowly, or do you seem to live 
through experiences exactly as you have had them before?) 
RATE CHANGED PERCEPTION OF TIME, INCLUDING DEJA VU 0(53) 
1 = Subject unable to describe the symptom precisely, 
but examiner thinks it is likely to have been present 
at some time during the past month. 
2 = Subject :describes symptom. Definitely present at 
some time (even if only briefly) during the past month. 
·'( 
Do you feel you have lost your emotions in some way? 
(that you are empty of all feeling, incapable of reacting 
emotionally?) 
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(Is this a definite dhange, or have you always been like 
that?) 0(54) 
(How do you explain it?) 
** RATE LOST EMOTIONS: Rate only subjective loss of affect 
i.e. subject can remember being able to react emotionally 
though this might have been months or even years ago. 
1 = Symptom definitely present during the past month but 
less than 50% of the time. 
2 = Symptom present more than 50% during the month. 
13. THOUGHT READING, INSERTION, ECHO, BROADCAST 
IF QUESTION HAS NOT BEEN COVERED IN SECTION 4 ASK: 
** Can you think quite clearly or is there any interference 
with your thoughts? 
(Are you in full control of your thoughts?) 
(Can people read your mind?) 
(Is anything like hypnotism or telepathy going on?) 
IF NO EVIDENCE OF THOUGHT READING, etc., CUT OFF-) 
SECTION 14. 
IF ANY EVIDENCE, ASK QUESTIONS BELOW': 
(These symptoms are often recorded as false positives. The 
examiner must be satisfied that the subject is not simply 
assenting to a question he does not understand, but genuinely 
recognises the experience and can describe it so that the 
examiner recognises it). It is particularly important to know 
the relev-ant . sections of the instruction Manual well before 
rating these symptoms. 
Are thoughts put into your head which you know are not your own? 
(How .do do know they are not your own?) 
(Where do they come from?) D · 
(55) 
RATE THOUGHT INSERTION: Include only thoughts recognised 
as alien. Do not include delusional elaboration, only basic 
experience. (Exclude hallucinations.) 
1 = Symptom described clearly, but subject thinks it may be 
due to 'own unconscious thoughts' etc., i.e. not 
certainly alien. 
2 = Symptom described clearly and thoughts described as alien 
i.e. inserted into mind from elsewhere (even if subject 
does not know from where). Not hallucinations. 
Do you ever seem to hear your own thoughts spoken alound in 
your head, so that someone standing near might be able to hear 
them? 
(Are your thoughts broadcast, so that other people know what 
you are thinking?) 
(How do you explain it?) 
RATE THOUGHT BROADCAST. 
1 = Hears own thoughts 'spoken' aloud but no~ broadcast. 
Subject must really hear them aloud in his head. If 
in doubt rate (8) or (0). 
2 = Thoughts transferred or broadcast so that others can 
share subject's thoughts even when they are not in 
the same room. (do not include 'thoughts being read' 
unless this is an explanation of thought broadcast. 
The subject must actually experience his thoughts 
being available to others.) 
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Do you ever seem to hear your own thoughts repeated or echoed? 
(What is that like? How do you explain it?) 
(Where does it come from?) 
RATE THOUGHT E~HO, 'OR COMMENTARY. D ( 57) 
l = Thought echop .. If _ any' doullit-, .. r'ate . (8) or (0). 
2 = Subject experiences alien thoughts related to his own 
thoughts, ie. association or comments on his own 
thoughts. Not hallucinations. 
DO you ever experience your thoughts stopp~ng quite 
unexpectedly so that there are none left in your mind, 
even when your thoughts were flowing freely before?) 
(What is that like?) 
(How often does it occur? What is it due to?) 
Do your thoughts ever seem to be taken out of your head, as 
though some external person or force were removing them? 
(Can you give an example?) 
(How do you explain it?) 
RATE THOUGHT BLOCK OR WITHDRAWAL 0(58) 
1 = Thought block. Do not include if due to anxiety or 
lack of concentration; only if it occurs totally unex-
pectedly when thoughts are flowing freely. One single 
occasion is not sufficient for rating. Be very critical 
in rating this symptom. 
2 = Delusional explanation that thoughts are withdrawn. 
Can anyone read your thoughts? D 
(How do you know? How do you explain it? ) (59) 
RATE DELUSION OF THOUGHTS BEING READ: only if subject does 
not mean that people can infer his thoughts from his actions. 
(Do not include subject reading thoughts of other people ""7 76) 
1 = 'Partiat' delusion. Subject entertains the possibility 
that thoughts might be read but is not certain about it. 
Exclude if subcultural explanation. 
2 = Full delusion. Exclude if subcultural explanation. The 
term 'thought reading' is commonly used to mean the ability 
to tell what someone is thinking from the way they behave 
- this use should be excluded. 
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USE JUDGEMENT ABOUT WORDING. 
** I should like to ask you a routine question which we ask 
of everybody. Do you ever seem to hear noises or voices 
when there is no one about, and nothing else to explain it? 
(Do you ever seem to hear your name being called?) 
** Is that true of visions or other unusual experiences, · which 
some people have? 
(Touch , taste, smell, temperature, pain, etc.) 
IF NO EVIDENCE FOR HALLUCINATION OF ANY SENSE, CUT OFF 7 
SECTION 15. 
IF EVIDENCE FOR NON-AUDITORY HALLUCINATIONS ONLY "7 
SUBSECTIONS 14 BAND 14 C. 
14A. AUDITORY HALLUCINATIONS 
IF ANY EVIDENCE THAT AUDITORY HALLUCINATIONS MIGHT BE PRESENT: 
Do your hear noises like tapping, or music? (What is it like?) 
Does it sound like muttering or whispering? 
Can you make out the words? 
RATE NON-VERBAL AUDITORY HALLUCINATIONS. [](60) 
t = Music, tapping, car engines, etc. Do not include tinnitus. 
2 = Muttering, whispering but subject cannot make out any · 
words at all. 
What does the voice say? 
(Write down examples of typical verbal hallucinations) 
(If accusatory: Do you think that it is justified? Do you 
deserve it?) 
Do you hear your name being called? 
RATE VERBAL HALLUCINATIONS BASED ON DEPRESSION OR ELATION [](61) 
OR VOICE CALLING SUBJECT: 
Content is congruent with mood; e.g. 1 He 1 s dirty 1 , in context 
of depression, or 1 So _t0 We1tmi~ster 1 , in elated subject who 
thinks he is Prime Minister. Include voice calling subject 
(e.g. calling name) or saying single words only. Be careful 
to distinguish from delusions of reference in which people 
whom the subject can see are thought to be talking about him. 
RECORD EXAMPLES. 
1 = Voice calling name, or single words only. 
2 = Other verbal hallucinations; congruent with depressed 
mood. 
3 = Other verbal hallucinations; congruent with elated 
mood. .. 
Do you hear several voices talking about you? 
Do they refer to you as 1 he' (she)? 
(What do they say?) 




RATE VOICE(S) DISCUSSING SUBJECT IN THIRD PERSON OR COMMENTING 
ON THOUGHTS OR ACTIONS (NOT BASED ON DEPRESSION OR ELATION) 
Do not include muttering or whispering if subject cannot make 
out words. Exclude 'dissociative' hallucinations (symptom 64). 
Do not include voice calling name or affectively based verbal 
haalucinations (symptom 61). There may be one voice commenting 
on subject's thoughts or actions, or several voices discussing 
the subject in the third person. 
RECORD EXAMPLES. 
1 = Hears a voice or voices commenting on thoughts or actions 
in third peron (e.g. 'Now he's going to go to bed 'or 
'Why would he thing a thing like that?'). (2) not present. 
2 = Hears voices talking about him/her in third person (e.g. 
'I think he's a homosexual, don't your 'Yes he wears a 
pink pullover, that is a sign of it.·, ) ( 1) may also be 
present. 
Do they speak directly to you? 
(Are they threatening or unpleasant?) 
(Do they call you names?) 
Do they give orders? (Do you obey?) 
RATE VOICE(S) SPEAKING TO SUBJECT (NOT BASED ON DEPRESSION OR 
ELATION). 
Include voice(s) speaking directly to subject, whether accusing 
threatening, giving orders or giving information. Exclude voice 
(s) calling name or based on depression or elation (symptom 61) 
or commmenting on subject's thoughts or actions (symptom 62) 
Exclude 'dissociative' hallucinations (symptom 63). 
RECORD EXAMPLES. 
1 = Pleasant, supportive or neutral voice(s) , not based on 
affect. No hostile voices. 
2 = Hostile, threatening or accusing voice(s), thought to be 
undeserved and not based on affect. 
N.B. If single isolated words, even with neutral affect, 
include under 61 ( 1) -. 
Can you carry on a two-way conversctt ion with - ? 
(You can reply, and then - replies to you, and you reply again 
just as in an ordinary conversation?) 
(Do you see anything, or smell anything at the same time as 
you hear the voice?) 
(Who is it you are talking to?) 
(What is the explanation?) 
(Do you know anyone else who has this kind 




The subject can hold a two-way conversation· with a presence 
(variously described as a person, ghost, spirit, god, etc. 
which may also be sensed in other ways, e.g. visually or by 
touch or smell. Often connected with people with whom the 
subject has had strong affective ties. Visual hallucinations 
can occur alone. There is usually a strong subcultural 
colouring, e.g. the subject belongs to a religious sect or 
to a subcultural group which sanctions hallucinatory 
experiences, or the subject , has been under the influence of 
someone who is involved with such practices. Exclude 
hypnogogic hallucinations. 
RECORD EXAMPLES. 
1 = 'Dissociative' hallucinations present. Subject belongs 
to subcultural group or sect in which such experiences 
are sanctioned. · 
2 = 'Dissociative' hallucinations present. Subject does not 
belong to subcultural group as in (1). If not known, 
rate ( 1 } • 





1 = Subject hears both pseudo-hallucinations 
and true hallucinations (through ears}. 
(within .mind) 
2 = Subject hears pseudo-hallucinations only. 
3 = Subject hears true hallucinations only. 
How do you explain the voice? 
RECORD EXPLANATION. 
14B. VISUAL HALLUCINATIONS 
IF QUESTION HAS NOT BEEN COVERED IN SECTION 12 OR 14A, ASK: 
** Have you had visions, or seen things other people couldn't 
see? 
IF NO EVIDENCE, HERE OR ELSEWHERE, FOR VISUAL HALLUCINATIONS 
CUT OFF - SECTION 15. 
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RATE VISUAL HALLUCINATION: In clear consiousness including · 
pseudo-hallucinations. Exclude 1 dissociativ·e 1 visual D 
hallucinations (sympto~ 64). (66) 
1 = Formless visu~l hallucinations - flashes of lighti 
shadows, etc. 
2 = Formed visual hallucinations - people, objects like a 
'fiery cross', faces, etc. 
RATE DELIRIOUS VISUAL HALLUCINATIONS 
14C. OTHER HALLUCINATIONS 
D (67) 
IF QUESTIONS HAVE NOT BEEN COVERED IN PREVIOUS SECTIONS: 
** Is there anything unusual about the way things feel, or 
taste, or smell? 
** Does your body function normally? 
IF NO EVIDENCE FOR OTHER HALLUCINATIONS CUT OFF "7' 
SECTION 15A 
IF ANY EVIDENCE FOR OTHER HALLUCINATIONS: 
po you sometimes _notice strange smells that other people 
don't notice? 
(What sort of thing?) D 
(How do you explain it?) (68) 
RATE OLFACTORY HALLUCINATIONS: Exclude delusion that patient 
himself smells. 
1 = Simple olfactoryhallucination. Not delusionally elab-
orated. Subject smells oranges, death, a burnt smell, 
scent, etc., which other people cannot smell. 
Can offer no explanation. 
2 = Delusional elaboration in addition, e.g.gas being put 
into room. 
Do you seem to think that you yourself give off a smell 
which is noticed? 
(What is the explanation?) D 
RATE DELUSION THAT SUBJECT SMELLS: Do not include simple (69 ) 
preoccupation with body odour, e.g. in anxious subject who 
sweats a lot. 
1 = Subject irrationally thinks he gives off a smell but 
is not certain. Not sure that others have noticed it 
but thinks it possible. 
2 = Subject sure that he gives off a smell and that others 
have noticed it and react accordingly. 
Do you ever feel that someone is touching you, but when you 
look there is nobody there? 
(Have you noticed that food or drink seems to have an unus-
ual taste recently?) 
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RATE OTHER HALLUCINATIONS AND DELUSIONAL ELABORATION: 
Exclude hypochondriacal and nihilistic delusions rated in D (70) 
(90) and (91). 
1 = Sensation of touch, food tastes burnti etc. but subject 
puzzled by the experience. No delusional' elaboration·. 
2 = Delusional elaboration in additon, e.g. fantasy lover, 






Delusions may be of two kinds, primary and secondary. Both 
are rated together in the following symptoms except where 
specified. For example, primary delusions are specifically 
rated in symptom (82). They are defined he.re for convenience. 
Primary delusions are based upon experiences in which a sub-
ject suddenii becomes convinced that a particular set of 
events has a special meaning (e.g. a subject undergoing a 
liver biopsy suddenly felt he had been chosen by God). 
The delusion cannot be explained and it is not shared by 
by other members of the subject's cultural social group. 
Secondary delusions are delusional elaborations of primary 
del~ons or other basic phenomena such as d~realisation, 
perceptual distortions, · hallucination, thought echo, mood 
changes, etc.: 
Above cut-off questions, likely to elicit delusions if pre-
sent, are included in many of the preceding sections. -There 
may also be evidence in the case- record or in the subject's 
spontaneous account. · 
IF NO EVIDENCE AT ALL THAT DELUSIONS ARE PRESENT, CUT OFF""7 
SECTION 16 
RECORD IF ANY PSYCHOTIC PHENOMENA PRESENT, OTHER THAN DELU-
SIONS; USE JUDGEMENT AS TO WHETHER TO PROCEED BEYOND 
CUT-OFF. 
IF ANY EVIDENCE FOR DELUSIONS, ASK ALL QUESTIONS NOT IN 
BRACKETS, AND ANY FURTHER QUESTION WHICH SEEM INDICATED. 
RATING OF PARTIAL AND FULL DELUSIONS. 
In general, all delusions are rated as follows: 
1 = P~rtial delusions, which are expressed with doubt, or 
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as possibilities which the subject entertains but . is not 
certain about. This rating should not be used if it is 
clear that full aelusions have been present during the 
month, or if the subject has acted as if fully deluded. 
2 = Full delusions have been present at some time during the 
month. Fully convinced. No insight. 
A useful question to elucidate the difference between partial 
and full delusions is as follows: 
Even when you seem to be most convinced, do you really feel 
in the back of your mind that it might well not be true, that 
it might be imagination? 
15A. DELUSIONS OF CONTROL 
Definition 
The subject's will is replaced by that of some external agency 
A simple statement that the radio is controlling the subject is 
notsufficient. (This statement, alone, should be rated 8.) 
The subje~t m~~t -describe a _ replacemeht of will by some other 
force. 
Do not include feeling that life is planned and directed by 
fate, or that the future is present already in embryo, or that 
subject is not very stong-willed, or that voices give subject 
orders. Do not include simple identification with God or 
being under God's direction. Do not include subcultural or 
hysterical possession states or multiple peronality (""7 100}. 
Do you feel under the control of some force or power other 
than yourself? 
(As though you were a robot or a zombie without a will of 
your own?} 
(As though you were possessed by someone or something else?} 
(What is that ·like?} 
(Does this force make your movements for you without your 
willing it, or use your voice, or your handwriting? Does it 
replace your personality? What is the explanation?} 
RATE DELUSIONS OF CONTROL. 
1 = Partial delusions 
2 = Full delusions 
15B. MISINTERPRETATIONS, M~SIDENTIFICATION AND DELUSIONS 
OF REFERENCE. 
Definition 
Delusions of reference: Do not include simple self-conscious-
ness of feeling that subject attracts comments, even if 
critical. These are rated under symptom 31. 
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There must be elaboration: e.g. someone crosses his knees in 
o'rder to indicate that the subject is homosexual; or the whole 
neighbourhood is gossiping. 
Delusional misinterpretations, etc. This is an extension of 
the delusion of reference, so that not only do people seem to 
refer to subject, but situations appear to be deliberately 
created to test him (exclude situations -of medical treatment), 
or objects appear to have special meanings. 
Do people seem to drop hints about you or say things with a 
double meaning, or do things in a special way so as to convey 
a meaning? 
Does everyone seem to gossip about you? 
(Do people follow you about or check up on you or record your 
mGvements?) -
(How do they do it? Why?) 
(Are there people about who are not what they seem to be?) 
RATE DELUSIONS OF REFERENCE. 
1 = Partial delusions 
2 = . Full delusions 
Do things seems to be specially arranged? 
(Is an experiment going on to test you out? 
(Do you see any reference to yourself on TV or in the papers? 
(Do you ever seem to see special meanings in advertisements, 
or shop windows, or in the way things are arranged?) 
(How do you explain this?) 
RATE DELUSIONAL MISINTERPRETATION 
1 = Partial Delusions 
2 = Full Delusions 
15C . . DEbUSIONS OF PERSECUTION 
AND MISIDENTIFICATION. 
0(73) 
Is anyone deliberately tying to harm you, e.g. to poison you 
or kill you? 
(How? Is there an organisation like the Mafia behi~d it?) 
(Is there any other kind of persecution? How do you explain 
this?) 
RATE DELUSIONS OF PERSECUTION 
1 = Partial delusions 
2 = Full delusions 
15D. EXPANSIVE DELUSIONS 
Do you think that people are organising things specially to 
help you? 
RATE DELUSIONS OF ASSISTANCE. 
1 = Partial delusions 
2 = Full delusions 
0(75) 
Is there anything special about you? Do you have special 
abilities or powers? 
(Can you read people's thoughts?) 
(Is there a special purpose or mission to your life?) 
(Are you especially clever or inventive? How do you explain 
this? 
RATE DELUSIONS OF GRANDIOSE ABILITIES 
1 = Partial delusions 
2 = Full delusions 
Can you do things other people can't do? 
(Are you a very prominent person or related to someone 
prominent, like Royalty?) 
(Are you very rich or famous?) 
(How do you explain this?) 
RATE DELUSIONS OF GRANDIOSE IDENTITY: (Exclude religious 
identification. 
1 = Partial delusions 
2 = Full delusions 
D (77) 
15E. DELUSIONS CONCERNING VARIOUS TYPES OF INFLUENCE AND 
PRIMARY DELUS!ONS 
Are you a very religious person? 
(Specially close to Christ or God?) 
(Can God communicate with you? How?) 
(Are you yourself a saint?) 
(How do you explain this?) 
RATE RELIGIOUS DELUSIONS: Including delusional religious 
explanations of other experiences. Exclude intense 
relig_ious belief or 12urely subcultural beliefs. D 
1 = Partial delusions (78) 
2 = Full delusions 
How do you explain the things that have been happening? 
(SPECIFY) 
Is there anything like hyponotism, telepathy, or the occult 
going on? 
What is the explanation? 
INCLUDE DELUSIONAL EXPLANATIONS IN TERMS OF PARANORMAL 
PHENOMENA: e.g. hyponotism, telepathy, magic, witchcraft, 
etc. Exclude purely subcultural beliefs, "7 83. 
1 = Partial delusions D (79) 
2 = Full delusions 
Is anjthing like electricity, or X-rays, or radio-waves 
affecting you? 
(In what way? What is the explanation?) 
INCLUDE DELUSIONAL EXPLANATIONS IN TERMS OF PHYSICAL FORCES 
e.g. radio, television, x~rays, electricity, transmitters, 
microphobes, machines of various kinds. 
1 = Partial delusions 0(80) 
2 = Full delusions 
DELUSIONS OF ALIEN FORCES PENETRATING OR CONTROLLING D 
MIND (OR BODY) (81) 
Include any delusion, whether rated elsewhere or not, which 
involves an external force penetrating the subject's mind 
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or body, e.g. rays turn liver to gold, alien thoughts p±~rce skull 
or are inserted into mind, hypnotism makes patient levitate, 
a spirit speaks with subject's voice, a radio transmitter has 
been implanted into brain and broadcasts thoughts or controls 
actions, etc. 
1 = Partial delusions 
2 = Full delusions 
Choose a likely delusion, and ask : 
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How did it come into your mind that this was the explanation? 
(Did it happen suddenly? How did it begin?) D 
RATE PRIMARY DELUSIONS : Based upon experiences in which ( 82) 
subject suddenly becomes convinced that a particular set of 
events has a special meaning. (See definition on page 214.) 
Not based on mood or explanation of other abnormal experiences. 
1 = Partial delusions 
2 = Full delusions 
15F. OTHER DELUSIONS 
(Examiner should question as ~ppropriate.) 
RATE SUBCULTURALLY INFLUENCED DELUSIONS: Include only subjects 
who belong to small groups with definitely idiosyncratic bel-
iefs; small sects, tribes, 'secret societies', etc. 
0 = No signitd,cant subcultural influence. For example, an 
English subject believing he is influenced by TV would 
be rated (0) since, although the delusion depends on TV 
being available in England, it is not in any way specific 
to a small subcultural group. 
1 ~ One or more of the 'delusions' rated earlier could 
easily be no more than a belief shared by other members 
of the subject's subcultural group, e.g. the Pentecos-
tal church with the gift of tongues. Voodoo, witchcraft 
communicating with God, are other examples of beliefs 
which may be taken quite literally by groups of people 
who are not clinically deluded. Rate (1) if subject 
holds such beliefs without elaborating them further. 
2 = As (1), but because of excitement, expansiveness, depres-
sion, confusion, intellectual retardation, etc., the sub-
ject holds the beliefs with exceptional fervour and 
conviction, or elaborates them further. Such a subject 
might well be regarded as abnormal by other members of his 
own sect or group. 
3 = More specific delusional states, e.g. Koro, Witigo, etc. 
(Do you have any reason to be jealous of anybody?) 
MORBID JEALOUSY. 
1 = Partial delusions 
2 = Full delusions 
DELUSION OF PREGNANCY. 
(Do you think a man can fall pregnant?) 
1 = Partial delusions 
2 = Full delusions 
0(84) 
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SEXUAL DELUSIONS: Any delusion with sexual content, e.g. fan-
tasy lover, sex changing, etc. Do not include an untrue claim 
that a subject is married or has children. 
1 = Partial delusions 
2 = Full delusions 
Have you had any unusual sexual experiences lately? 
Do your sexual organs feel normal? 
D (86) 
Have you had any unusual experience or adventures recently? 
RATE FANTASTIC DELUSIONS, DELUSIONAL MEMORIES, DELUSIONAL 
CONFABULATIONS, FANTASTIC DELUSIONS: 
Confab~lation: Su b ject make s up delusions on the spot. Very 
rare. Delusional memories: Subject seems to be describing 
actual memories. Describes the same delusions time and again. 
Not confabulations. Rare, e.g. 'I came down to earth on a 
silver star.' Fantastic delusions: The commonest of the three 
e.g. England's coast melting. 
1 = Partial delusions D (87) 
2 = Full delusions 
15G. SIMPLE DELUSIONS BASED ON GUILT, DEPERSONALISATION, 
HYPOCHONDRIASIS, ETC. 
Definition 
These symptoms often appear to be based on a depressed mood 
and are relatively consistent and unelaborated. Do not incl~ 
ude more bizarre elaborations of any of them, e.g. having a 
metal nose= possibly symptom 87, not 89. Having been turned 
into another specified person= possibly symptom 71, not 90. 
Liver turned to lead by x ... rays = symptoms 80 and 81, not 
91. England's coast melting= symptom 87, not 92. 
Do you feel you have committed a crime, or sinned greatly, 
or deserve punishment? 
(Have you felt that your presence might contaminate or ruin 
other people?) 
RATE DELUSIONS OF GUILT 
1 = Subject has brought ruin to family by being in present 
condition, or thinks that symptoms are a punishment for 
not doing better, etc. Does not elaborate as in (2) 
2 = Subjects says has sinned greatly or committed some terr-
ible crime or brought ruin upon the world. May feel 
deserving of punishment, even of death or hell-fire, 
because of it. 
(Do you think your appearance is normal?) 
RATE SIMPLE DELUSIONS CONCERNING APPEARANCE: 
(Nose too large, teeth misshapen, body crooked, etc.) 
1 = Strong feeling that there is something wrong with app-
earance; subject looks old or ugly or dead, skin cracked 
teeth misshapen, nose too large, body crooked, etc. 
Can be reassured temporarily. There may be only one 
limited preoccupation. 
2 = Subject acts accordingly (plastic operations, etc.) 
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(Is anything the matter with your brain?) 
RATE DELUSIONS OF DEPERSONALISATION: Subject has no head,o (90) 
does not exist, hollow instead of a brain, etc. 
1 = Unable to think, no thoughts in head, feels as though 
he has no brain or as though it does not function at all. 
2 = Symptom more intense. Subject has no head, no brain, 
does not exist. 
(Is anything the matter with your body?) D (91) 
RATE HYPOCHONDRIACAL DELUSIONS: Subject has incurable cancer~ 
bowels are stopped up, insides are rotting, etc. 
1 = Subject feels body is unhealthy, rotten, diseased, but 
without the force of (2) 
2 = Subject has incurable cancer, bowels are stopped up or 
rotting away, etc. 
(Do you have the feeling that something terrible is going 
to happen? What?) 
RATE DELUSIONS . OF CATASTROPHE: World is about to end, 
catastrophe has happened or will occur, evei;iything is 




1 = Subject feels sense of impending doom; something awful 
will happen. Non-specific but outof proportion to 
circumstances. 
2 = Delusional conviction that world is about to end or some 
other enormQU~ catastrophe is about to occur or has occ-
urred. World is dirty, decayed, rotten: ie. further 
Gelusional elaboration of (1). 
15H. GENERAL RATINGS OF DELUSIONS AND HALLUCINATIONS 
(Include both partial and full delusions.) 
CONSIDER BOTH DELUSIONS AND HALLUCINATIONS IN FOLLOWING RATINGS 
RATE SYSTEMATISATION OF DELUSIONS 
Scoring: 
0 = No delusions or -hallucinations. 
1 = Delusions and hallucinations not elaborated into a 
general system affecting much of the subject's exper-
ience. Include encapsulated delusions or isolated hal-
lucinations. 
2 = Some systematic elaboration, but substantial areas of 
the subject's experiences are not affected. 




0 = No attempt at concealment suspected. 
D (94) 
x 1 = Examiner suspects that there may be (either) delusions or 
hallucinations in the background, but the subject is 
not concealing much of the psychopathology. 
2 = Examiner suspects that there is a considerable pre-
occupation with delusions (even a delusional system) 
or hallucinations, but the subject tries to conceal them. 
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3 = No concealment but other delusions or hallucinations 
probably present. Not elicited beca~se of poor 
intelligence and education or incoherence or muteness, 
etc. 
OVERALL RATING OF PREOCCUPATION WITH DELUSIONS AND HALLUCINATIONS 
Scoring: ~(95) 
0 = No delusions or hallucinations. 
1 = No delusions or hallucinations definitely rated but 
examiner suspects that they may be present. 
2 = Preoccupied with past delusions or hallucinations only. 
Not actively deluded or hallucinated at present. 
3 = Delusions or hallucinations definitely present but 
subject is not preoccupied with them for much of the 
time. Can turn attention to other things without 
difficulty. 
4 = Delusions or hallucinations present and take up most of 
the subject's attention. Preoccupied to the exclusion 
of many other matters. 
5 = Patient can hardly discuss anything but delusions. 
RATE ACTING OUT DELUSIONS 
(Rate from case-record, etc.) 
~(96) 
Scoring: 
O = No delusions or hallucinations. 
1 = Subject able to keep delusions or hallucinations to 
himself, or to confide them only to a few trusted 
people (sympathetic relatives, friends, doctors, etc.) 
He does not express them in public nor act upon them. 
Does not talk out loud to voices. 
2 = Subject has acted upon delusions or hallucinations 
during past month, or expressed them in public (i.e. 
outside the small circle of people who would be 
expected to be sympathetic). This has not, however, 
resulted in severe social disturbance or a social crisis. 
3 = As (2) but acting out, or public expression, has resulted 
in severe social disturbance or a social crisis. 






Have you had any lapses of memory recently? 
(Have there been any periods in which you completely 
forgot what happened?) 
(What was it like?) 
(How do you explain it?) 
RATE FUGUES, BLACKOUTS, AMNESIA LASTING MORE 
Irrespective of aetiology. 
less than 12 hours. 
12-24 hours. 
more than 24 hours. 
What medicines or drugs do you take? 
THAN ONE 
~(97) 
(Do you take anything for your · n:erves or your mood?) 
(Obtain list of drugs:) 
(Who prescribes?) 
HOUR: 
RATE DRUG ABUSE DURING MONTH. One category only. 
1 = Cannabis 
2 = Amytal, etc. 
3 = LSD, amphetamine, etc. 
4 = Cocaine, heroin, etc. 
** May I ask about your drinking habits? How much do you 
usual~y dririk each day? 
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(Is al~ohol in any way a problem for you? In what way?} 
(GHECK . L~ST: Pres-e-nt~ on card ,if. -needed. During the _past 
month have you: had ·.£-a:mily problems becau·se of drinking?° 
missed work because of drinking? 
had morning shakes or other withdrawal symptoms? 
had blackouts for several hours? 
heard voices or seen visions?} 
RATE ALCOHOL ABUSE DURING PAST MONTH D (99} . 
1 = Agrees alcohol has been a problem but not 2. 
2 = Any check-list item applies. 
RATE DISSOCIATIVE STATES DURING PAST MONTH: D (100) 
'Narrowing of consciousness which serves an unconscious pur-
pose and is commonly accompanied or followed by a selective 
amnesia'. e.g. trance, possession state, fugue, h_ypersomnia, 
stupor, etc. 
Do not include if caused by drugs, alcohol, epilepsy, etc. 
1 = Present during month, not at examination. 
2 = Present at examination. 
RATE CONVERSION SYMPTOMS, e.g. paralysis, anaesthesia, blind-
ness, tremor, seizures, etc. if mentioned during interview. 
1 = Present during month, not at examination. 
2 = Present at examination. 
RATE CLOUDING OR STUPOR AT EXAMINATION 
D (101) 
D (102) 
1 = Clouding: Inadequate comprehension of external impress-
ions, with perplexity, and impairment of attention and 
orientation. 
2 = Stupor: Subject appears comatose but there is no clouding 
or impairment of consciousness. 
IF ANY SUSPICION OF POOR MEMORY OR DISORIENTATION: 
May I ask one or two standard question we ask of everybody? 
How old are you? 
Can you tell me the year and the month? 
What . is the name of the Prime Minister? 
RATE ORGANIC IMPAIRMENT OF MEMORY. 
ition. 
1 = Mild 
2 = Moderate 
3 = Severe 
See glossary for defin-
D (103) 
17. INSIGHT 
** Do you think there is anything the matter with you? 
(What do you think it is?) 
(Could it be a nervous condition?) 
(What do you think the cause is?) 
(Why did you need to come to hospital?) 
(Do you think (specify delusions or hallucinations) were 
part of a nervous condition?) 
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IF PSYCHOTIC SYMPTOMS (i.e. SYMPTOMS FROM SECTIONS 12 - 15): 
O = Full insight (in intelligent subject, able to appreciate 
the issues involved). 
1 = As much insight into the nature of the condition as soc-
ial background and intelligence allow. 
2 = Agrees to a nervous condition but examiner feels that 
subject does not really accept the explanation in terms 
of a nervous illness (e.g. gives delusional explanation, 
the result of persecution, or rays, etc.). 
3 = Denies nervous condition entirely. 
9 = Psychotic illness not present. 
IF NEUROTIC SYMPTOMS (i.e. SYMPTOMS F.Jill,M SECTION 1 - 11 ONLY) 
0 = Full insight (in intelligent subject, able to appreciate 
the issues involved). 
1 = As much insight into the nature of the condition as social 
background and intelligence allow. 
2 = Gives physical explanation for neurotic 
3 = Denies neurotic symptoms entirely. 
9 = Neurotic illness not present. 
symptoms. 
D(1as, 
** Of all the problems you have told me about, which one 
affects you most? 
How much does it interfere with your work or your relat-
ionships·-:. wi th other people? 
(Have you actually been out of work, or been unable to do 
do some housework, or go shopping, travelling, etc. during 
the past month?) 
(Have the symptoms impaired your efficiency in any other 
way?) 
RATE SOCIAL IMPAIRMENT DUE TO NEUROTIC CONDITION 
0 =:,No neurotic or psychotic symptoms present. 
1 ~ Ne·urotic symptoms present but -little diminution of su-
bject's efficiency or interference with everyday activ-
ities. 
2 = Neurotic symptoms interfere with subject's efficiency 
to a moderate extent but are not incapacitating, e.g. 
subject neglects housework or can't enjoy leisure 
activities or social relationships, or finds work-
efficiency reduced because of worry, tension, irritab-
ility, depression, anxiety, etc. Subject does not, 
however, stop work altogether or completetely neglect 
household. 
3 = Subject severely incapacitated by neurotic symptoms: 
had to have at least a week off work during past month; 
was housebound for a week or more; was actively with-
drawn from all social relationships, etc. The subject 
does not have to be totally incapacitated for the whole 
\ 
176 
month for this rating to .be made, but impairment has to 
be very severe. 
8 = Examiner unsure. 
9 = Psychotic condition present. 
(If both psychotic and neurotic condition, rate whichever 
shows more impairment.) 







No neurotic or psychotic symptoms present. 
Psychotic symptoms present but little diminution of 
subject's efficiency or interference with everyday 
activities. 
Psychotic symptoms interfe~e ~ith subject's efficiency 
to a mbderate extent but are fncapacita~ing, e.g. 
subject neglects housework or can't enjoy leisure 
activities or social relationships, or finds work-
efficiency reduced. Subject does not, however, stop 
work altogether or completely neglect household. 
Subject severely incapacitated by psychotic symptoms: 
had to have at least a week off work during past 
month; was housebound for a week or more; was 
actively withdrawn from all social relationships, etc. 
The subject does not have to be totally incapacitated 
for the whole month for this rating to be made, but 
impairment has to be very severe. 
Examiner unsure. 
Neurotic condition, and no psychotic condition, present. 
FINAL QUESTION 
** Have there been any other things lately that I haven't 
covered? 
Specify; 
Note here any points that seem to be important or unusual about 
the subject or the interview which are not covered in the 
-=schedule. 
Reconsider schedule to make sure that all obligatory questions 
have been asked. Also consider whether behaviour, affect and 
speech rating can be made or whether further observation or 













Present in fairly severe degree, or very S-eY_e.i:e:.:bU:.t 
~ntermittent during interview. 
Present in very severe degree and almost continuous 
during interview. 
Examiner not sure. 
Subject not examined, or examination not appropriate. 
If in doubt, rate (0). A rating of (1) means there is 
no doubt ~bout the symptom being present in fairly 
severe form. 
B§haviour during interview r:=](108) 
Self -neglect (cleanliness, shaven, make~up, state of hair 
and clothe~). 
Bizarre appearance (secret documents openly displayed, spec-
ial c.iotbes or ornaments with symbolic significance, etc. 0( 109} 
Do not include mannerism or posturing= symptom 116}. 
Slowness and underactivity (sits abnormally still, walks D 
abnormally slowly, delay in performing movements). (110) 
~ Agitation (Fidgety, restlessness, pacing, frequent 
unnecessary movements). I. 1 (111} 
0 (112} 
~Gross excitement and violence (thro\i_s things, runs or jumps 
about, waves arms wildly, shouts or screams). 
Irreverent behaviour (sings, facetious, silly jokes, flipp- 0 (113) 
ant remarks, unduly familiar}. 
Distractibility (stops talking or changes subject due to dist-
raction by trivial noises or events outside the room or turns 
attention to furniture, etc.) _ [ ! (114) 
Embarrassing behaviour (mal{ing sexual suggestions or advances 
to in_terviewer ;. loss of social rei:rtraint ~ scratche_s-geni tacJ 
passes loµd flatus, ~tc.) _ (115} 
Mannerisms and posturing (odd, stylised movements or acts, D 
usually idiosyncratic to the patient, often suggestive Qf (116) 
special meaning or purpose: assuming and maintaining uncom-
fortable or inappropriate postures}. 
Stereotypies, etc. (constant repetition of movement or post-
ures such as rocking, rubbing, grimacing: no special signif-
-icance) • D( 117} 
Behaves as if hallucinated (non-verbal: as though hears voices 
or visions: lips move soundlessly, looks round, giggles to self 
not just from embarrassment, shyness, etc.). [](118) 
Catatonic movements 
(Negativism: does the opposite of what is asked. [](119) 
Ambitendence: begins to take proffered hand, then withdraws; 
etc. 
Echopraxia: imitates examiner's movement. 
Flexibilitas cerea: arm remains where it is put, for at least 
15 seconds. 
178 
Mitgehen: excessive co-operation in passive. movement; 
Echolalia: imitates words and phrases with same intonation 
and inflection of voice.) 
(These items can be separately rated in special projects.) 
Affect during interview 
Observed anxiety (tense worried look or posture, feaful 
apprehensive look, frightened tone of voice, tremor). 
D (120) 
Observed depress ion (sad, mournful look, tears, gloomy tone D ( 121 ) 
of voice, deep sighing, voice chokes on distressing topic). 
Histrionic (feeling expressed in exaggerated, dramatic, his~f-
ionic manner) • i_J( 122) 
8:ypomanic affect (unduly cheerful, smiling, euphoric, elated) • 0·.(123) 
Hostile irritability (unco-operative, irritable, angry, overtly 
hostile, discontented, haughty, antagonistic). I p24) 
Suspicion 0 125) 
Perplexity (puzzlement) 
Lability of mood (whether lability ~f one mood, or changing 
from one mood to another). 
Blunted affect (expressionless face and voice, uniform 
blunting whatever the topic of conversation, indifference · 
to distressing topics, whether delusional or normal). 
1 t 126 ) 
LJ(127) 
0'-128) 
1 = Blunting not uniform, e.g. at times responds affectively 
but at other times is markedly flat; or responds with 
some evidence of affect, but definitely less than 
expected. 
2 = Severe and uniform blunting. 
Incongruity of affect (emotion is shown, but not congruent 
with topic) . D (129) 
Speech during interview 
Slow speech (long pauses before answering, long pauses 
between words). 
Pressure of speech (more copious speech than normal, too 
rapid speech, very loud voice, too circumstantial speech). 
D (130) 
D (131) 
Non-social speech (talks, mutters, whispers, out loud, out D(132) 
of context of conversation with examiner). 
Muteness 
1 = Almost mute, fewer than twenty words in all. 
2 = Totally mute. 
Restricted quantity of speech (subject frequently fails to 
answer, questions have to be repeated, restricted to minimum D (134) 
necessary, no extra sentences, no additional comments). 
Neologisms and idiosyncratic . use of words or phrases, e.g. 'O~ 
is called "Per-God" and the other is called "Per-the-Devil", L_J (135) 
179 · 
' ••• miracle-willed through God's "tarn-harn" ••• 1 , 'Well, 
there is a frequenting of clairvoyance ••• •·: 'Per-God' , 
'Per-the-Devil' and 'tarn-harn' are neologisms; 'frequenting 
clairvoyance' is an example of ordinary words used idiosyncra-
tically. DO NOT RATE THIS SYMPTOM PRESENT UNLESS EXAMPLES 
ARE WRITTEN DOWN. 
Disorder of content of speech 
Three .t:ypes of disordered content are specified: in each case, 
the effect is to make it very difficult to grasp what the sub-
ject means. However, the sympt0ms are defined in terms of spec-
ific components so that it should, in most cases, be possible 
to say . that whether one, two, 6r all three symptoms are present. 
If in doubt, rate hierarchically, i.e. rate incoherence in 
preference to flight of ideas and flight of ideas in prefer-
ence to poverty of speech. 
If the patient does not talk enough to give a rateable sample 
of speech, rate all three symptoms Y. 
Incoherence of speech. The subject's meaning is obscured by 
distorted grammar, lack of logical connection between one part 
of a sentence and another or between sentences, sudden irrel-
evances or 'Knight's move', grossly pedantic phrases, answering 
_?ff thepoint, etc. For example: 0(136) 
'We've seen the downfall of the radium crown by the Roman 
Catholics, whereas when you come to see the drinking side of 
the business, God saw that Noah, if he lost his reason, he 
got nobody there to look after them. 
'I did suggest to you, that intrinsic or congenital sentiment 
of refinement of disposition would be so miracle-willed 
through God's "tarn-harn" as to assume quite the opposite. 
'I believe we live in a world, in an age, where the elements 
ars~a force that elders of professionalism hope, not to con-
quer, but to control. 
'What's your address?" 'It's supposed to be Salisbury near 
Birmingham.' 
(Vorbe ireden.) 
DO NOT RATE THIS SYMPTOM PRESENT UNLESS EXAMPLES ARE WRITTEN 
DOWN. 
A rating of 2 means that very little normal speech is present. 
N.B. A free flow of delusions is not necessarily incoherent. 
A subject may talk about delusions quite coherently. 
Flight of ideas. Words are associated together inappropriat-
ely by sound or rhyme(clang association). Altogether the ori-
ginal aim of the sentence may quickly be lost, a path can be 
traced through associations of the white-black-coffin or ring 
or ring-wrong variety, or through associations with distract-
ing stimuli, e.g. 
'How is your appetitS ?' 'I feel as if I have lost my appe-
tite. I have had an orange. A real juicy orange' (See pat-
ient walking past window.) 'She is going for E.C.T. Etcetera 
treatment or teddy bear' s picnic. I call it.' 
180 
DO NOT RATE THIS SYMPTOM PRESENT UNLESS EXAMPLES ARE WRITTEN DOWN 
A rating of 2 means that very little normal speech is present. 
Poverty of content of speech. The subject talks freely but 
so vaguely that little information is given in spite of the 
number of words used: rambles on without corning to a point; 
may wander far from original theme. Exclude incoherence or 
f~ight of ideas. Rate only if severe and always give 
writ ten example. D ( 13 8) 
Misleading answers. Subject's answers are misleading because 
answers 'yes or 'no' to everything, or frequent self-contra-
dictions, or appears to be deliberately misleading. Do not 
include incoherence, flight of ideas or poverty of speech here. 
Re-rate adequacy of interview 
D ( 139) 
O = Ratings made adequately represent the symptoms present. 
1 = Some problem - but key symptoms have been rated. 
2 = Serious question as to adequacy of interview for rating 
key symptoms (other than sections 18-20). 0(
140
) 
3 = Only sections 18-20 could be rated. 
Check that every box has an entry except those below ticked 
cut-off points. 
Complete coding· sheet if one is being used. 
For glossary of definitions see Wing, Cooper and Sartorius, (1974). 
APPENDIX D 















41 Subjective euphoria 
42 Ideomotor pressure 
43 Grandiose ideas and actions 
123 Hypomanic affect 
137 Hypomanic content of speech 
111 Agitation on examination 
108 Self-neglect 
49 Unfamiliar and delusional 
mood 
50 Heightened perception 
53 Changed perception of time 
60 Hears music, tapping etc. 
61 Hears voices calling name 
66 Minor visual hallucinations 
70 Other minor hallucinations 
94 Evasiveness concerning delusions 




129 Incongrous affect 








113 Irreverent behaviour 
115 Embarrasing behaviour 
Residual Syndrome 60 Hears muttering, whispering 
118 Behaves as if hallucinated 
132 Non-social speech 
Organic impairment 67 Delirious visual hallucinations 
103 Organic impairment of memory 
Flattening 128 Blunt affect 
Catatonic syndrome 116 Mannerism and posturing 
119 Catatonic movements 
Slowness 110 Slowness and underactivity 
130 Slow speech 
133 Muteness 
182 
134 Restriction of quantity of speech 
Incoherent Speech 135 Neologisms 
136 Incoherence of speech 
Sexual and 59 Thoughts read 
Fantastic 70 Delusional elaboration of Delusions 
hallucinations 
75 Delusions of assistance 
79 Delusional explanation 
(hyponotism etc.) 




































Delusions of pregnancy 
Sexual Delusions 
Fantastic Delusions 
Delusions concerning appearance 
Delusions concerning lack of 
organs 
Primary delusions 
Delusions of reference 
Delusions of misinterpretation 
Delusions of grandiose ability 
Delusions of grandiose indentity 
Religious delusions 





Voices about patient 
Delusions of control 
Delusions of alien ~enetration 




















68 Olfactory hallucinations 




Voices to patient (not 
depressive) 
Depressive hallucinations 
Delusions of guilt 
91 Hypochondrical delusions 
( bowels. blocked up) 







23 Depressed mood 
24 Hopelessness 
25 Suicidal plans or acts 
121 Depression on examination 
32 
33 
Guilty ideas of reference 
Guilt 
51 Dulled perception 
54 Lost affect 
11 Anxiety 
14 Panic attacks 
120 Anxiety on examination 
ON Obsessional Neurosis 





IR Ideas of reference 
44 Checking and reporting 
45 Cleanliness and rituals 
46 Obsessional ideas and 
rumination 
15 Situational anxiety 
17 Specific phobias 
18 Anxiety avoidance 
185 
64 Dissociative hallucinations 
(not sub-cultural) 
- ~00 Dissociative states 
101 Conversion symptoms 
122 Histrionic 
40 Irritability 
124 Hostile irritability 
4 Worrying 
6 Tirec!ness 
10 Nervous tension 
21 Neglect through brooding 
35 Delayed sle8p 
5 Tension pains 
7 Muscular tension 
8 Restlessness 








Loss of interest and 
concentration 
Somatic symptoms of 
Depression 
Lack of energy 
Depersonalization 
Hypochondriasis 
16 Anxiety on meeting people 
28 Social withdrawal 











Loss of interest 
Morning depression 
Loss of appetite 
Early waking 








Subscores derived from the PSE. 










Incoherence of speech 
DELUSIONAL AND HALLUCINATORY SYNDROMES (DAH) 
Sexual and fantastic delusions 
Delusions of reference 
Grandiose and religious delusions 



























Depressive delusions and hallucinations 
Sub-cultural delusions and hallucinations 
SPECIFIC NEUROTIC SYNDROMES (SNR) 
Simple depression 









Ideas of reference 
Social unease 
Loss of interest and concentration 
Somatic symptoms of depression 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.... \0 CJ) 
APPENDIX G 
Formulation of Visualizing agents for toxicological screens. 
i IODINE REAGENT 
Dissolve 2,5g iodine in 250ml carbon tetrachloride 
ii DRAGENDORFF'S REAGENT 
Stock solution: Dissolve 5,2g bismuth carbonate and 15g sodium 
iodide in 50ml glacial acetic acid. Filter sodium acetate crystals 
after 12 hours through a scincered glass funnel. Dilute 60ml of the 
filtrate with 25ml glacial acetic acid. Store in a dark bottle. 
Working solution: 10ml stock solution 
60ml ethyl acetate 
25ml glacial acetic acid 
iii IODOPLATINATE REAGENT 
Dissolve 1g of hexachloroplatanic acid and 20g potassium iodide in 
400ml water. Dilute to 2L with 2N hydrochloric acid (400cHCL/2L). 
iv MARQUIS REAGENT 
Add 20ml formaldehyde solution to 200ml concentrate sulphuric acid 
After spraying, view under long UV. Heat at 100°c for 5-10 minutes. 
Note colour change. 
V MANDELIN'S REAGENT 
Add 2,5g ammonium monovadonate to 250ml concentrate sulphuric acid 
and stir for 30 minutes. Allow the sediment to settle overnight. 
Fitler though a scintered glass funnels. 
197 
vi FORREST REAGENT 
Dissolve 125mg potassium dichromate in about 150ml water. Add 20ml 
concentrate sulphuric acid, 12,5ml perchloric acid (60%) and 30ml nitric 
acid (65%). Dilute to 250ml with water. 
vii FPN REAGENT 
Dissolve 1,25g ferric nitrate 9H2o in 50ml water. Add 15ml perchloric 
acid (60%) and 38ml nitric acid (65%). Dilute to 200ml with water. 
viii DIPHENYL CARBAZONE REAGENT 
Make up a 0,1% diphylcarbazone solution in ethanol. 
ix TRINDER'S REAGENT 
198 
Dissolve 10g mercuric chloride and 15g ferric nitrate 9H2o in 200ml water 
and 30ml Hydrochloric acid. Dilute to 250ml with water. 
x MERCUROUS NITRATE REAGENT 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Statistical Tests used 
The following tests were used as applicable in this study. 
1. Chi squared test (Siegel, 1956 Table C). 
2. McNemar test for the significance of changes (Siegel, 1956 Table C). 
3. Wilcoxon matched-pairs signed-ranks test (Siegel, 1956 Table G). 
4. Spearman rank correlation coefficient (Siegel, 1956 Table B). 
5. Kruskal-Wallis one-way analysis of variance (Siegel, 1956 Table C). 
All p values quoted were for 2 tailed tests and a p value of less than 
or equal to 0,05 was regarded as statistically significant. 
' L 
APPENDIX J 
Suppliers of materials and equipment 
Stasar III Spectrophotometer 
(Gilford Instrument Laboratories 
Ohio, U.S.A) 
Syva CP 5000 EMITR Clinic~l Processor 
(Oxbridge Incorporated 
California , U.S.A.) 
Syva Pipetter-Diluter Model 15BB 
(CAVRO Scientific Instruments 
California, U.S.A.) 
EMITR - d.a.u. Cannabinoid Assays 
EMITR - d.a.u. Cannabinoid Calibrators 
(Syva, California, U.S.A.) 
Silica gel 60F 254 plates 
ammonium sulphate 
Isopropanol, methanol 
(Merck, Darmstadt, Germany) 
Gow.Mac Series 750 Gas 
Chromatograph (Model 69-752) 
(Gow-Mac Instruments, New Jersey, 
U.S.A.) 
Hewlett Packard Automation 
System 3385A Integrator 
Recorder 
(Hewlett Packard, U.S.A.) 
207 
American Hospital 
Supply Co. (Pty) Ltd. P.O.Box 816 
Cape Town 8000 
T & C Scientific Supplies 
(Pty) Ltd., P.O.Box 2953 
Cape Town 8000 
Packard Instruments 
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